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71. INTRODUCTION
The spectrum of anxiety and depression ranges from genetically determined, life-saving 
primitive response and behaviour (e.g. fight-flight response) via normal, yet strenuous, 
reactions to daily stress and life events to severe long standing disorders with considerable 
risk for fatal outcomes (e.g. suicide). These highly different manifestations of anxiety and 
depression make understanding, interpretation, and classification of symptoms particularly 
challenging for researchers, clinicians, and policy makers. It is, therefore, standards of 
assessment and classification are continuously being developed and debated. Current 
classification of mental disorders is based on a semi-structured interview (1). Self-report of 
anxiety and depression symptom severity does not serve a diagnostic purpose, but instead is a 
tool, which is commonly used in clinical and research settings for screening and evaluative 
purposes. However, risk factors, course, and outcome in anxiety and depression has 
previously, for the most part, been studied for diagnostic categories, and not for self-rated 
symptoms.  
Though anxiety disorders and depression are highly prevalent in the general population (2;3), 
under-identification and under-treatment still prevails (4-6). As a result, the individual and 
societal burden of anxiety and depression is considerable and manifests itself through 
increased rates of sick leave, disability pension at a young age, and early death (7-9). 
Unfortunately, previous attempts to improve detection, treatment, and outcome of anxiety and 
depression have been less than successful (10;11).
In the Nord-Trøndelag Health Study (HUNT 2), a three-step intervention sub-study was 
carried out. This included, first, a mental health educational programme, which was followed 
by a population based screening for anxiety and depression, and then a psychiatric 
intervention programme. To our knowledge this combination of methods had not been 
attempted before.  This population study gave the opportunity to pursue the following 
research aims in this dissertation:  
1) Examine and discuss the feasibility, the response to, and the consequences of psychiatric 
screening and intervention in a general population study setting (Paper II). 
 2) Study self-reported anxiety and depression symptoms prospectively, both as outcome 
measures and as predictors for future symptom course and mortality (Papers I,III, and IV). 
82. ANXIETY AND DEPRESSION: BACKGROUND
2.1 Clinical features 
Symptoms of anxiety and depression can often be distinguished by their clinical expression. 
Anxiety is mostly associated with extensive worrying, the feeling of tension, hyper vigilance 
and fear of possible negative incidents (12), while depression usually presents itself as 
sadness or lowered mood, psychomotoric retardation, indifference regarding the present 
situation and the future, and anhedonia (13).
Both anxiety and depression symptoms are often subtyped into psychological, somatic or 
functional, and social symptoms. While psychological symptoms often differ in anxiety and 
depression, functional symptoms like sleep disturbance and lack of energy, and social 
symptoms such as avoidance and passiveness, often overlap in these two conditions (12;13). 
Anxiety and depressive symptoms are not specific to each category; they often overlap as well 
as appear in other psychiatric disorders, and even in somatic illnesses. Insomnia, lack of 
energy or appetite, for example, can all occur in both depression and anxiety as well as in 
coronary heart disease or in cancer. While the gender difference in prevalence of anxiety and 
affective disorders are one of the most consistent findings in psychiatric epidemiology, it is 
still controversial as to how symptoms of anxiety and depression are affected by gender and 
age (12-18). In addition, symptom expression as well as symptom tolerability shows great 
inter-individual variance. 
2.2 Underlying core dimensions of anxiety and depression  
Due to the complexities of clinical and theoretical constructs, it has been difficult to agree on 
the core characteristics of anxiety and depression. In a primary care setting, Goldberg et al 
(19) identified highly correlated dimensions of anxiety and depression. Later, Goldberg 
proposed a dimensional model for common mental disorders, which included anxiety, 
depression, and somatisation (20). Similar models of common psychopathology have been 
developed by others over the last decade; this supports the idea that co-morbidity of anxiety 
and depression emerges from common, underlying core psychopathological processes 
(21;22).
After an extensive review of studies addressing symptoms of anxiety and depression in 
various populations and health care settings Clark and Watson (23) suggested a tripartite 
9model. First, the model contains a common factor for anxiety and depression consisting of 
general distress or negative affect including both anxious and depressed mood, insomnia, and 
poor concentration. Second, a specific factor for anxiety consisting of tension and anxious 
arousal manifested as shortness of breath, dizziness or light-headedness, and dry mouth was 
described. Third, the depression factor was described as anhedonia and absence of positive
affect, i.e. loss of interest and feeling that nothing is interesting or enjoyable.
Anhedonia had the most specific variance (58%) among depressive symptoms examined (24). 
With further progress in genetic and phenotypic research, Mineka, Watson, and Clark (25) 
were able to present an integrative hierarchical model after new testing of this model in 1998. 
Though quite similar to the original model, generalised anxiety and depression shared 
common genetic and phenotypic characteristics in this refined model; and within the group of 
anxiety disorders there was substantial heterogeneity concerning genetic and cognitive 
aspects. Consistent with observations in adults, the general ideas of the tripartite model were 
supported in a large multiethnic school sample of children and adolescents (26).  
2.3 Assessment and classification of anxiety and depression 
Measurements of health have been used for more than a hundred years to indicate health 
problems confronting society, to contribute to forming policy, and to monitor the 
effectiveness of treatment and health care (27). On an individual level, health measurement 
can range from the assessment of global health indicators to more narrow and specific 
instruments covering, for instance, the above described (sub)dimensions of anxiety and/or 







Figure 1. Domains and levels of health measurement
As a general distinction, anxiety and depression can be measured either by self-report of 
symptoms (subjectively) or by observer-rating (objectively, by the means of an interview or 
testing). However, these methods often serve different purposes, often defined as primarily 
diagnostic, prognostic, evaluative, or a combination of these (28).
2.3.1 The psychiatric interview: dichotomous approach 
A semi-structured diagnostic interview is the gold standard for collecting systematic
information about the diagnostic criteria for relevant mental disorders according to the current 
editions of the DSM or ICD-system (29;30). In general, diagnoses based on operational 
criteria is related to diagnostic thresholds based on number and duration of symptom or 
behavioural criteria, presence of functional impairment, and non-presence of exclusion 
criteria.
The introduction of the third edition of the DSM by the American Psychiatric Association 
(31) in 1980 represented a dramatic change towards more detailed and standardised 
classification of mental disorders. One of the main aims of this reform was to provide 
clinicians with a common language (32) that would be independent of etiological 
considerations; this, after decades of inconsistent and unreliable classifications. With the 
DSM-IV (1994) (29) a variety of new constructs of mood and anxiety disorders emerged (33-
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35). Despite the high prevalence (36;37) and the unfavourable outcome in co-morbid anxiety 
and depression disorders compared to single diagnosis (38;39), the current classification 
systems do not allow for a mixed diagnosis, except for at a sub-clinical level and only in the 
group of adjustment disorders (30;40).  
Examples of commonly used structured interviews are the Diagnostic Interview Schedule 
(DIS) (41), the Present State Examination (42), the Structured Clinical Interview for DSM-III 
(SCID) (43), the Composite International Diagnostic Interview (CIDI) (44), the Schedule for 
Clinical Assessment in Neuropsychiatry (SCAN) (45), and the MINI International 
Neuropsychiatric Interview (MINI) (46).  
The theoretical constructs of DSM and ICD are based on the assumption that increasing 
severity and duration of self-rated symptoms in a person increase the probability for meeting 
the criteria for a disorder (47). Though this is often the case, the association between self-
rated symptom severity and diagnostic categories has turned out to be weaker than expected 
(48). As a consequence, the authors recommend combining these methods before treatment is 
decided upon.
2.3.2 Self-rating of anxiety and depression: dichotomous or continuous approach 
Self-rating often serves screening and evaluative purposes, and is widely used for both 
clinical purposes and research purposes. Though it is not a diagnostic tool according to the 
DSM and ICD, a dimensional symptom score from a rating scale with proven psychometric 
properties may be defined as probable case above a defined cut-off level on the scale (Figure 













Figure 2: Assessment of anxiety and depression in HADS.
Continuous approach: All three persons above have a HADS-T score of 20 points, yet with different
contributions from the anxiety and depression subscales.
Dichotomous approach: When using dimensional, separate cut-off values for anxiety and depression (8
points), the persons 1-3 get three different labels; anxiety case, depression case, and co-morbid case,
respectively. If a syndromal cut-off value for mixed anxiety and depression (HADS-T > 19 points) is used,
all three subjects reach the defined caseness.
In a continuous approach, the symptom level for each subscale or total HADS-score is described using the
actual symptom score (e.g the left example above; HADS-T = 21, HADS-A = 12, and HADS-D = 9).
Commonly used screening scales for anxiety and depression in health surveys are: The Beck 
Depression Inventory (BDI) (49), the Centre for Epidemiologic Studies Depression Scale 
(CES-D) (50), the General Health Questionnaire (GHQ) (51), Hopkins Symptom Check List 
(HSCL)(49), Spielberger State-Trait Anxiety Inventory (STAI) (50), and the Hospital Anxiety 
and Depression rating Scale (HADS) (51).
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Some scales mainly meet the diagnostic criteria of the DSM- or ICD-system (52), yet most 
vary in their focus on the psychological, somatic, and social symptoms of anxiety and/or 
depression. While the depression subscale of the HADS (HADS-D) focuses mainly on 
psychological symptoms, the scales BDI, CES-D, and GHQ all contain vegetative and 
somatic symptoms such as insomnia, reduced appetite, and loss of energy. Differences in the 
scope and coverage of the instruments are of great importance when comparing results 
between surveys.
2.4 Prevalence and co-morbidity of anxiety and depression  
Epidemiological population studies consistently find that women have a considerably higher 
prevalence of anxiety disorders compared to men. This is also the case for moderate and 
severe depression, though minor depressive symptoms show little gender variance (3;53-56). 
In contrast, several population studies, including HUNT 2, find that there are no or few 
qualitative or quantitative gender differences in self-reported depressive symptoms 
(14;17;57).
Anxiety disorders and affective disorders are common in the general population, yet 
prevalence estimates show great variation. While the 12-month prevalence of major 
depressive episode was 5.8% in the Epidemiologic Catchment Area Study (ECA) (56), it was 
10.3% and in the National Co-morbidity Study (NCS) (55). The recent European Study of the 
Epidemiology of Mental Disorders (ESEMeD) (3) found that only 3.9% fulfilled the same 
criteria. The corresponding 12-month prevalence of any anxiety disorder showed the same 
pattern: 6.4% in ESEMeD, 12.7% in the ECA, and 17.2% in the NCS. Life-time prevalence 
for any anxiety disorder or any mood disorder has typically varied between 14% and 25% in 
previous studies (3;55;56;58), yet the NCS Replication study from 2005 (59) found 29% for 
anxiety disorders and 21% for mood disorders.  
Though cultural and historical effects might have had some bearing on the results (60-63), the 
various methods of assessment (different psychiatric interviews) and the use of different 
versions of ICD or DSM probably account for most of the discrepancy between the three 
studies. Regier et al (64) pointed at these discrepancies and questioned the clinical 
significance and interpretation of the findings. As a consequence, Narrow et al (2) revised the 
prevalence estimates in 2002 from the ECA and NCS using data on clinical significance. This 
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resulted in a general reduction of the past-year prevalence rates in both surveys and reduced 
disparities between them.  
Symptoms of anxiety and depression show great overlap (65), and this overlap increases with 
symptom severity (66). More than half of those diagnosed with MDE in the general 
population (37;67), in primary care settings (68), and in patient samples (66) have co-morbid 
anxiety disorder(s).  The increasingly overlapping indications in psychopharmacological 
treatment further support that anxiety and depression are part of the same functional 
biological spectrum both at symptomatic and diagnostic levels (69;70); and neither genetic 
studies (71) nor neurobiological studies (72) have found clear evidence that generalised 
anxiety and depression should be separated. In accordance with this literature, anxiety and 
depression symptoms were highly inter-correlated in HUNT 2. Stordal et al (73) found that 
5,827 (62%) out of the anxiety cases had “pure anxiety” (HADS-A > 8 and HADS-D < 8) 
while 2,988 (45%) of the depression cases fulfilled the criteria of “pure depression” (HADS-
D > 8 and HADS-A < 8) in the total HUNT 2 population. The rest of the cases (38% and 
55%, respectively) fulfilled the criteria for both conditions.
In conclusion, a dimensional distinction between anxiety and depression might, therefore, 
make more sense when studying anxiety and depression in a general population sample with 
modest psychiatric morbidity and great variation in symptom scores. In contrast, clinical 
samples and psychiatric risk groups in the general population are, by nature, characterised by 
mixed anxiety and depression (74) and could better be studied using a syndromal approach.
For these reasons, the HADS-T score was used as inclusion criteria in the highly selected 
sample in the IDANT study (Papers II-IV). In the post-MI study (Paper I), which included a 
much larger general population sample, HADS-A and HADS-D were studied separately as 
outcomes. It is noteworthy that the original viewpoint of Zigmond and Snaith (75) was to 
always keep separate the HADS-A and HADS-D subscales.
2.5 Risk factors for anxiety and depression 
2.5.1 General comments 
Anxiety and depression symptoms may represent emotional responses to one or more 
stressors. Despite a close association, it has, so far, been difficult to establish biological causal 
connections between stress and mental disorders (76). Therefore, the literature on risk factors 
for anxiety and depression is largely based on variables that determine the biological 
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susceptibility to anxiety and depression (e.g. genetic factors, gender, age), mediators of stress 
(e.g. sociodemographic situation, lifestyle and life events, and physical illness), and
characteristics associated with stress coping (e.g. education, gender, personality). In general, 
co-morbid anxiety and depression show associations with nearly all established 
sociodemographic and vulnerability factors, whereas pure depression and pure anxiety 
disorder can each be linked to only about half of the factors (77).
2.5.2 Genetic factors 
Recently, comprehensive same-sex twin studies by Kendler, Hettema, and co-workers (71;78) 
have demonstrated that the underlying structure of genetic and environmental risk factors (e.g. 
family disruption, poor parental monitoring, or low SES) for depression and anxiety disorders 
show little difference between men and women. Within the internalizing disorders, the 
strongest genetic factor loaded on major depression and GAD in these studies. Apart from a 
possible midlife and late age gene action in females for depression, genetic determinants of 
anxiety and depression also appear relatively stable across the lifespan for both genders (79).
2.5.3 Sociodemographic factors 
Though often hypothesised, studies have not been able to confirm whether gender differences 
in prevalence of anxiety and depression can be explained by the different distribution of 
sociodemographic factors  (marital status, employment status, educational level, number of 
children, or social class) in women and men (80). The established gender differences might be 
better explained by the symptom pattern and symptom severity in depression. In their study of 
subtypes of depression in 1,920 primary care patients, Chen et al (81) demonstrated that 
depression characterised primarily by anhedonia (defined as a mild subtype) showed similar 
prevalence in both genders. In contrast, the risk for suicidal depression and severe depression 
was more than doubled in women compared to men. This is consistent with findings from the 
large DEPRES Study (Depression Research in European Society) covering representative 
population samples of six European countries (53).
Though anxiety and depression symptoms might differ qualitatively with age (82), the 
literature review by Jorm (15) found no consistent pattern for the prevalence of anxiety and 
depression at symptomatic or diagnostic levels in different age groups. In sum, the 
determinants of gender and age differences in common mental disorders are still far from 
being understood (80). Among the sociodemographic factors that clearly increase the risk for 
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common mental disorders are low educational level (83), financial deprivation, 
unemployment, and low socioeconomic status (84-87).  
2.5.4 Psychosocial and coping factors 
Concerning the psychosocial determinants for anxiety and depression, previous symptoms of 
the same conditions have proven to be the strongest risk factors for the onset of new episodes 
(88-90). In a lifespan perspective, negative childhood events, poor social support, and a 
vulnerable personality style represent potent determinants for the onset of depressive 
disorders (90;91). Since fearful-anxious, dependent, and self-critical personality traits are 
more common in women than in men, they are likely to explain some of the excess 
psychiatric morbidity in women (90;92-95).  
Stressful life events have a substantial causal relationship with the first onset of major 
depression in both genders (96), though the coping strategies and symptom course often differ 
between the genders (18;97-99). In the DEPRES Study of 78,000 individuals from six 
different European countries, Angst et al (53) showed that depressed men often cope by 
increasing their physical activity and alcohol consumption and women through emotional 
release and religion. In general, women reported that depression influenced their quality of 
sleep and general health, and men reported feeling the influence of depression more so in their 
ability to work. 
2.5.5 Lifestyle, biological markers, and physical illness
While physical inactivity (100) and daily smoking (101) have proven to predict common 
mental disorders, longitudinal studies of excessive alcohol consumption and the onset of 
anxiety and depression have been inconclusive (102;103). Social and lifestyle determinants of 
depression and anxiety seem to be the same or similar across cultural settings (84;90). The 
adverse effects of obesity (most often defined as BMI > 30) on mental health have, so far, 
been demonstrated only for depression (104). However, the mechanisms have yet to be fully 
elucidated, though both behavioural (e.g. social isolation, feeling of shame) and 
pathophysiological aspects (inflammation, metabolic processes) probably play important roles 
(105-107).
Though biological markers like serum cholesterol level (108-111) and blood pressure (112-
115) have been topics of various studies, their role as risk factors for anxiety and depression 
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remain unclear. A wide range of physical illnesses, however, increase the risk for anxiety 
(116-118) and depression (119;120).
2.5.6 Myocardial infarction as a risk factor for anxiety and depression
There has been much research done on psychiatric outcome after cardiac events and cardiac 
procedures. Clinical studies have repeatedly reported 17% to 22% prevalence of major 
depression during the first year after MI, regularly higher in women than in men (89;121-
125). Post-MI depression is associated with poor medical outcome and increased mortality 
(125;126). Female gender and history of pre-MI depression(s) are well-established risk factors 
for post-MI depression in the first 12 months, yet the impact of pre-MI demographic, 
psychosocial, and lifestyle characteristics on post-MI depression are still disputed 
(89;122;125;127).
Although co-morbid anxiety and depression is common, surprisingly few studies have 
investigated the prevalence post-MI anxiety (128). Recently, a five-country comparison study 
found high symptomatic anxiety scores the first days after MI to be a general phenomenon 
across cultures (129). As found for post-MI depression, prevalence of anxiety symptoms were 
consistently higher in women than men in all countries studied (130). Lane et al (131) 
demonstrated that 40% still had elevated anxiety and depression scores 12 months post-MI 
according to the STAI and BDI, respectively, and symptom overlap was common. 
Nevertheless, the prognostic value of post-MI anxiety symptoms have not been well 
documented compared to depression (128). Given the high prevalence and the chronic course 
of CHD, anxiety, and depression it is also remarkable that few studies have done follow-up 
studies lasting past 12 months. In addition, most previous studies have been performed in 
clinical populations, and, therefore, little is known concerning the psychiatric long-term 
outcome after MI in the general population.
2.6 Course of anxiety and depression 
The natural course of depression can vary from a single episode, via recurrent episodes, to a 
chronic course. The main risk factors for a recurrent or chronic course are a high genetic risk 
for depression and many previous depressive episodes (88). The ECA study (132) and the 
NEMESIS study (133) both found that median duration of MDE was 3 months in the general 
population and that about 20% were still depressed after two years. Mean duration was 6 
months in both genders.  In a primary care study of 1,111 patients, Vourilehto et al (68) 
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demonstrated that mild to moderate recurrent MDD was the most prevalent depressive 
disorder (66%). In this study, 59% of the depressed subjects had co-morbid Axis I disorders.  
Two studies of  psychiatric patients by Kennedy, Abbot, and Paykel (134;135) showed that 
illness severity at baseline was the strongest predictor for a recurrent or chronic course, and, 
despite recent advantages in psychological and medical treatment, that the long-term outcome 
of depression had not changed in the last 20 years.
Though conclusions regarding gender differences in the course of major depression are 
inconsistent (136), several studies have found a prolonged and more severe course in women 
and discuss whether this can be partially ascribed to sex differences in employment status, 
education, and marital status (35;137). The fact that severe depression, which is associated 
with female gender seems to emerge about a decade earlier in life than the more gender 
neutral anhedonia type (81) might also help explain gender differences in course and 
outcome. The Zurich Cohort Study (54) confirmed that women continued to report a greater 
number of symptoms than men over time, yet there were no gender differences in subjective 
impairment at work.  
GAD is a common mental disorder that typically has an early age of onset, a chronic course, 
and a high degree of co-morbidity with other anxiety and mood disorders (138). GAD is often 
temporally primary, especially in relation to mood disorders, and is associated with an 
increased risk for the subsequent onset and severity of secondary disorders (139). The NCS 
Replication by Kessler and co-workers in 2005 (59) confirmed this temporal relationship 
between anxiety and depression showing a median age of onset of only 11 years for anxiety 
disorders and 30 years for mood disorders.  
Though the impairment of GAD is more severe than previously assumed, there is little doubt 
that the course of co-morbid anxiety and depression is more chronic and the outcome poorer 
than for anxiety and depression alone (35;38;39;140-143). There is more supportive evidence 
in studies with 5 to 15 years of observation, and they seem to apply to most outcome variables 
studied: duration of mental symptoms, social and work impairment, health service utilisation, 
total mortality, and suicide risk.  
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2.7 Determinants for poor outcome and excess mortality in anxiety and depression 
The individual and societal burden of anxiety and depression is considerable and manifests 
through increased rates of sick leave, disability pension at a young age, and early death (7-9). 
The negative impact of depression and anxiety on the workforce is increasing world wide, and 
projections from the Global Burden of Disease Study (9) have predicted that unipolar 
depression will become the leading cause of disability among adults in the Western countries 
by 2020. 
Current etiological models have several limitations, yet determinants of chronic depression do 
not seem to differ qualitatively from those who predict acute depression (144); and these 
determinants seem independent of age (145;146). It is suggested that a high genetic risk, 
increased levels of childhood adversity, chronic environmental stress, and increased 
individual stress reactivity predict chronic rather than single episodes of depression (88;144). 
In a study of 117 psychiatric outpatients with MDE by Szadoczky et al (147), anxious 
personality features, lack of social support, and low educational level were associated with 
non-remission at the end of a 2-year follow-up period.  In agreement with other studies 
(81;148), initial symptom severity was the strongest predictor for a chronic course. In anxiety 
disorders, avoidance coping has shown to be a major predictor for overall improvement. Yet, 
the mechanism that often leads to a poor outcome in anxiety disorders is that anxiety often 
acts as a precursor for subsequent depression and substance abuse (139;149). The Nottingham 
Study of Neurotic disorders found that the above mentioned determinants for depression also 
predicted poor outcome after five (39) and twelve years (143) in subjects with co-morbid 
anxiety and affective disorder.
Excess mortality has, for the most part, been studied separately in anxiety (150;151) and 
depression (152) using diagnostic interviews for classification purposes. Though most 
previous studies are poorly controlled and have inconsistent findings, the majority of well-
designed studies agree that MD increases the risk for early death across various health care 
settings (152-156). A combination of mediating factors related to lifestyle, behaviour, and 
biological changes occurring in anxiety and depression may be responsible for this association 
(152;154).
In the relatively few reports from the general population, different definitions of anxiety 
disorders have often been used, and their associations with mortality has been inconsistent 
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(151;157). However, Allgulander’s study in Stockholm County, Sweden (158) that included 
3,302 inpatients with the "pure" anxiety neurosis showed a strong association with excess 
mortality.  Nevertheless, most studies suffered from limited information on co-morbid 
physical disorders and depression. A study by Murphy et al (159) confirmed excess mortality 
in co-morbid depression and GAD, though early death was associated with the affective 
disorder and not with co-existent GAD. In previous studies linking anxiety and depression 
with increased total mortality, adjusted ORs typically vary between 1.3 and 2.0.  
In sum, the mechanisms and mediating factors by which depression, and to some extent 
anxiety, increase the risk for early death are: increased risk for coronary heart disease, 
smoking, excess alcohol intake, male gender, and suicide or non-natural deaths 
(150;152;160). There seems to be a dose–response relationship between anxiety and 
depression severity level and total mortality both when using self-rating of symptoms (153) 
and diagnostic categories (140;154;161). However, the dose-response relationship theory 
cannot be absolutely backed up as different studies often use one cut-off for case-level 
depression and case-levels vary across studies. It is still unclear whether self-report or clinical 
interview is the more precise predictor for excess mortality in anxiety and depression.
Given the high prevalence, the risk for a chronic or recurrent course and poor outcomes, and 
the available treatment regimes, anxiety and depression should be suited for ethical scientific 
research and intervention (162). 
2.7 Mental health help-seeking, screening, and intervention
Despite increasing knowledge about risk factors, course, and treatment of anxiety and 
depression under-identification and under-treatment still prevails in both the general  
population (6) and in primary care settings (4;5). The most common reasons are lack of help-
seeking by patients and relatives (163;164), poor detection in primary care (4;165), and 
inadequate treatment for those detected (166;167). 
Stigma and the general attitude towards help-seeking and mental problems still create major 
barriers to help-seeking and problematic personal interaction between patient and GP 
(168;169). The nature of anxiety and depression, characterized by introversion, social 
withdrawal, and often somatic presentation of symptoms, further contributes to low detection 
rates.
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The results from educational interventions designed to improve detection, treatment, and 
outcome of mental disorders in primary care have long been inconsistent (10;170;171). Some 
RCTs, mostly educational programmes, have demonstrated improved detection rates and 
outcome measures in primary care settings (172-174). Nevertheless, the majority of recent 
studies yielded negative results (175-177). Several studies address the general problem of 
recruiting those in need for psychiatric treatment (178) and physicians in a primary care 
setting (179). In the extensive review by Hodges et al (10), the authors concluded that future 
studies to a larger extent need to address the GPs’ needs and premises, choice of outcome 
measures, and attitudinal issues. The literature review by Gilbody et al (180) demonstrated 
that routine administration of screening instruments for anxiety and depression in non-mental 
health settings had little impact on detection, management, and outcome of anxiety and 
depression in 12 RCT studies. Though two relatively small studies (181;182) showed that 
selective feedback for only high scorers increased the rate of detection, it did not improve 
management and outcome of depression. A combination of population strategies and 
intervention towards individuals at high risk could improve these results.  
2.8 Suicide intervention 
Almost one million lives are lost every year through suicide worldwide, and several 
developed countries have implemented mental health treatment programmes and suicide 
intervention plans (183). Still, the prevalence of suicidal thoughts, plans, gestures, or attempts 
did not change in the United States from 1990 to 2003 (184).  
The optimistic findings from the Gotland Study (185) were later questioned, mainly because 
the total number of suicides was limited and the suicide reduction was transient and only 
evident in females (186). Recently, Bruce et al (187) studied 598 individuals diagnosed with 
depression in primary care settings, and demonstrated that suicidal ideation declined faster in 
the intervention group compared to controls regardless of depression severity.
However, in 1995 the impact of the Gotland study was still strong. Therefore, a mental health 
advisory group suggested an educational programme in primary care settings in the months 
before HUNT 2 combined with an intervention towards individuals with the highest levels of 
anxiety and depression in HUNT 2. The main goal was to reduce the rate of suicides in Nord-
Trøndelag County.  
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3. OBJECTIVES 
The general aims of this dissertation are:
1) to examine and discuss the feasibility, response, and consequences of psychiatric screening 
and intervention in a general population study setting, and
2) to study self-reported anxiety and depression symptoms in a prospective design, both as 
outcome measures and as predictors for future symptom course and mortality  
The specific aims of this dissertation, papers I-IV:
1. Clinical studies report a 4-5 fold increased prevalence of MD throughout the first 12 
months post-MI, regularly higher in women than in men. The following questions 
were explored in our five year prospective population study (Paper I):
x Is the risk for anxiety (HADS-A > 8) and depression (HADS-D > 8) increased 
throughout the first five years post-MI?  
x Are there gender differences in the risk for post-MI anxiety and depression in a 
five year perspective?  
x What is the impact of the actual MI on anxiety and depression compared to the 
impact of pre-MI risk factors?  
2. To investigate feasibility, response among participants and GPs, and consequences of 
a mental health screening and intervention study (IDANT) carried out in a population 
study setting (Paper II).
3. To study the association between self-reported mixed depression and anxiety symptom 
severity level (HADS-T) and 4.5 year mortality in a subsample (N=2,624) in HUNT 2 
(Paper III). 
4. To study the four year stability of mean HADS-T, HADS-A, and HADS-D scores, and 
to observe the individual changes across three HADS-T severity levels in the general 
population. Three groups (N=1,326) scoring 0-19 points, 19-24 points, or 25 or above 
on the HADS-T, were selected in HUNT 2 and invited to a follow-up.
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THIS STUDY
4. MATERIAL AND METHODS
4.1 The Nord-Trøndelag County, Norway
Nord-Trøndelag County is located in the central part of Norway and is divided into 24 
municipalities (Figure 3). The county is about 3% of the total Norwegian population and 
increased from approximately 127,000 in 1984 to 127,500 in 1995. The population is 
considered ethnically homogenous with 97 % of the population being of Caucasian origin, 
and net migration is only 0.3% per year. Nord-Trøndelag has a geographical, demographical,
and occupational structure fairly representative of the whole of Norway. Yet, the county has 
no large city and the educational level and the income level are slightly lower than the
average for Norway. The socioeconomic inequalities in mortality in Nord-Trøndelag are at the 
national level (188)




4.2 The Nord-Trøndelag Health Studies (HUNT)  
4.2.1 General description of HUNT 
HUNT is a population based general health survey and has been carried out in two waves so 
far, HUNT 1 in 1984-86 (133) and HUNT 2 in 1995-97 (13). HUNT 3 is in the planning stage 
and will take place from 2006 to 2008. The general purposes, methods, and questionnaires are 
described at the HUNT website (http://www.hunt.ntnu.no/index_nyforside.php?side=english).
All inhabitants aged 20 or above were invited to the surveys; among those who were eligible, 
74,977 (88.1%) and 66,140 (71.2%) attended HUNT 1 and HUNT 2, respectively. Attendance 
varied considerably with age, and was generally better in women in both surveys (Table 1).
Table 1. Attendance in HUNT 1 (1984-86) and HUNT 2 (1995-97) 
Age HUNT 1 HUNT 2 
Eligible (n) Participated (n) % Eligible (n) Participated (n) %
20-29 14,330 10,994 76.7 18,025 8,828 49.0
30-39 17,769 15,943 89.7 16,896 11,550 68.3
40-49 13,244 12,253 92.5 17,636 13,569 77.0
50-59 11,877 10,852 91.4 13,785 11,205 81.2
60-69 13,294 12,466 93.8 10,611 9,089 85.6
70-79 9,837 8,769 89.2 10,401 8,310 79.9
80-89 4,162 3,081 74.0 4,851 3,202 66.0
90+ 587 319 54.3 731 387 52.9
Total 85,100 74,977 88.1 92,936 66,140 71.2
The same two-step procedure was used in both surveys: Questionnaire 1 (Q1, Appendix 1.1 
and 2.1), which included the HADS in HUNT 2, was mailed out with a personal invitation 
and was to be filled in at home and brought to the physical examination a few days later. At 
the examination the attendees also received Questionnaire 2 (Q2, Appendix 1.2 and 2.2), 
which was filled in at home and then returned by mail.  
While HUNT 1 was primarily designed to study arterial hypertension, coronary heart disease, 
lung diseases, diabetes, and quality of life, HUNT 2 included mental health and a wide range 
of other topics.  Sociodemographic variables, lifestyle issues, health care utilisation, somatic 
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symptoms and diagnosis, alcohol intake, and functional impairment were also extensively 
covered. All variables except for age, gender, address, marital status, and results of somatic 
examination and blood tests were collected by self-report.
About three to six weeks after the examination, every participant received a personal letter 
with results from the health examination, and if they had pathological clinical or biochemical 
values they were asked to visit their GP. The GPs received copies of the same letter.  
4.2.2 Mental health education, screening, and intervention in HUNT 2 (IDANT) 
In 1994, a mental health advisory group of four psychiatrists was formed to plan, carry out, 
and organize mental health research in HUNT 2: Alv A Dahl, Nils Håvard Dahl, Marit 
Bjartveit Krüger, and Eystein Stordal. The advisory group recommended to the Steering 
Committee that HADS be included in HUNT 2. The strategy was to combine a mass mental 
health educational programme (Appendix 4.4) prior to HUNT 2 with the Intervention study 
against Depression and Anxiety in Nord-Trøndelag (IDANT), which was to be embedded in 
HUNT 2.
The advisory group developed the Structured Psychiatric Interview for General Practice 
(SPIFA), which is a diagnostic instrument for mental disorders for primary care setting. A 
validation of SPIFA against SCID I (43) was performed by psychiatrists in general practice 
patients prior to HUNT 2. The kappa for major depression was .73 and for anxiety disorders it 
was .69. How the SPIFA is used was part of the educational programme that was offered as 
two-day seminars to all 90 GPs and all psychiatric nurses in the 24 municipalities a few 
months before HUNT 2 reached their communities. The aim was to improve and update the 
diagnostic and treatment skills for common mental disorders (29) in primary care settings, and 
in particular to prevent suicides (189). Treatment guidelines for common mental disorders and 
suicidal behaviour were based on updated literature reviews. Three of the members in the 
advisory group (NHD, MBK, and ES) held these educational programmes. 
In the IDANT, the Steering Committee suggested an intervention study aimed at individuals 
with the assumed highest prevalence of mental disorders and highest suicide risk in HUNT 2. 
The advisory board, therefore, chose to include the subgroup that had the highest total score 
on HADS-T in HUNT 2. It was expected that the GPs in the County could take on about 650 
participants in the IDANT study, therefore the cut-off was set at HADS-total score 25 (99th 
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percentile) after a pilot testing of the first 2500 individuals in HUNT 2. This value is 
considerably higher than the conventional cut-off for co-morbid anxiety and depression 
(HADS-T > 19 points). The group was defined as the psychiatric high risk group (PHRG). In 
the PHRG (n = 662), two did not give informed consent to follow-up and six moved shortly 
after HUNT 2, leaving 654 individuals eligible for IDANT (Figure 4). The advisory board 
then suggested a randomisation to intervention in the PHRG, but the HUNT Board of 
Directors found randomisation to be unethical due to the expected increased risk for suicide. 
Instead, they suggested the same procedure as used in the somatic screening and intervention, 
and as a result all individuals in the PHRG received a written notification concerning their 
very high level of anxiety/depression and a strong request to see their GP (Appendix 4.4). 
Then, the GPs were supposed to fill in and return a baseline form (Appendix 3.1) with clinical 
background information on the individuals in the PHRG.  
For several reasons, the IDANT study showed poor attendance both among participants and 
GPs. Therefore, a follow-up study was conducted four years later. Due to the lack of a defined 
control group in the IDANT, a random sample of 654 individuals (28%) was drawn from 
among the 2,334 who had HADS-T scores between 19 and 24 points (95th to 98th percentile) 
and constituted the “psychiatric risk group” (PRG). In addition, a random sample of 1,308 
(2.2%) among the 58,498 individuals scoring 18 or less (under the 95th percentile) on the 
HADS-T were selected and defined as the “reference group”. The participants in the reference 
group and the PRG did not receive any notification about their HADS-T score after HUNT 2. 
Of the 2,616 subjects in this cohort, 2,502 (95%) were still alive at the time of follow-up. 
They were invited by mail (Appendix 4.5) and asked to fill in a questionnaire that included 
the most relevant variables from Q 1 and Q2 in HUNT 2, which included the HADS 
(Appendix 3.2). In addition, a random sample of 300 subjects from the PHRG was invited to a 
clinical follow-up interview a few days after they had filled in the questionnaire. If the 
interview revealed untreated or inadequately treated mental disorders, and the participant gave 
consent, the results from the interview and therapy suggestions were sent to the person’s GP 
(Appendix 4.5).
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Figure 4. Design: HUNT 1, HUNT 2, IDANT, and the follow-up study. 
1984-86 1995-97 2000, Follow-up
HUNT 1 HUNT 2 
4.2.3 Sampling and study designs
While the sample studied in Paper I was drawn from the total HUNT 1 and HUNT 2 
populations, Papers II-IV studied feasibility and outcome in the IDANT study and the four 
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Figure 5. Sampling procedures, Papers I-IV. 
Outcome: Anxiety (HADS-A > 8) and
depression (HADS-D > 8) in 512 cases
0-5 years post-MI and in 23,181
controls still free of CHD/CVD
Paper I: Anxiety and depression post-MI.
Included: 23,693 individuals free of CHD
and cerebrovascular disease (CVD).
HUNT 2 (1995-97)HUNT 1 (1984-86) Follow-up (2000)
Paper III: Self rated mixed anxiety
and depression and mortality
Included: three groups (n=2,624)




in HUNT 2 and four year
mortality
Paper IV: Anxiety and depression
symptom stability
Three groups (n=2,616) with
different HADS-T levels at
baseline
Outcome: Change in mean
HADS-T, HADS-A, and
HADS-D scores. Changes in
HADS-T symptom level at
follow-up. Prevalence of
mental disorders
Paper II: Feasibility of psychiatric
screening and intervention in HUNT 2
Included: 654 individuals with HADS-T
score > 25 points (PHRG).
Outcome: Attendance among
participants and GPs, reactions, and
consequences of psychiatric intervention
4.3 Measurements and variables
General note: if not otherwise specified below, variables were the same in HUNT 1 and
HUNT 2.
4.3.1 The Hospital Anxiety and Depression rating Scale - HADS (All papers)
HADS was only available in HUNT 2. The instrument was originally developed by Zigmond
and Snaith in 1983 (51) to identify depression and anxiety in medical patients. 
Functional/somatic symptoms of depression and anxiety that could be related to somatic
diseases, such as dizziness, headaches, insomnia, anergia, or fatigue were, therefore, 
deliberately excluded. The two subscales consist of seven items for anxiety (HADS-A) and 
seven for depression (HADS-D), each scored from 0 (symptom not present) to 3 (symptom
maximally present) on a Likert scale. The HADS-A contains items mainly concerned with 
restlessness and worry, as in generalised anxiety disorder, plus one item on panic attacks. 
HADS-D focuses mainly on the reduced pleasure response aspect (anhedonia) of depression, 
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as well as psychomotor retardation and depressed mood. HADS does not address symptoms 
of severe psychopathology, the language is easily understood, and the general acceptability of 
HADS is good across study settings (190). Zigmond and Snaith did not recommend 
summation of the sub-scale scores into a total HADS score (51), and argued that the separate 
anxiety and depressive subscales were valid measures of severity of different mental 
disorders.
At the time when HADS was selected for HUNT 2, the psychometric properties had mostly 
been studies in relatively small samples, and factor structure reported in these studies differed 
from one (common mental distress) to four factors (190). Though international experiences 
from about 200 studies were positive, the review by Hermann-Lingen in 1997 was restricted 
to medical patient settings and had several methodological limitations. In 2002, Bjelland et al 
(191) reviewed about 750 papers to examine the validity of the HADS in various health care 
settings. They found that most factor analyses supported a two-factor solution in good 
accordance with the HADS-A and HADS-D subscales. The correlations between the two 
subscales varied from .40 to .74 (mean .56), and the mean Cronbach's alpha for HADS-A and 
HADS-D were .83 and .82, respectively. The best balance between sensitivity (0.80) and 
specificity (0.80) was achieved when defining caseness at a cut-off of 8 points or above on 
both subscales. Correlations between HADS and the most commonly used self-rating 
instruments are, in general, high (at average between .60 and .70) (191), and the total HADS-
score (HADS-T) tends to have slightly higher correlations than the two subscales. For 
example, the HADS-T correlated .71, .73, and .75 with the STAI-T (anxiety), the BDI 
(depression), and the GHQ-12 (anxiety and depression).
Though there was good agreement concerning the internal consistency and two-factor solution 
of HADS across different settings, the results regarding the case-finder abilities were more 
inconsistent. First, in the three studies from primary care settings, the optimal cut-off values 
varied from 3 to 9 points on HADS-A and 6 to 8 points on HADS-D (192-194). Second, only 
one population-based study had included a structured diagnostic interview and could be 
included in this review (195). Finally, a study of medical patients and psychiatric patient 
samples by Spinhoven et al (196) found good sensitivity, yet considerably lower specificity 
and PPVs than reported in most other studies. Spinhoven et al (196) recommended to use the 
total HADS score (HADS-T) to screen for any psychiatric disorder in samples with a high 
base-rate of psychiatric disorders, rather than using the HADS subscales to discriminate 
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between anxiety and depression. In contrast, Hamer et al (197) demonstrated good case-finder 
performance of the HADS in psychiatric in-patients who had been referred to a deliberate 
self-harm team. However, only the ability of HADS-D to detect major depression and 
dysthymia was tested in this study. Recently, a Swedish primary care study (52) compared  
HADS-A and HADS-D scores with two self-rating scales meeting diagnostic criteria for GAD 
and MDE, respectively, and confirmed that optimal cut-off for both HADS subscales was 8 or 
above.
The characteristics and performance of self-report instruments and diagnostic tests, by and 
large, depend on sample characteristics (e.g. different base-rate of the condition of interest) 
and the external validity criterion used (e.g. DSM-IV or ICD-10). The studies of psychiatric 
patients (196;198) were, along with the community study (195), the only papers in the review 
that had validated HADS against the ICD diagnostic system instead of the DSM. It is unclear 
what impact this methodological difference had on the result. The literature review showed 
good agreement regarding the recommended HADS cut-off across the various studies; and the 
few discrepancies that were found (193;194) could be explained by dissimilar cultural 
settings. Based on the literature, a caseness of depression and anxiety was defined by a score 
of  8 on each subscale, and co-morbid anxiety and depression at HADS-T  19 points. 
HADS-A and HADS-D scores were also examined as a continuous measure in Paper I.  
In sum, HADS is a brief self-rating scale (14 items) suitable for screening purposes. It covers 
central psychological dimensions of both anxiety and depression, and it was designed to 
minimize the risk of identifying depression and anxiety due to symptoms of somatic illnesses. 
These were the main reasons for choosing this instrument in a general health study, the 
HUNT 2.
4.3.2 The Anxiety Depression Index – ADI (Paper I) 
HADS was only available in HUNT 2. But four questions concerning anxiety and depression 
symptoms that addressed issues of nervousness, calmness, mood, and vitality were included in 
both HUNT 1 and HUNT 2 (Appendix A 1.2 and A 2.2).
Since these four questions could not differentiate sufficiently between anxiety and depression, 
a compound index (ADI, Anxiety and Depression Index) based on these four variables was 
validated against HADS in the total HUNT 2 population. Cut-off was set at the 88th percentile 
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in the total population sample in HUNT in order to quantitatively match the HADS cut-off. 
This provided an acceptable indicator as to whether psychiatric caseness was present in 
HUNT 1 (Sensitivity 0.51; specificity =0.93; Cohen`s kappa = 0.55). ADI, therefore, 
constituted our baseline measure of anxiety and depression in HUNT 1, and was used to 
adjust for mental distress level at baseline in cases and controls in Paper I. 
4.3.3 Sociodemographic variables (All papers) 
Information concerning age, place of residence, and marital status were obtained from the 
National Population Registry; all other variables were self-reported in Q1 and Q2. Participants 
that were not registered as married and did not report having a cohabitant or live-in partner 
were labelled as living alone. Educational level was divided into three subgroups: low 
(elementary school, 7-10 years), middle (secondary school, middle school, and senior high 
school), and high (four or more years at a college or university). In the analyses, the highest 
level (university level) was compared to low and middle level education. Persons who 
reported that they had a current job, and did not receive any kind of financial social services 
or pension were classified as employed. Since most employees receive retirement pension 
from the age of 67 years in Norway, the prevalence of disability pension was only examined 
in those 66 years of age and younger.
4.3.4 Lifestyle characteristics (All papers) 
Increased alcohol intake was defined according to frequency of intake in the last month in 
HUNT I (Paper I) and according to yearly intake of pure alcohol in HUNT 2. In Paper II, the 
cut-off was at the 97th percentile (> 660 cl in HUNT 2), and in Paper III, it was at the 95th 
percentile (> 548 cl). In retrospect, these cut-off values were probably too high because of the 
relatively high prevalence of alcohol abuse in the Norwegian population (58) and the 
relatively small samples in the IDANT study. In Paper IV, cut-off was, therefore, set at the 
75th percentile (> 210 cl). In HUNT 1, those who reported using leisure time for physical
exercise once or more often a week were defined as exercisers (frequency only). In HUNT 2, 
the dimension of intensity was taken into consideration; participants who reported three hours 
or more of moderate leisure time physical activity and/or one hour or more of hard physical 
activity (sweating/out of breath) weekly in the last year were labelled as physically active. 
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4.3.5 Clinical measurements (Paper I) 
Obesity was defined as a Body Mass Index (BMI - weight in kg/height in m2) > 30, and 
represents a commonly used cut-off (104;199). The possible influences of arterial 
hypertension at baseline on anxiety and depression post-MI were tested in separate models for 
diastolic (> 90 mmHg) and systolic hypertension (> 160 mmHg). 2,283 participants (9.6%) 
who were taking antihypertensive medication in HUNT 1 were excluded in these analyses. 
Specially trained nurses measured blood pressure at the beginning of the physical 
examination, using a Dinamap 845XT (Criticon) based on oscillometry.  
4.3.6 Clinical characteristics (All papers) 
The presence of  1 of the following conditions was defined as chronic physical illness: self-
report of diagnosis of asthma, myocardial infarction, angina pectoris, stroke, diabetes, or 
cancer. A follow-up study after HUNT 1 showed that self-report of diabetes showed 
concordance with the medical files of the general practitioners in more than 95% of the cases 
(200). Participants with chronic pain were those who had reported thath a doctor had 
diagnosed rheumatism/degenerative joint disease, musculoskeletal pain, and/or headache 
lasting for more than one year. To assess lifetime psychiatric help-seeking in HUNT 2 (Papers 
III and IV), the participants were asked, “Have you ever had mental disorders for which you 
sought help?” Lifetime major depressive episode (MDE) in HUNT 2 (Papers III and IV) was 
defined as probable in cases self-reporting three or more out of five listed DSM-IV criteria 
phrased as, “During your life, have there ever been periods of 2 consecutive weeks or more 
when you (yes/no): 1) Felt depressed, sad, and down? (obligatory criterion); 2) Had problems 
with your appetite or ate too little? 3) Were troubled by loss of energy or lack of spare 
energy? 4) Really reproached yourself and felt worthless? 5) Had problems in concentrating 
or difficulty in making decisions?” 
4.3.7 Instruments used in the IDANT study and the follow-up study 
Attitude Toward Psychiatry – ATP (Paper II) 
The attitude toward psychiatry and willingness to take on psychiatric examination and 
treatment varies among GPs (168); and this would probably affect their attitudes towards the 
IDANT. Therefore, the 30 item Likert-type Attitudes Toward Psychiatry Scale (ATP-30) was 
filled in by the GPs in the county prior to HUNT 2. The ATP-30 was originally developed to 
measure medical students' attitudes toward psychiatry (201-203). The items of the ATP-30 
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address attitudes regarding psychotherapy, psychiatric treatment in general, and the scientific 
basis of psychiatry. A total score of 90 points indicates a neutral attitude towards psychiatry, 
whereas higher scores indicate a more positive attitude.  
The Mini International Neuropsychiatric Interview, MINI (Paper IV) 
The Norwegian version of the MINI (46;204) version 5.0 was applied for the diagnoses of 
DSM-IV Axis I disorders in the 152 interviews in the follow-up study. The MINI covers 23 
current and lifetime axis I disorders, it has been translated into many languages, and has been 
used in many multi-centre studies.  
MINI has shown good concordance with current psychiatric disorders in the SCID-I interview 
for most mild and moderate psychopathology (e.g. 0.84 for major depressive episode and 
between 0.64 and 0.76 for most anxiety disorders and alcohol abuse), but poor concordance 
for current psychotic disorder (0.53), drug abuse (0.43), and social phobia (0.51). Kappa 
values for inter-rater reliability were all above 0.75, and 16 out of 23 values were above 0.90. 
For test-retest reliability kappa values were somewhat lower, still 14 out of 23 values were 
above 0.75.(205). The MINI has skipping rules if obligatory criteria are not met. Dimensional 
criteria scores for various disorders, therefore, cannot be established with the MINI. The 
rating of each criterion on the MINI is present or absent, and the number of positive criteria is 
summarized as to conclude if a disorder is present or not.
The IOWA personality disorder screen (IPDS, Paper IV) 
The IPDS (206) was developed in order to offer a brief and sensitive personality disorder 
screen for both research and clinical settings. It was used as a supplement to the MINI in the 
follow-up study. Validation in a non-psychotic psychiatric patient sample yielded a sensitivity 
of 92% and specificity of 79%.
4.4 Data management
The HUNT 1 and HUNT 2 databases are extensive, containing several hundred self-reported 
variables and results from clinical tests from more than 60,000 participants. Data quality 
control was performed by SHUS and HUNT Research Centre. Storage and distribution of data 
files to researchers was done according to the regulations from the Data Inspectorate, Norway. 
The 11-digit person number of each participant was replaced by a reference number unique 
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for every research project in HUNT, in order to provide anonymity and avoid linkage of data 
files between different projects.
In the statistical analysis, missing data on self-reported variables were generally excluded, 
assuming that the individual did not know what to answer. Yet, in some variables where the 
person was assumed to know what to answer, the missing value was coded as a negative 
answer (e.g. not answering the question, “Have you ever had a myocardial infarction?”). 
Missing data on HADS were substituted if five or six items were completed on HADS-D or 
HADS-A by scores based on substitutions with the sum of completed items multiplied with 
7/5 or 7/6, respectively. In the total HUNT 2 population, 61,494 (93.0 %) individuals met this 
criterion.
4.4.1 Statistical analysis
All statistical analyses were done by using SPSS (Statistical Package for Social Sciences) 
versions 11 and 12. Statistical significance was set at p <.05 and two-sided tests were used 
where applicable.
4.4.1.2 Descriptive statistics and univariate analysis 
Chi-square statistics were used to examine differences between group frequencies (All 
Papers), whereas Fisher’s exact test was used in Paper II due to few observations. 
Univariate analyses of variance (UNIANOVA) were used in order to analyse differences 
between group means and estimation of confidence intervals (Papers I, II, and IV). 
Paired-sample T-tests were used to examine mean HADS symptom scores in three study 
groups in HUNT 2 and at follow-up after four years (Paper IV). Cohen’s d (effect size) was 
used to estimate the effect size of symptom change for each group.  
Sensitivity, specificity, and PPV of the HADS-T for detecting mental disorders with the MINI 
as gold standard were calculated using standard two by two tables. 
4.4.1.3 Multivariate analysis 
The advantage of multivariate models is that they give the opportunity to control for variables 
which potentially confound the association of interest. In general, these covariates were 
organised thematically in blocks: demographic characteristics, lifestyle factors, and clinical 
characteristics. Each block was entered separately into the model using forced entry; the last 
step of the analysis was adjusted for all variables.  
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Binary logistic regression analysis was utilised to estimate the odds ratio (OR) for anxiety and 
depression post-MI compared to controls without CHD, as well as for interaction tests (Paper 
I). To assess time trends in the risk for post-MI anxiety and depression, time since MI was 
entered as a continuous variable (0-5 years) to the logistic regression model. Logistic 
regression was also used to predict non-response at follow-up in the IDANT study (Paper IV) 
using forced entry for the independent variables included in the model.   
A hierarchical linear regression model was used to compare the impact of the first MI with 
impact of pre-MI characteristics on long term anxiety and depression (Paper I). Due to 
important gender differences both in CHD and in coping strategies in general, all multivariate 
analyses were performed stratified in terms of gender. The same technique was used for 
interaction tests to examine whether protective factors and risk factors were specific to post-
MI for anxiety and depression, or if they have validity in the general population. Linear 
regression models require normal distribution of the outcome variable (HADS). HADS did 
not satisfy these conditions and were ln transformed before the analyses. 
For survival analyses, Cox`s proportional hazards regression model (207) was used to obtain 
the hazard ratios (HR) for mortality in the two psychiatric risk groups compared to the 
reference group (Paper II). This is a robust mathematical model used to analyse data where 
survival time is available. To assess a possible trend in the mortality risk with increasing 
symptom severity, the HADS-T score was entered into a separate Cox regression model as a 
continuous variable. Cox regression analyses were also carried out to test for possible 
biological interactions of age, gender, smoking habits, and physical illness with HADS-T 
score in the prediction of mortality. In these analyses, HADS-T score was entered as a 
continuous variable and tested with each of the other factors separately.  
4.4.2 Linkage with Population Registries
The Death Registry, Statistics Norway, records the date and cause of all deaths in Norway 
according to the WHO standards for classification (30). After obtaining approval from the 
National Data Inspectorate, this information was merged by Statistics Norway with data files 
of the participants included in the studies (Paper III).  
4.4.3 Ethics 
The Norwegian Data Inspectorate and the Regional Committee for Ethics in Medical 
Research approved the protocols for HUNT 1, HUNT 2, and for the follow-up study. Each 
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participant in HUNT 2 was asked to sign a document of personal consent, which stated that 
his or her data can be used for medical research (Appendix 4.2 and 4.3). Only participants 
who gave informed consent in HUNT 2 were contacted in the follow-up study. 
Participants were also given the opportunity to withdraw the information they had provided 
and/or their informed consent at any time. Specific ethical issues concerning the notification 
of possible mental health problems and invitation of a psychiatric high risk group to an 
intervention study (IDANT) will be further addressed in the discussion of results. 
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5. RESULTS   
5.1 Review of Paper I  
Anxiety and depression following myocardial infarction; gender differences in a five 
year prospective study. Bjerkeset O, Nordahl HM, Mykletun A, Holmen J, Dahl AA.  
Journal of Psychosomatic Research 2005; 55(2): 153-161.  
Background and aims: To examine the impact of the first myocardial infarction (MI) and the 
relative influence of pre-existing confounding factors on anxiety and depression in the 
following five years.
Methods: Gender-stratified prospective study of 23,693 participants 35-79 years of age, who 
were free of angina pectoris, MI, and cerebrovascular diseases in HUNT 1 (1984-86). 
Outcome measure was the Hospital Anxiety and Depression rating Scale (HADS) in HUNT 2 
(1995-97).
Results: 512 subjects (2.2%) experienced their first MI in the last five years before attending 
HUNT 2 (mean time 2.6 years). Among these, women showed an increased risk for both 
anxiety (adj. OR 2.47, p=.018) and depression (adj. OR 2.45, p=.020) in the first two years 
post-MI compared to the reference group; this was followed by a significant reduction of 
these symptoms after the two-year mark. Trend tests confirmed this risk reduction over time 
in women. In contrast, the risk for depression, but not anxiety, was increased after two years 
post-MI in men (adj. OR 1.61, p=.003). Many of the baseline risk factors for anxiety and 
depression in HUNT 2 had stronger impact than the MI per se, and these risk factors were the 
same in the MI group and in the reference group. Anxiety and depression caseness in HUNT 1 
was by far the strongest predictor for anxiety and depression in HUNT 2 in both genders. 
Daily smoking and obesity (BMI > 30) at baseline predicted depression in both genders, while 
excess alcohol intake increased the risk for depression in men and anxiety in women at 
follow-up. Completed high school or university level education and employment protected 
both women and men from anxiety and depression in HUNT 2. Weekly exercise reduced the 
risk for depression in both genders.
Conclusion: There is considerable risk for anxiety and depression post-MI, yet the symptom 
course might be gender-specific and could require different clinical approaches in men and 
women. General risk factors for anxiety and depression were the same in cases and controls. 
38
5.2 Review of Paper II 
Feasibility of psychiatric screening and intervention in the HUNT population study.
Bjerkeset O, Dahl AA , Stordal E, Dahl NH, Krüger MB, Linaker O. 
Social Psychiatry and Psychiatric Epidemiology, published online January 19th 2006.
Background and aims: To investigate feasibility, response, and consequences of mental health 
screening and intervention in a population study setting.
Methods: In the Intervention study against Depression and Anxiety in Nord-Trøndelag 
(IDANT), all GPs and psychiatric nurses were invited to a psychiatric educational programme 
prior to HUNT 2 (1995-97). All participants scoring 25 points or above (99th percentile, n = 
654) on the Hospital Anxiety and Depression rating Scale (HADS) in HUNT 2 were defined 
as the Psychiatric High Risk Group (PHRG) and received a written notification with a request 
to see their GP and to participate in the IDANT.
Results: In total, 422 (64%) baseline forms could be retrieved in the IDANT. Only 177 of the 
forms (27%) were returned by the GPs, the rest had to be collected by the GPs’ secretary (13 
forms, 2%) or doctors from the two psychiatric clinics in the County (232 forms, 35%).The 
last 232 forms (36%) were not possible to retrieve because essential information was missing 
in the patients’ records (20%) or because the GP refused to cooperate (16%).  And in the 
collected baseline forms several variables had high rates of missing values.  
Three out of four participants in the PHRG were already recognised by their GPs as patients 
with mental disorders prior to the IDANT. Despite few negative reactions to the notification 
letter (4 %) and to the invitation to IDANT (14%), only half of the subjects in the IG accepted 
the invitation to the study. The Attitude Towards Psychiatry questionnaire (ATP-30) 
confirmed a generally positive view of psychiatry and psychiatric treatment among the GPs in 
the county (mean score 107 points, SD 17.8). For 64% of the respondents in the PHRG, the 
GPs started new treatment, revised ongoing treatment, or referred the participant to the 
psychiatric outpatient clinic as a consequence of the IDANT.
Conclusions: Although attitude towards psychiatry among GPs and participants was generally 
positive, the response to the IDANT study was inadequate. An extremely high cut-off score, 
as was used in the IDANT study (25 points), offers the possibility to re-evaluate diagnosis and 
ongoing psychiatric treatment rather than detect new cases.
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5.3 Review of Paper III 
Mortality in relation to self-reported mixed anxiety and depression symptoms – the 
HUNT population study. Bjerkeset O, Mykletun A, Dahl AA, Linaker O. 
Nordic Journal of Psychiatry, accepted for publication January 17th 2006. 
Background and aims: Though there is a great overlap between anxiety and depression, 
excess mortality has mostly been studied for diagnostic categories of each condition 
separately. Our aim was to study the association between self-reported mixed anxiety and 
depression symptom level and mortality in the general population.  
Methods:  In the HUNT 2 population study, 2,624 individuals with different symptom levels 
on the total Hospital Anxiety and Depression rating Scale (HADS-T) were divided into three 
groups: 0-19 points (reference group), 19-24 points (Psychiatric Risk Group, PRG), and 25 
points or above (Psychiatric High Risk Group, PHRG).
Results: 114 deaths (4.3%) occurred during 4.5 years of observation. Of these, all seven 
suicides (6%) were predicted by the conventional HADS-T cut-off (>19 points) at baseline. 
Only the PHRG had increased total mortality risk after adjustment for all relevant 
confounding factors (Hazard Ratio 1.59, p=.043), yet trend tests supported a dose-response 
relationship between continuously increasing HADS-T score and increasing total mortality 
across the three groups (p for trend = .02). Excess mortality was similar to estimates from 
mortality studies of diagnostic categories of anxiety and depression. The relevance of the 
confounding factors established in the literature was, except for high alcohol consumption, 
confirmed by our study.  
Conclusion: Our sample is limited and the findings therefore tentative, yet there was a 
positive correlation between HADS-T symptom level and total mortality risk in a 4.5 year 
perspective. As shown in previous studies, excess mortality in the anxious and depressed was 
confounded by male gender, somatic diseases and daily smoking. Conclusions regarding the 
association between symptom level and suicide risk cannot be made. It remains unclear which 
is the more precise predictor for early death, self-reported symptoms or clinical interview 
obtained mental disorder(s). 
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5.4 Review of Paper IV 
Four year stability of syndromal and sub-syndromal anxiety and depression symptoms 
in the general population: The HUNT study.
Bjerkeset O, Nordahl HM, Larsson S, Dahl AA, Linaker O. 
Psychological Medicine, submitted February 23rd 2006.
Background and aims: Both syndromal and sub-syndromal symptoms of anxiety and 
depression are associated with residual symptoms and a recurrent or chronic course. 
Although the percentage of persons at each symptom level seems to be rather constant 
over time, individual symptom fluctuation between levels has been considerable. Our 
aim was to study stability and change in self-rated anxiety and depression symptom 
levels in a large general population sample.  
Methods: Three groups (N=2,616) with total score on the Hospital Anxiety and 
Depression rating scale (HADS-T) less than 19 points (N=1,308), 19 to 24 points 
(N=654), and 25 or above (N=654) in HUNT 2 were selected in HUNT 2 and 
followed up after four years. In addition, a random sample (N=152) of those at the 
highest symptom level at baseline was evaluated with the Mini International 
Neuropsychiatric Interview (MINI) at follow-up.
Results: At follow-up, 1,326 individuals (53.0%) participated and had valid HADS 
scores. Unfavourable sociodemographic characteristics and lifestyle factors, and the 
prevalence of life-time mental health problems, were highly associated with 
increasing HADS-T levels in HUNT 2. Self-rated mixed anxiety and depression 
symptoms followed similar longitudinal patterns as described for diagnostic levels 
found previously. From the lowest symptom level at baseline, 22% had reached 
HADS-T caseness level (19 points) or above at follow-up. HADS-T caseness at 
baseline predicted a chronic or recurrent symptom course in 74%, and HADS-T > 25 
at baseline predicted current mental disorder(s) in 72% at follow-up four years later.
Conclusion: HADS-T caseness (> 19 points) is a reliable predictor for high, long-term 
symptom stability in the general population, and indicates need for further psychiatric 
assessment and follow-up. Psychiatric morbidity is shared by many persons in the 
general population, and it is therefore more population initiatives and self-help 
strategies might be in order.  
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6. GENERAL DISCUSSION 
In this dissertation, descriptive and analytical epidemiological methods as well as clinical 
methods were used in prospective studies of anxiety and depression in different samples from 
HUNT. The observed associations in our studies may have also been influenced by alternative 
factors that require further discussion. Sections 6.1.1-6.1.4 will address the methodological 
challenges within the HUNT study (internal validity): the role of chance, limitations in design, 
selection bias, information bias, and confounding factors. In section 6.1.5 we will discuss the 
implications for generalising the results to other populations and settings (external validity).
 6.1 Methodological considerations 
6.1.1 The role of chance 
A general assumption in epidemiological studies is that we can draw conclusions for the total 
population based on the evaluation of a sample of that population. Since sample size is the 
major determinant of the degree to which chance affects the findings in a study (208), some 
findings from Papers III and IV (the IDANT study) must be considered tentative. This 
especially applies to the study of rare conditions and events (e.g. suicide) as their prevalence 
often shows great random variation in different sub samples from a total population. Among 
hundreds of variables available in HUNT, we only included exposure variables known or 
assumed to be causally related to the outcome of interest. Together with adjusted multivariate 
analysis this procedure reduces the likelihood of reporting significant associations by pure 
chance.
 6.1.2 Study designs 
Linkage between data sets from HUNT 1 (1984-86), HUNT 2 (1995-97), and the follow-up 
survey (2000) coupled with register data offered unique possibilities for prospective research 
in many fields. At the same time, several common limitations should be taken into 
consideration.
The long time lag between the HUNT 1 and HUNT 2 (Paper I) gave little opportunity to 
adjust for potentially important life events in the follow-up period that might have influenced 
the outcomes of interest. If these events were not randomly distributed between cases and 
controls, which is likely, it could lead to under- or overestimation of the influence of the 
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baseline exposure variables on anxiety and depression in HUNT. Though a high rate of loss to 
follow-up could be expected when the studies are 10 years apart, 31,283 (84.1%) of those 
eligible for both HUNT 1 and HUNT 2 in this particular age group attended both studies.
An advantage of this design, however, was the opportunity to adjust for important 
confounding factors at baseline (Papers I and III), which has long been neglected in 
psychiatric epidemiology. The accessibility of a reference group from the same study 
population makes estimation of effect size of the outcome more reliable than in most clinical 
studies.
The HADS was only available in HUNT 2, and, therefore, the four-item ADI (described in 
4.3.2) was used as a proxy for the HADS in HUNT I (Paper I). Though we found the 
psychometric properties of the ADI adequate for adjustment for mental distress at baseline 
and definition of caseness, it does not discriminate sufficiently between anxiety and 
depression, and as such, we cannot directly compare the anxiety and depression level in 
HUNT 1 and HUNT 2.   
The IDANT study was designed by clinicians in order to identify and help those with the 
assumed highest suicide risk in the population sample (HADS-T score > 99th percentile). This 
is a noble approach, yet from an epidemiological point of view subpopulations at the very end 
of the distribution on a symptom scale yield little information about the widespread mental 
health problems of the general population (209). It is also given that the individuals above the 
99th percentile are bound to experience symptom reduction at follow-up (Paper IV) due to 
regression towards the mean (RTM); this makes the interpretation of change in the HADS 
symptom score difficult. Even if a RCT had been allowed in IDANT, a more frequent 
outcome than suicide would have been necessary to prove efficacy (e.g. referral rates to 
psychiatric specialist service, help-seeking in primary care, or perhaps prevalence of sick-
leave due to common mental disorders).
The variable length of delay between the HADS screening in HUNT 2 and further assessment 
at the GPs’ offices (3-11 weeks) in IDANT brings about a questionable association between 
inclusion criteria (HADS-T score) and the GPs’ findings (Paper II).
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6.1.3 Selection bias in HUNT 1 and HUNT 2 
When the association between the two factors to be examined is different in the participants 
and the non-participants, the selection of participants has resulted in a systematic error, a 
selection bias (210).
While HUNT 1 showed a high overall attendance rate (88.1%), the rate was lower, though 
still acceptable, in HUNT 2 (71.2%). However, participation in HUNT was not evenly 
distributed in the population. The younger and older age groups in both genders, and men in 
all age groups, were under-represented in both studies (figure 6). 
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Figure 6: Participation rates in both genders in different age groups in HUNT 1 and HUNT 2.
A telephone survey among 685 randomly selected non-responders after HUNT 2 showed that 
the age adjusted prevalence of chronic somatic diseases and the use of cardiovascular and 
lung medication was the same as in the participants (211). Non-participants were primarily
men in the younger age groups who were too busy to participate or studied or worked outside 
the county and elderly individuals of both genders with poor health (Table 2).
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Table 2. The non-responder study. Reasons for not attending HUNT 2 in 326 (47.6%) out of 
685 randomly selected non-responders in HUNT 2. 
20-44 years 45-69 years >70 years Total
Reasons for non-participation n (%) n (%) n (%) n (%) 
Follow-up by physician/hospital 11 (5.8) 10 (13.7) 8 (28.6) 29 (10.0)
Long waiting at screening site 8 (4.2) 4 (5.5) 0 (0.0) 12 (4.1)
Busy at work 42 (22.1) 18 (24.7) 2 (7.1) 62 (21.3)
Immobilised by disease 16 (8.4) 6 (8.2) 6 (21.4) 28 (9.6)
Moved, or long time absent 59 (31.1) 10 (13.7) 6 (21.4) 75 (25.8)
Forgot/no reason/other 36 (18.9) 21 (28.8) 3 (10.7) 60 (20.6)
Unnecessary/unwilling 18 (9.5) 4 (5.5) 3 (10.7) 25 (8.6)
Total 190 (100.0) 73 (100.0) 28 (99.9) 291 (100.0)
In general, the proportion of missing data increased in older age in HUNT. The rate of valid 
HADS-T scores in participants aged 69 or younger was 97% in both genders in HUNT 2. Yet, 
this rate was significantly lower (78.3%, p<.001) in those aged 70 and above; and elderly men 
had a higher response rate on HADS-T compared to women (81.8 % and 75.6%, respectively, 
p<.001).
The literature shows that those with mental problems and mental disorders are under-
represented in population studies (212-214). Participants in HUNT 1 who did not attend 
HUNT 2 (Paper I) had less education and higher ADI scores. They also had significantly 
more unfavourable sociodemographic characteristics and health behaviours as well as poorer 
somatic health compared to those who attended both surveys (215). 
In sum, population surveys (including HUNT 2 and the papers in this dissertation) generally 
underestimate the prevalence, severity, and consequences of mental illness. Due to sampling 
in HUNT (only those > 20 years) and low participation in the elderly (Figure 6), information 
concerning the onset of anxiety and depression in early adulthood and the consequences of the 
same disorders in citizens above 70 years is limited in this study. For the same reasons, data 
reported in those between 40 and 70 years yield better validity in our studies.
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6.1.4 Selection bias in the IDANT sub-study in HUNT 2 
The main focus on physical health issues in HUNT might have increased the participation 
among those with stigma against mental health problems (216) and those unaware of their 
mental health problems (e.g. psychosomatic problems) (5;217). The fact that the IDANT 
follow-up study four years after HUNT 2 was presented as a mental health study and yielded 
considerably lower response rates than HUNT 2 supports this assumption.  
The skewed sampling towards high HADS-T scorers (PRG and PHRG) compared to controls 
in IDANT combined with a low participation at follow-up certainly made selection bias an 
important consideration for the interpretation of the results in Papers II-IV. In general, highly 
selected groups (PHRG) often show less variance in their characteristics compared to a 
general population sample (reference group), and are, therefore, less vulnerable to low 
participation rates. Because of this, we suggest that results regarding participants in PRG and 
PHRG might be generalised more easily than for the reference group (Papers II-IV). This is in 
agreement with the PART study by Lundberg et al (213), which found that study participants 
and non-participants with mental disorders in the general population shared clinical and 
sociodemographic characteristics.  
However, the under representation of people with mental disorders in population surveys 
(212) confine the possibilities for individual risk strategies (Paper III), and particularly suicide 
prevention. Only 29 (52%) of the 56 inhabitants of Nord-Trøndelag who committed suicide in 
the first five years after HUNT 2 took part in the study.  
6.1.5 Information bias 
Information bias (recall and observer bias) can be defined as a flaw in measuring exposures or 
outcome data that results in different quality (accuracy) of information between comparison 
groups (218).
In HUNT, the risk for recall bias was reduced or removed because the same information was 
self-reported in both cases and controls prior to the onset of interest (Papers I and III). In 
Papers II and IV, however, the fact that participants, GPs, and interviewers knew that all 
participants, being in the PHRG, had scored very high HADS-T scores in HUNT 2 might 
have led to overestimation of mental health symptoms and related problems. Though one of 
the purposes of a structured interview is to minimize information bias, recall bias in 
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participants and observer bias in the interviewers could also have led to artificially high rates 
of mental disorders in MINI in Paper IV. Enns et al (219) found that age, educational level, 
depressive subtype, high neuroticism, and low extraversion predicted higher self-rated scores 
relative to observer ratings. These variables also demonstrated greater ability to explain 
discrepancies between self-ratings and observer ratings of psychological symptoms of 
depression, such as anhedonia, compared to somatic/functional symptoms of depression. 
Psychiatrists see anxiety and depression as being more distinct than patients report (220). This 
taken into consideration, supports the combination of these two methods to better assess the 
severity and need for treatment.  
A fundamental issue in psychiatry is the validity of a diagnosis. For functional mental 
disorders there are no trait- or state diagnostic markers, as are frequently found in somatic 
medicine. Spitzer (1), therefore, laid down certain requirements for valid psychiatric 
diagnoses in the absence of specific tests for diagnostic validity, which he called the LEAD 
standard (obviously hinting at the lack of gold standard for functional mental disorders). The 
LEAD acronym was derived from Longitudinal observation made by clinical Experts who 
have All relevant Data for making a Diagnosis. In clinical settings, these requirements are 
often met. However, individuals examined in most psychiatric epidemiological investigation 
are seen only once for one to three hours by an interviewer who usually has no clinical 
expertise in psychiatry. And as such, diagnostic research in psychiatric epidemiology is rather 
far from the LEAD standard of validity. 
It has been criticised that HUNT is based on self-report of physical illnesses. However, the 
agreement between self-report and medical records has proven to be substantial (kappa 0.73-
0.80) in studies of cardiovascular diseases, hypertension, angina pectoris, myocardial 
infarction, cancer, and diabetes. Lower agreement was found for diseases with less established 
diagnostic criteria (e.g. lower back disorder, claudication, and arthrosis) (221-223). However, 
self-report of physical health variables is often sensitive to the level of anxiety or depression. 
While anxiety might cause a stronger awareness, sensitivity, and worry about somatic 
symptoms, the dominating pessimistic cognitions in the depressed could have resulted in an 
artificially strong association between somatic health problems and mental symptoms, 
especially in the PRG and PHRG (224;225).
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6.1.5.1 Assessment and categorisation of self-reported anxiety and depression
The HADS score was only operationalised as a continuous variable in Paper I, while cut-off 
values (dichotomisation or trichotomisation) were used in all papers to define inclusion 
criteria and/or outcome caseness level. A dichotomous measure certainly makes less use of 
the available information in the dataset than a continuous approach, and can, therefore, be 
considered a sort of information bias (e.g. labelling participants scoring 0-18 as healthy and 
all scoring 19 or above as cases in Paper IV). Nevertheless, models for screening, diagnostic 
purposes, and decision making often require the usage of cut-off values and thresholds. Two 
or more cut-off levels (Papers II and IV) represent something in between these two 
techniques, and, therefore, utilise more of the information and offer the possibility to analyse 
trends and gradients. New research clearly suggests that a combination of self-report and 
diagnostic interview is necessary in order to provide the clinician with enough information to 
make adequate treatment decisions for patients with anxiety and depression (47;48;219;226). 
In this setting, we suggest that using a continuous HADS score would be more appropriate.
6.1.6 Confounding factors
A confounder (from the Latin confundere, to mix together) is an independent risk factor for 
the outcome and simultaneously associated with the exposure, but should not be an 
intermediate step in the causal pathway between exposure and outcome (Figure 7) (208).
The previously identified confounding factors for post-MI anxiety and depression and for 
excess mortality in mental disorders (sociodemographic, psychosocial, lifestyle, and clinical 
characteristics) were available in the HUNT dataset; they showed similar associations with 
self-rated anxiety and depression (Papers I and II). A consequence of choosing gender 
stratification instead of adjusting for gender to avoid confounding in Paper I was not being 
able to directly compare the outcome in women and men. These issues will be addressed in 
more detail in the discussion of each paper. 
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Figure 7. Mechanisms of association (statistical dependence) between exposure and outcome.
6.1.7 External validity (generalizability)
If an observed association is considered internally valid, a subsequent judgment of the extent 
to which results are applicable to other populations should follow (external validity, 
generalizability).
6.1.7.1 The construct of anxiety and depression in HADS 
While the HADS was already well established as a screening questionnaire before HUNT 2, a 
major concern was the external (diagnostic) validity of the construct of anxiety and depression 
measured in this instrument. The last decade has offered extensive research on the HADS
showing acceptable or good case finder abilities in various cultural and health care settings
(191;227-231). Recently, Tambs (Personal communication, 2004) showed that the main
problem with the HADS-subscales as casefinders in the general population was the high 
proportion of false-positive cases if sensitivity and specificity were set at .80. It is, therefore, 
likely that information collected by HADS in Paper I could have systematically over-rated 
caseness compared to the DSM-IV defined threshold for anxiety disorders and depressions. 
However, Tambs demonstrated that the proportion of false negatives was quite low, and it is
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independently associated with
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Table 3. Sensitivity and specificity of HADS-D: consequences for diagnostic classification* 
Depressed in the population: 5% 
Sensitivity: .80 
5% * .80 = 4% are classified as true depressed 
5% * .20 = 1% are classified as healthy 
Healthy in the population: 95% 
Specificity: .80 
95% * .80 = 76% are classified as true healthy 
95% * .20 = 19% are classified as depressed 
Observed depressed: 4% (correctly classified) + 19% (wrongly classified) = 23% 
Observed healthy: 76% (correctly classified) + 1% (wrongly classified) = 77% 
Total: 80% correctly classified, 20% wrongly classified 
*Modified with permission from a slide made by Professor Kristian Tambs, PhD 
The diagnostic performance is to a large extent dependent on the base-rate of mental disorders 
(196), and cannot be judged adequately in our study because of the low number of controls 
(MINI negative) cases in the PHRG. We argue that the construct validity of diagnostic anxiety 
and depression increase with HADS symptom score (232); the extraordinarily high rates of 
mental disorders found in the PHRG support this assumption (Paper IV).  
In conclusion, our results indicate that the HADS measures essential core symptoms of 
anxiety and depression because risk factors, course, and outcomes in our studies were largely 
the same as in diagnostic categories of the same conditions (Papers I, III, and IV). Given the 
good validity across different cultures and health care settings for the HADS, we suggest that 
our results might be generalised to other population settings to the same, or even a greater, 
extent than results from diagnostic studies. In addition, we should consider that observer 
characteristics and observer bias, type of interview, and choice of diagnostic system (DSM or 
ICD) often differ in these studies, and this often influences the results in an unsystematic 
fashion.
Two important characteristics of the HADS-D scale should be pointed out. First, the HADS-D 
score increased linearly with age in HUNT 2(233). Whether these results primarily reflect age 
effects or cohort effects, or both, cannot be answered due to the cross-sectional design in 
HUNT 2. However, this is in agreement with the observation that the anhedonia subtype of 
depression has a later onset than more severe subtypes of depression (81). A review by Jorm 
(15) concluded that the cross sectional relationship between anxiety, depression, and age is 
still controversial. Second, while there is general agreement on an increased risk (often two-
fold) of depressive disorders in women compared to men, mean HADS-D score was the same 
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in both genders in all age groups in HUNT 2 (17). The most important explanatory factor is 
probably that symptoms of anhedonia are more evenly distributed in women and men than 
other symptoms of depression (81;234;235). Also, self-rated symptoms of depression seem to 
show less gender difference than observer-rated diagnostic categories in the same individuals 
(14;236). It might, therefore, be especially important to collect self-report information from 
men because they may not communicate subjective symptoms of depression, e.g. guilt, to 
observers as freely as women.  
6.1.7.2 Other variables 
Epidemiological studies have established a close association between mental disorders and 
substance use disorders (237). This could not be verified cross-sectionally in HUNT 2 when 
studying the relationship between total alcohol intake per year with a cut-off ranging from the 
75th to the 97th percentile and HADS scores (Papers II-IV). One explanation might be that 
self-reported frequency and amount (cl alcohol) of alcohol intake, which were used in our 
analysis, are less sensitive to problematic alcohol use than e.g. cognitive or behavioural 
aspects associated with excessive alcohol use. Diagnostic interviews take into consideration 
both these dimensions. A particularly low attendance among those with alcohol abuse or 
dependence in HUNT could also have explained this finding. However, negative long-term 
consequences of high alcohol consumption (102;238) were confirmed in Paper I, though the 
effects on anxiety and depression were different in men and women in our study. 
Inhabitants of Nord-Trøndelag County have a lower educational level and a lower income 
than average for Norway, which could lead to a higher level of anxiety and depression 
compared to the rest of the country (84-86). However, a recent UK study of 7,659 individuals 
showed that rural residents had slightly better mental health than those settled in non-rural 
areas (239). And there is a predominance of rural areas and lack of large cities in Nord-
Trøndelag. Other characteristics are at the National level for Norway. Since HADS has 
proven great cross-cultural stability, we expect our results to also have considerable validity 
outside Norway.
6.2 Implications of specific results 
6.2.1 Gender differences in post-MI anxiety and depression (Paper I) 
Studies have repeatedly shown that men have less varied , often showing anger and 
aggression after stressful life events, while women tend to approach their problems actively in 
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a pro-social way (18;97-99). As observed in our study, these studies show that women express 
more symptoms of anxiety and depression in the time directly after the stressful event. If 
future studies replicate the gender-specific symptom course of anxiety and depression post-MI 
found in our study, mental health screening and follow-up should be focused on the first two 
years post-MI for women and after two years post-MI for men.  
Though treatment of post-MI depression has proven to be safe and effective, it remains to be 
seen as to whether systematic treatment of post-MI depression and anxiety has the potential to 
also improve cardiac prognosis and reduce mortality (240). Finally, clinicians should keep in 
mind that most pre-existing risk factors for anxiety and depression, and especially previous 
episodes of the same conditions (241), have greater impact on post-MI anxiety and depression 
than the MI per se.
There was a lowering of the diagnostic threshold for MI from ICD-9 (242) to ICD-10 in 1992 
(30). This most likely resulted in an increased incidence, but a decreased mean severity of 
CHD in those included after the introduction of ICD-10. However, psychological reactions 
post-MI have proven to be largely independent of MI severity (89;124;127;243). We do not 
expect that this change of criteria influenced our results in a significant way.
6.2.2 Risk factors for anxiety and depression (Paper I) 
A supplementary finding was that risk factors for self-reported anxiety and depression (HADS 
caseness) much resembled established risk factors for diagnostic categories of the same 
conditions (80;83;84;86). Spijker and co-workers (241) also found that the risk factors for 
persistence and poor outcome in depression were largely the same in the general population 
and in clinical samples.  
Given the low help-seeking in depressed persons in general and the high prevalence of 
depression in cardiac patients, hospitalisation after MI offers a unique chance for detection 
and treatment of common mental disorders. During hospitalisation after MI (and probably 
various other medical conditions), the assessment of relevant pre-existing risk factors for 
anxiety and depression should be combined with a reliable self-report of current anxiety and 
depression symptoms before considering a diagnostic interview and treatment measures 
(48;89;244).
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6.2.3 Mental health screening and intervention (Paper II) 
6.2.3.1 Feasibility and methodical aspects 
Mass mental health screening and intervention have several limitations. In addition to the low 
participation rate among individuals with mental disorders in population studies (212;213), 
we confirmed previously demonstrated recruitment problems both among GPs and 
participants included in follow-up studies of mental health issues (178;179). Last year’s 
extensive review by Mann and co-workers (183) as well as a study by Gunnell and Lewis 
(245) strongly recommended widespread physician education in detection and treatment of 
mental disorders rather than intervention restricted to individuals at particularly high risk. In 
addition, the 2005 Cochrane review by Gilbody et al (246) confirmed results from their 
previous review (180) that routine administration of instruments for anxiety and depression in 
non-mental health settings had little impact on detection, management, and outcome of 
anxiety and depression.  The authors of this review concluded that routine administration of 
psychiatric measures in these settings is costly and does not show improved patient outcome, 
and that this strategy should, therefore, not be used.
In general, population strategies are often more appropriate if the risk is widespread in the 
population, if the disease is common, or if it is hard to identify and control the minority at risk 
(209). The observation that 22% of the reference group had developed HADS caseness at 
follow-up (Paper IV) underlines the importance of considering population strategies.
If one still chooses the individual high risk screening strategy in general population settings, 
perhaps more selective screening for anxiety disorders early in adolescence and screening for 
depression in young adults (25-35 years) would yield better results (59). An extremely high 
cut-off score, as used in the IDANT study, offers the possibility to re-evaluate diagnosis and 
ongoing psychiatric treatment rather than detect new cases. The somewhat lower conventional 
cut-off (HADS-T > 19) would probably be more suited for the detection of new cases. Due to 
the remarkable stability of  symptoms above cut-off on HADS, as pointed out in Paper IV, a 




There was a general decrease in the annual suicide rate in Norway during the 1990ies, 
primarily explained by a reduction in male suicidal deaths (Figure 8). Although the numbers
are small, the same tendency was observed in Nord-Trøndelag.
Figure 8.  Suicides/100.000 inhabitants in Nord-Trøndelag County















In the target population for HUNT 2 (n=94,194), the annual number of suicides varied 
between 7 and 15 from 1995 to 1999. However, since only 51.8% of those who committed
suicide in the first five years after HUNT 2 attended the study, only between 3 and 9 suicides 
were recorded yearly among the 66,140 HUNT 2 participants in the same period.
In order to demonstrate efficacy, a RCT design combined with a more frequent outcome than 
suicide would have been necessary in IDANT. Using, for instance, referral rates to psychiatric 
specialist practise, suicidal ideation, help-seeking in primary care, or prevalence of sick-leave 
due to common mental disorders could have yielded the necessary statistical power to make
conclusions concerning the efficacy of such interventions.
Though previous suicide prevention programmes have often been carried out on a large scale, 
the effects have been poorly documented. The above mentioned studies by Gunnell (245) and 
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Mann (183) showed reduced suicide rates only when widespread physician education was 
combined with practical measures, e.g. restricting access to lethal methods. There has also 
been a variety of more resource saving approaches attempted recently. A simple and 
inexpensive postcard intervention was carried out in a group of 772 individuals who had been 
hospitalised after deliberate self poisoning (8 postcards over 12 months) This reduced 
repetitions of episodes by approximately 50% (247), though the proportion of individual 
repeaters did not change.
6.2.3.3 Ethical considerations
The Norwegian Data Inspectorate and the Regional Committee for Ethics in Medical 
Research approved the protocols for HUNT and for IDANT. Participation in HUNT and 
IDANT was voluntary, and non-attendance was not questioned. All follow up projects after 
HUNT 2 required informed consent from the participants, and this consent could be 
withdrawn without explanation at any time after HUNT 2. The main focus in HUNT was to 
gain new knowledge about the risk factors, prevalence, and outcomes of different health 
conditions and illnesses based on self-reported data combined with national registries. 
However, several projects established cut-off values and strongly requested probable cases to 
contact their GP for follow-up. When this individual high-risk strategy is applied to 
population studies, as in the IDANT study, it is important to consider what possible burden or 
harm the test might inflict in those scoring above cut-off without being mentally ill (false 
positives) and in those showing negative test results despite a mental disorder (false 
negatives). Although the extremely high cut-off level in IDANT reduced the amount of false 
positive cases compared to using the conventional cut-off value, a substantial proportion of 
the PHRG group may have experienced unwanted emotional reactions and unmet intervention 
and treatment needs as a result of the notification and poor follow-up from the GPs.   
6.2.4 Association between anxiety and depression and mortality (Paper III) 
Though coming from a relatively small sample, our results indicate that increasing HADS-T 
symptom levels in HUNT 2 was associated with increased total mortality risk the next 4.5 
years. Excess mortality estimates were comparable to results from diagnostic studies of 
anxiety and depression, and the same covariates mediated this effect: somatic disease, male 
gender, and smoking. This further strengthens the assumption that the HADS covers core 
symptoms of anxiety and depression.  
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The association between the HADS-T score and suicide risk cannot be stated in this study. 
This is due to lack of statistical power and the under-sampling of the reference group (the 
1,308 randomly selected individuals represented only 2.2% of the 58,500 scoring 19 points or 
less on HADS-T). Hence, the prevalence of a rare event like suicide would vary widely in 
different randomly selected sub-samples from this large population. It is likely that both self-
rated symptom severity and diagnostic categories can predict subgroups at increased risk for 
suicide, but do not perform as reliable suicide predictors in individuals.  
6.2.5 Temporal stability of syndromal and sub-syndromal anxiety and depression (Paper IV) 
Mechanisms of symptom stability and symptom change in anxiety and depression are similar 
for patient samples and population samples. Another observation of commonality is that 
considerable help-seeking and treatment does not seem to improve overall outcome.  
In a public health situation where the risk is widespread and the population at risk is 
hard to control (e.g. due to symptom fluctuations), population strategies, in theory, 
have several advantages over an individual high-risk strategy (209). We do know that 
many of the risk factors associated with anxiety and depression are behavioural 
(exercising, smoking, eating habits, etc.). Since these negative health behaviours are 
often socially conditioned, population-wide strategies are often needed in order to 
alter harmful behaviour in a large part of a population. Example of informal self-help 
strategies that have proven effectiveness, are exercise, relaxation training, self-help 
books, and light therapy (248). Particularly in depression, the individual high risk 
strategy has shown discouraging results despite great efforts to improve detection and 
treatment (10;246).    
Anhedonia might not be the most severe of the depressive symptoms, yet is often associated 
with a recurrent or chronic course in depression (249;250). In contrast, functional symptoms 
like sleep and appetite disturbance often show better spontaneous remission and response to 
treatment. When using self-report instruments to assess both psychological and functional 
aspects of anxiety and depression, it is, therefore, crucial to differentiate between total 
symptom reduction (used in most pharmaceutical trials) and specific improvement of 
symptom types, for example, anhedonia or appetite.  
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6.3 Limitations
The results from these studies should be interpreted in light of the following limitations: 
x Non-participants in HUNT 2 (about one third of the adult population) have higher 
levels of anxiety symptoms and depression symptoms and higher suicide risk than 
participants. 
x Anxiety, depression, and somatic illnesses were self-reported in HUNT.
x HADS covers psychological core symptoms of anxiety and depression, yet not the 
functional and somatic symptoms required for a clinical diagnosis according to ICD-
10 and DSM-IV.
x HADS is a sensitive screening tool. It yields a considerable number of false-positive 
cases compared to diagnostic categories of anxiety disorders and depression when the 
conventional cut-off values are applied in the general population. 
x Results from the IDANT study (Paper II) should be interpreted with caution due to the 
low response in this sub-study of HUNT 2.
6.4 Future research
Most previous studies of anxiety and depression in the general population, including HUNT, 
have been cross sectional. Therefore, we will mainly stress the importance of further 
prospective studies of anxiety and depression: 
x Because participation in population studies is falling, it is crucial to make further use 
of data from HUNT 1 and HUNT 2. It is unsure to what extent data from HUNT 3 
(2006-08) will be representative of the general population. 
x A more comprehensive use of available biological markers (e.g. blood samples from 
HUNT 2) and linkage with national register data (mortality, disability pension, etc.) 
would improve the quality of the self-reported data in HUNT. In addition, multi-level 
analysis that includes social and environmental characteristics should be prioritised. 
x HUNT 3 will allow for a direct comparison of HADS scores assessed ten years earlier 
(HUNT 2) in about 45.000 individuals. This design could clarify whether the 
sensitivity to age in HADS-D is primarily caused by actual age effects, cohort effects, 
or both, and to what extent historical effects explain changes in anxiety and depression 
symptom level in the population. 
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x Because anxiety and depression evolve at different ages (59;79), a linkage between 
HUNT and the Young-HUNT database (13 to 19 years) is necessary to better study 
determinants for, and the temporal relationship between, these conditions over the 
lifespan.
x Further development of models of clinical significance and adequate case criteria is 
crucial not only to identify those in need for therapy, but also to avoid unnecessary 
screening and possible harmful treatment in many individuals. Characteristics 
associated with a positive outcome could be reinforced in population strategies. 
x Research on co-morbid cardiac and mental disorders should further explore common 
etiologic pathways, and be used to decide whether treatment of post-MI depression 
and anxiety can reduce mental symptom burden, improve cardiac prognosis, and 
reduce mortality in both genders.
x Future epidemiological studies of large population samples might be able to further 
shed light on the mechanisms of excess mortality in anxiety and depression as both 




Overall, we argue that the HADS measures core symptoms of anxiety and depression, 
and that the HADS-T score showed good internal and clinical validity in a prospective 
population study setting:
x HADS-T symptom level in HUNT 2 reflected the level of previous help-
seeking and self-rated lifetime MDE (retrospective associations), and was 
associated with a wide range of unfavourable sociodemographic variables, 
lifestyle factors, and clinical risk markers known to be associated with 
diagnostic categories of anxiety and depression (cross sectional associations). 
x In a four year perspective, HADS-T caseness (> 19 points) in HUNT 2 
predicted high stability of symptoms and increased total mortality (prospective 
associations). HADS-T > 25 points in HUNT 2 was a strong predictor for 
mental disorder(s) at follow-up (PPV=0.72).
Specific conclusions:
x Underlying risk factors for post-MI anxiety (HADS-A > 8) and depression 
(HADS-D > 8) could be generalised to the general population, and were 
largely the same as for diagnostic categories of these disorders. Risk factors 
were similar in women and men, yet the course of anxiety and depression after 
a stressful event (MI) might differ in women and men compared to controls of 
the same gender.  
x Though invitation to IDANT provoked few negative reactions in HUNT 2 
participants and GPs were reported to have had a positive attitude towards 
psychiatry, response was low for both participants and GPs. Currently, there is 
a prevailing agreement that mental health screening and intervention has 
limited influence on detection, treatment, and course. Hence, using population 
strategies should be re-evaluated. 
x Quantitatively, HADS-T caseness (> 19 points) predicted excess mortality 
similar to diagnostic categories of anxiety and depression. Though all seven 
suicides in IDANT occurred among HADS-T cases, our study lacks statistical 
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power to establish a reliable connection between HADS symptom severity and 
suicide risk.  
x Self-reported anxiety and depression symptoms in the general population show 
similar stability patterns as those reported for diagnostic levels in clinical 
samples. Overall, symptoms were remarkably stable above HADS-T cut-off 
(19 points) over four years. However, there was considerable fluctuation 
across the symptom levels; this suggests that psychiatric morbidity is shared 
by a large number of individuals in the general population.
In sum, the assessment of self-reported symptom severity in HADS takes little effort 
and adds important information to standardised diagnostic classification. We suggest 
that the established caseness (> 19 points) is a reliable indicator of need for further 
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Abstract
Objective: The aim of this study was to examine the impact of
the first myocardial infarction (MI) and the relative influence of
preexisting confounding factors on anxiety and depression in the
following 5 years.Methods: A total of 23,693 participants, 35 – 79
years of age at baseline, attended two population-based prospective
studies in 1984–1986 and in 1995–1997. They underwent physical
examination and self-reported demographic, lifestyle, psychoso-
cial, and medical health characteristics in both surveys. Outcome
measure was the Hospital Anxiety and Depression rating Scale
(HADS). Results: Five hundred twelve participants suffered their
first MI in the last 5 years before follow-up. Women showed an
increased risk for both anxiety and depression in the first 2 years
post-MI, followed by a significant symptom reduction. In contrast,
the risk for depression in men increased after 2 years post-MI.
Anxiety and depression, low educational level, obesity, daily
smoking, and physical inactivity pre-MI significantly predicted a
poor psychiatric outcome at follow-up. Conclusion: Five-year
follow-up after MI revealed gender-specific outcomes of anxiety
and depression not previously described.
D 2005 Elsevier Inc. All rights reserved.
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Introduction
In patients with myocardial infarction (MI), clinical
depression is underdiagnosed [1– 3], associated with poor
medical outcome [4 – 8] and with increased mortality [5–7].
Clinical studies report 17% to 22% prevalence of major
depression during the first year after MI, regularly higher in
women than in men [2,4,6,9 –11]. Previous studies agree
that post-MI anxiety and depression occur unrelated to the
severity of MI and other medical factors [2,11–13]. Both
Frasure-Smith et al. [6] and Schleifer et al. [11] found that
two thirds of patients with major depression in the first
3 months post-MI were still depressed at their 12-month
follow-up. MI patients with an initial minor depression often
developed major depression within the first year [10,11],
and according to Lesperance et al. [2], 50% of those
depressed 1 year post-MI had developed major depression
after discharge from the hospital.
Among the post-MI depressed, 30 – 40% had recurrence
of previous depressive episode(s); this group also showed
poorer medical prognosis and increased mortality compared
with those without previous depression(s) [2,14]. Female
gender and history of pre-MI depression(s) are well-
established risk factors for post-MI depression in the first
12 months, yet the impact of MI demographic, psychoso-
cial, and lifestyle characteristics on post-MI depression are
still disputed [2,3,6,9,12]. Major depression tends to take a
recurrent and chronic course [15], and comorbid anxiety
disorders are common and add to the disease burden and the
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level of impairment [16,17]. Although two studies indicate
that anxiety symptoms are transient in most participants
post-MI [16,17], the association between MI and anxiety
has not been clearly demonstrated.
The majority of previous studies have a selection bias in
regards to the focus on depression, and not anxiety, in
middle-aged male patients in cardiac units, with follow-up
limited to 12 months post-MI. Several questions concerning
long-term outcome, gender differences, and the role of
confounding factors still remain unanswered.
The population studies of Nord-Trbndelag County, Nor-
way, HUNT 1 (1984 –1986) and HUNT 2 (1995–1997),
allowed for the baseline assessment of risk factors pre- and
post-MI examination of anxiety and depression in a
prospective, comparative design.
The following questions were explored in our study:
1. Is the risk for anxiety and depression increased
throughout the first 5 years post-MI?
2. Are there gender differences in the risk for post-MI
anxiety and depression in a 5-year perspective?
3. What is the impact of the actual MI on anxiety and




All citizens residing in the Nord-Trbndelag County
aged 20 years and above received a written invitation to
participate in the first (HUNT 1) and second (HUNT 2)
health studies. A total of 74,997 attended HUNT 1 in
1984 –1986 (88.1%), and 64,194 attended HUNT 2 in
1995 –1997 ( 70.4%; [18] ). In the cohort selected for our
study, 35 to 79 years of age at baseline, 31,283 (84.1%)
of the eligible attended both studies; 25,207 individuals
had no angina pectoris, MI, or cerebrovascular diseases at
HUNT 1 (Fig. 1). According to the Death Registry of
Statistics Norway, 1108 of them (4.4%) died of MI before
the follow-up at HUNT 2. Excluded also were 329
participants (1.3%) who reported their first MI 6 years
or more before HUNT 2 and 77 participants (0.3%) who
did not report the time of their first MI. The remaining
23,181 (92.0%) participants who were still free of MI
at HUNT 2 were defined as the reference group. They
were compared with the group of 512 (2.0%) participants
who had suffered their initial MI less than 6 years be-
fore HUNT 2.
Procedure
Demographic data, medical diagnoses, physical symp-
toms and level of impairment, lifestyle factors, psychoso-
cial characteristics, well-being, and symptoms of anxiety
and depression were obtained by self-report on two ques-
tionnaires in HUNT. In both HUNT 1 and HUNT 2,
Questionnaire 1 was mailed to the participants, together
with the invitation to attend the study. Questionnaire 1 was
filled in at home and brought to the physical examination.
At the examination, the participants received Question-
naire 2 and were asked to fill it in at home and return it
by mail.
Hospital Anxiety and Depression rating Scale (HADS)
In HUNT 2, the Hospital Anxiety and Depression rating
Scale (HADS) was included in Questionnaire 1. HADS is
a widely used self-rating scale originally designed for
detecting depression and anxiety in patients with cardiac
disease and other medical conditions [19]. HADS consists
of seven items concerning depression (HADS-D) and
seven concerning anxiety (HADS-A), each with a four-
point ordinal scale to describe the symptom severity. Those
who filled in only five or six items were also included in
the study, and their scores were based on the sum of
completed items multiplied by 7/5 or 7/6, respectively. By
Fig. 1. Selection of cases and controls, the Nord-Trbndelag Health Study (HUNT).
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using this procedure, the total number of individuals with
valid HADS ratings was 62,344 (94% of attendants) in
HUNT 2. HADS does not cover vegetative symptoms like
sleep and appetite disturbance because they represent
potentially overlapping symptoms between somatic and
mental disorders. HADS-D covers mainly anhedonia and
loss of interest, which are core depressive symptoms, while
HADS-A covers the core anxiety features of worry and
tenseness. Principal component analyses confirmed a two-
factor solution in accordance with the two subscales in
HUNT 2 [20]. Caseness of anxiety disorder on HADS-A
and of depression on HADS-D was defined by a score of
eight or above on each subscale, as recommended in the
literature [21].
HADS was only available at the time of HUNT 2.
However, four questions concerning anxiety and depression
symptoms that addressed issues of nervousness, calmness,
mood, and vitality were included in both HUNT 1 and
HUNT 2. Because these four questions could not differ-
entiate sufficiently between anxiety and depression, a
compound index (anxiety and depression index, ADI) based
on these four variables was validated against HADS in the
total HUNT 2 population. Cut-off was set at the 88th
percentile in the total population sample in HUNT, to match
the HADS cut-off. This provided an acceptable indicator of
whether psychiatric caseness was present in HUNT 1
(sensitivity 0.51; specificity = 0.93; Cohen’s j =0.55). ADI
constituted our baseline measure of anxiety and depression
in HUNT 1.
Other variables
Workers who did not receive any kind of financial
social services or pension were classified as employed.
The smokers consisted of only daily cigarette smokers, and
high alcohol intake was defined as alcohol consumption
above the 97th percentile (frequency of intake) the last
month. Those who reported doing physical exercise once
or more a week were defined as exercisers. The influence
of arterial hypertension at baseline on anxiety disorder and
depression post-MI were tested in separate models for
diastolic (N90 mm Hg) and systolic hypertension
(N160 mm Hg). In these analyses, 2283 participants
(9.6%) who were taking antihypertensive medication in
HUNT 1 were excluded.
Statistics
SPSS version 11.01 was used for data analysis, cross
tables to explore the differences between group frequencies
and chi-square tests to estimate the corresponding P values.
Univariate ANOVA was used to analyse differences
Table 1
Baseline characteristics (HUNT 1) in the reference group without MI and cases with MI at follow-up (HUNT 2)
Reference group MI group
P P adjustedan % n %
Total (n = 23,693) 23,181 97.8 512 2.2
Demographic characteristics
Males 10,537 45.5 365 71.3 .001
Females 12,644 54.5 147 28.7 .001
Mean age (years) 50.1 56.2 .001
Males (S.D.) 49.6 (10.6) 54.9 (9.8) .001
Females (S.D.) 50.5 (10.8) 59.3 (9.2) .001
Married 19,595 84.7 414 81.2 .028 .098
Length of education .001 .004
V9 years 13,544 60.3 349 70.5
9–12 years 6430 28.6 116 23.4
z12 years 2491 11.1 30 6.1
Employed (sample b67 years) 16,030 75.3 343 79.0 .082 .773
Lifestyle characteristics
Exercise zonce a week 13,958 61.4 279 55.5 .007 .001
Excessive alcohol intake 722 3.2 25 5.0 .012 .360
Daily smoker 7012 30.9 224 44.5 .001 .001
Psychosocial characteristic
Anxiety and depression 2800 12.1 60 11.7 .805 .337
Clinical characteristics
Diabetes 239 1.0 23 4.5 .001 .001
Diastolic BP N90 mm Hg 5728 24.7 207 40.4 .001 .001
Systolic BP N160 mm Hg 2068 8.9 89 17.4 .001 .001
Body mass index (BMI) N30 2367 10.2 68 13.3 .024 .023
a Adjusted for age and gender.
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between group means and estimation of confidence
intervals, whereas binary logistic regression analysis was
utilised to estimate the odds ratio (OR) for post-MI anxiety
and depression. To assess time trends in the risk for post-
MI anxiety and depression, time since MI was entered as a
continuous variable (0 – 5 years) to the logistic regression
model. Logistic regression was also used for interaction
tests. To compare the impact of the first MI with the impact
of pre-MI characteristics on long-term anxiety and depres-
sion, an hierarchical linear regression model was used, with
HADS as a continuous outcome variable. The covariates
adjusted for were entered in one block using forced entry.
All multivariate analyses were performed stratified in terms
of gender. This is due to the reported gender differences in
coronary heart disease, which might also have implications
on the psychological reaction to the disease. Interaction
tests showed that none of the baseline predictors (see
Tables 3 and 4) for anxiety and depression were specific to
the MI group. All factors performed as a general risk or
protecting factor for subsequent anxiety and depression in
the general population. The result for the total sample is
presented in Tables 3 and 4. Statistical significance was set
at P b .05, and two-sided tests were used.
Ethics
The Norwegian Data Inspectorate and The Regional
Committee for Ethics in Medical Research approved the
protocols for HUNT 1, HUNT 2, and for this study. All
participants in our study gave informed consent.
Results
In HUNT 1, the baseline anxiety and depression level
based on the ADI index was the same in the MI and the
reference groups (Table 1). Compared with the reference
group, the MI group was older, dominated by men, not as
educated, exercised less, smoked more, and had a higher
prevalence of diabetes, diastolic, and systolic hypertension.
The 1108 deceased due to MI (Fig. 1, 64% males, mean
age 66.9 years at baseline) were less likely to be married
compared with the MI survivors (MI group); other baseline
characteristics were the same in these two groups. More
Table 2
Prevalence, mean HADS-D and HADS-A scores, and OR for anxiety and depression in the MI groups (b2 and 2–5 years since MI) compared with the
reference group without MI
Women Men












years ago Pa Pb
Total N=23,693 n=12,643 n=39 n=108 n=10,538 n=102 n=263
Depression
Mean HADS-D score 4.06 5.36 4.32 .009 .382 4.25 4.76 4.85 .098 .002
95% CI 4.00–4.11 4.20–6.52 3.68–4.95 4.19–4.31 4.08–5.43 4.45–5.25
Prevalence, age adjusted (%) 14.0 26.4 13.7 .026 .927 14.4 18.9 21.8 .195 .001
OR HADS-D z8 adjustedc 1.00 2.45 0.75 .020 .350 1.0 1.36 1.61 .241 .003
95% CI 1.15–5.24 0.41–1.37 0.81–2.27 1.17–2.20
Anxiety
Mean HADS-A score 4.72 5.12 3.88 .467 .015 3.79 4.22 3.85 .157 .749
95% CI 4.65–4.77 3.77–6.47 3.26–4.49 3.73–3.85 3.59–4.84 3.46–4.26
Prevalence, age adjusted (%) 19.0 32.6 16.6 .033 .527 11.3 14.7 12.0 .277 .720
OR HADS-A z8 adjustedc 1.00 2.47 0.78 .018 .412 1.0 1.34 1.11 .336 .635
95% CI 1.17–5.23 0.44–1.41 0.74–2.45 0.73–1.70
a Testing hypothesis of differences between Groups II and I.
b Testing hypothesis of differences between Groups III and I.
c Adjusted for age, educational level, marital status, employment status, exercise, alcohol consumption, smoking, BMI, systolic blood pressure, diastolic
blood pressure, diabetes, and depression and anxiety score at HUNT 1.
Fig. 2. Depression following MI. Adjusted (age, educational level, material
status, employment status, exercise, alcohol consumption, smoking, BMI,
systolic blood, pressure, diastolic blood pressure, diabetes, lack of social
support, conscientiousness, and depression and anxiety score at HUNT 1)
odds ratio for post-MI depression dependent on time since MI (compared
with the reference group without MI). *Significant risk reduction after 2
years in women (reference is MI b2 years ago; P = .004). No significant
change in men (P = .33).
O. Bjerkeset et al. / Journal of Psychosomatic Research 58 (2005) 153–161156
women than men reported taking anxiolytics (6.5% and
2.9%, P b .001) and antidepressants (5.3% and 2.5%,
P b .001) daily, yet the consumption was the same in the
MI and the reference groups (age adjusted P = .93 and .64,
respectively). In the MI group, 88% of both genders
reported daily use of cardiotropic medication.
Women were older at the onset of the first MI (68 vs.
63.6 years in men, P b .001), and the mean observational
time since the first MI was 2.6 years in both genders.
Overlap between anxiety and depression was substantial in
HUNT 2. Unadjusted prevalence for having both conditions
in the reference group was 7.9% and 5.6% for women and
men, respectively, while 8.2% and 7.1% had this overlap in
the MI group.
During the 5 years following MI, the risk for developing
depression and anxiety was gender specific (Table 2, Figs.
2 and 3). After MI, women had a high initial risk for both
anxiety and depression, with a significant decrease after
2 years. In contrast, the risk for depression in men was
only increased after 2 years post-MI. There was no
significant change in the risk for anxiety disorder found
in men over time. Trend tests confirmed the risk reduction
over time for depression in women (adjusted OR=0.29,
Pb .01), while borderline significance was found for
anxiety (OR=0.47, P = .05). No significant trends were
found in men (adjusted OR=1.20, P = .297 for depression
and adjusted OR=1.03, P = .92 for anxiety). In addition,
the biological interaction between gender and time since
MI was significant for depression (P = .015) and margin-
ally for anxiety (P = .050).
In the entire MI group (0 –5 years since MI, mean time
2.6 years) and in the reference group, anxiety and depression
caseness at baseline was, by far, the strongest predictor for
anxiety and depression in HUNT 2 (Tables 3 and 4). During
the 5-year period, the relationship between MI and anxiety
and depression was only significant in men. Increasing age
contributed to depression in women and reduced anxiety in
both genders. A completed high school or university level
education and employment protected both women and men
from future anxiety and depression, whereas weekly exercise
Fig. 3. Anxiety following MI. Adjusted (for age, educational level, marital
status, employment status, exercise, alcohol consumption, smoking, BMI,
systolic blood pressure, diabetes, lack of social support, conscientiousness,
and depression and anxiety score at HUNT 1) odds ratio for post-MI
anxiety dependent on time since MI (compared with the reference group
without MI). *Significant risk reduction after 2 years in women (references
is MI b 2 years ago; P = .002). No significant change in men (P = .62).
Table 3
Risk factors for anxiety (HADS-A) in HUNT 2: the impact of the first MI
compared with the impact of demographic, lifestyle, psychosocial, and







Model 1 .019 .023
The first MI .010 .270 .024 .015
Age .082 .001 .168 .001
Education N
9 years
.066 .001 .053 .001
Employed
(age b67 years)
.041 .001 .063 .001
Married .017 .082 .005 .645
Daily smoking .074 .001 .016 .122
Excessive
alcohol intake
.025 .008 .005 .586
Exercise z
once a week
.003 .740 .011 .267
BMIz30 .017 .070 .009 .343
Model 2 .150 .114
Anxiety and
depression
.301 .001 .220 .001
Linear regression model. All characteristics were entered in one block
(forced entry) in Model 1. In Model 2, baseline anxiety and depression
score were entered to Model 1.
Table 4
Risk factors for depression (HADS-D) in HUNT 2: the impact of the first
MI compared with the impact of demographic, lifestyle, psychosocial, and







Model 1 .028 .023
The first MI .000 .959 .025 .011
Age (35–79 years) .082 .001 .014 .225
Education N
9 years
.061 .001 .057 .001
Employed
(age b67 years)
.046 .001 .065 .001
Married .008 .381 .020 .040
Daily smoking .061 .001 .023 .020
Excessive
alcohol intake
.010 .277 .021 .037
Exercise z
once a week
.056 .001 .058 .001
BMI z30 .033 .001 .038 .001
Model 2 .040 .019
Anxiety and
depression
.200 .001 .136 .001
Linear regression model. All characteristics were entered in one block
(forced entry) in Model 1. In Model 2, baseline anxiety and depression
score were entered to Model 1.
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only reduced the risk for depression. Daily smoking and
obesity at baseline predicted depression in both genders,
while excess alcohol intake at baseline increased the risk for
depression in men and anxiety in women at follow-up.
Neither diabetes, diastolic, nor systolic hypertension at
baseline influenced the risk for anxiety or depression.
Discussion
Post-MI depression: why do women adjust while men
remain depressed?
The increased risk for depression above cut-off (HADS-
D N 8) during the first 2 years post-MI found in our study,
only significantly elevated in women, is likely to represent a
continuation of depression found in previous studies with
12-month follow-up [2,4,6,9–11]. Our results apply to the
finding that women, in general, have increased vulnerability
for distress and depression during the first months after
adverse life events compared with men [22,23]. However,
the further symptom adjustment in women and continued
risk for depression in men up to 5 years post-MI has, to our
knowledge, not been described earlier. In the prospective
study of van Elderen et al. [24] of the coping strategies of
patients with coronary heart disease, approach predicted
high initial levels of anxiety and depression, which
diminished within a year for most participants, while
avoidance was favourable initially but caused increasing
mental symptoms throughout the same period. However,
this study consisted of 244 men (88%), and analyses were
not carried out for each gender separately. Nevertheless, the
recent study by Ketterer et al. [25] clearly linked denial of
anger, depression, and anxiety in CHD patients to male
gender. In addition, two other studies [26] also demonstrated
that men generally had more limited coping strategies for
stressful life events than women did, both in the general
population and in patients with cardiac diseases. Physio-
logical, behavioural, and psychological adaptation was
poorer in men than in women in these studies.
In sum, these findings give support to the gender-specific
long-term outcome in post-MI depression in our study
(Fig. 2). Women tend toward an initial and time-limited
psychological reaction and adaptation to the actual event
(MI), while men seem less able to cope with the long-term
consequences of the MI.
Post-MI anxiety: a transient condition
Increased risk for anxiety above the cut-off (HADS-A
N8) was found only in women and was limited to the first
2 years post-MI. In contrast, Stern et al. [8] observed an
increased risk for anxiety disorder post-MI in their total
sample, which was small (N =68) and consisted of 85% men
(n=55). However, our findings are consistent with the
majority of the studies on anxiety symptoms following
severe somatic illness and other adverse life events. When
exposed to a variety of stressors or life events, women
experience markedly higher levels of distress and anxiety
than men do [22,23,27,28]. The recent study by Ginzburg
et al. [13] showed that anxiety symptoms 1 week after MI
were transient in most cases and did not predict subsequent
development of PTSD. Our results support these findings, as
well as the authors’ opinion that such acute stress related
symptoms should be labelled acute stress reaction (as in the
ICD-10) instead of ASD (acute stress disorder, DSM-IV) to
avoid unnecessary psychiatric stigmatisation.
Post-MI anxiety and depression: confounding factors
The large sample size in HUNT allowed us to identify a
risk profile for post-MI anxiety and depression, in contrast
to the divergent findings in smaller clinical studies
[2,3,6,9,12]. In accordance with previous studies, we found
that anxiety and depression at baseline was the strongest
predictor for post-MI depression [2,14], indicating that MI
triggers new episodes of recurrent depressions. The preva-
lence of coronary heart disease increases with age and is
therefore to be expected in the elderly. This probably
explains the decreased risk for post-MI anxiety at a late
onset, as found in our sample. The association between
higher education and reduced risk for depression concurs
with previous studies [29]; our findings also indicate that
this favorable effect exists concerning future risk for
anxiety. The review by Wilson and Walker [30] found that
women were not as psychologically affected by unemploy-
ment as men are. Our prospective data also show slightly
differing effect sizes; however, employment had a protective
effect regarding both anxiety and depression and was
significant in both genders.
Regular physical activity is associated with reduced risk
for depression and anxiety in large prevalence studies [31],
yet our results indicate that the long-term protective effect of
exercise is limited to depression symptoms.
Smokers report more adverse life events and psychiatric
problems than nonsmokers do [32 – 35]. Nevertheless, the
underlying mechanisms differed across the samples inves-
tigated in the previous studies. Both Black et al. [32] and
Roy et al. [34] suggested that unfavourable demographic
and lifestyle characteristic in the smoking population, and
not the smoking per se, explained the increased risk for
psychiatric symptoms. Our results, though, are from a
larger sample and agree with the studies [33,35] that claim
that smoking is an independent risk factor for post-MI
depression and anxiety after adjusting for relevant con-
founding factors.
Our findings confirmed negative psychological conse-
quences of high alcohol consumption [36,37], yet the effects
on anxiety and depression were different in men and women
in our study. Our data confirmed the prospective risk for
depression in the middle aged and elderly obese (BMI N30),
as found in the recent 5-year observational community study
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by Roberts et al. [38]. Social discrimination and isolation, as
well as metabolic complications like dyslipidemia, inflam-
mation, and arteriosclerosis, contribute to adverse mental
and physical health outcomes in the obese [39,40]. In spite
of this, obesity did not increase the risk for subsequent
anxiety in our sample. The weak association between
medical diagnosis, such as diabetes and hypertension, and
the development of post-MI depression was confirmed in
our study [2,11,12].
Conclusion and implications
This epidemiological population study supplements the
findings that there is considerable risk for anxiety and
depression during the first 5 years post-MI. The gender-
specific symptom pattern has not been shown earlier but
may be important. Nevertheless, the relative impact of the
first MI alone on long-term anxiety and depression is
moderate and weaker than the influence of many preexisting
sociodemographic, lifestyle, and psychological risk factors.
Clinicians need to assess a number of preexisting character-
istics, as well as current psychiatric symptoms, during a
minimum of 6 months post-MI [2]. Reliable, valid, and cost-
efficient self-rating scales should be used to screen for
anxiety and depression before considering a diagnostic
interview [41].
Future studies need to explore the potential benefits of
treating post-MI depression and anxiety disorder in terms of
improved cardiac prognosis and reduced mortality. As yet,
this has not been demonstrated [42]. In addition, our
findings indicate that population strategies, such as prevent-
ing smoking, obesity, and physical inactivity, could reduce
both psychiatric and physical suffering.
Strengths and weaknesses of the study
HUNT is a large prospective health study of an entire adult
population. Women and the elderly population were better
represented, and the overall attendance rate was equal to or
higher than in clinical trials on post-MI depression
[2,7,11,12].
In a nonparticipant study of HUNT 2, the age-adjusted
prevalence of chronic somatic diseases and the use of
cardiotropic medication was the same as in the participants
[43]. In HUNT, all predictors of interest were assessed
before the onset of the cardiac disease. This prospective
design has the potential to reduce recall bias, which may
occur in clinical studies where background information is
collected after MI. The results from HUNT can therefore be
generalised to the total MI population, with greater
confidence than in most clinical studies.
A large population study most certainly offers methodo-
logical limitations and challenges. Both mental symptoms
and the MI diagnosis were self-reported in HUNT. Despite
the good case-finding ability of HADS in the general
population and in post-MI samples [21,41], the assessment
and diagnosis of mental disorders are best done by means
of a structured diagnostic interview. Although ADI and
HADS do not share questions, results from the internal
validation in HUNT 2 indicate that the ADI compound
index is an acceptable indicator of anxiety and depression
severity at baseline. HUNT 1 was not primarily designed to
cover specific psychiatric topics. The absence of interna-
tionally validated instruments to assess anxiety and
depression, personality dimensions, and stress at baseline
still leave us with somewhat preliminary conclusions
concerning the psychosocial risk profile for long-term
anxiety and depression.
Researchers in HUNT did not have access to the medical
records of the participants, and it is likely that the validity of
self-reported somatic diagnosis varies depending on the
characteristics and severity of the disease. Still, we expect
valid data on MI, even by self-report, because acute MI with
chest pain leads to detection and hospitalisation in more
than 95% of cases [44]. A substantial agreement between
self-reported MI and the GP record has been demonstrated
in the British Regional Heart Study [45].
Post-MI anxiety and depression were only measured
once as an outcome score in each participant, and we do
not know the course of these symptoms over time.
Differences in the quantity of exposure to reinfarction or
other stressful life events between the surveys could have
influenced the psychiatric outcome. That could not be
adjusted for in our study. However, previous studies concur
that both the 5- and 10-year reinfarction rate and MI-related
mortality are the same in both genders when adjusting for
age and other confounding factors [46,47]. In theory,
gender differences in psychiatric detection and treatment
after MI, as well as different adherence to cardiotropic
medication, might have affected the HADS scores. How-
ever, the reported use of antidepressive, anxiolytic, and
cardiotropic medication in our large sample makes this an
unlikely explanation.
Predictors of post-MI anxiety disorder and depression
were recorded several years before the onset of the MI, and
it is uncertain to what extent or in what direction they might
have changed in regards to the time of the cardiac event. We
still assume that they are no less valid than the character-
istics assessed at the time of the MI (hospitalisation)
because risk factors often need several years to induce
coronary heart disease.
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1Mortality in relation to self-reported mixed anxiety and 
depression symptoms - the HUNT study
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Background Excess mortality in anxiety and 
depression has mostly been studied for diagnostic 
categories of each condition separately.  
Aims To study the association between self-
reported mixed anxiety and depression and 
mortality in the general population. 
Method Population survey of 2624 individuals, 
defined in three groups according to their total 
score on Hospital Anxiety and Depression rating 
Scale (HADS-T); 0-19 points, 19-24 points and 25 
points or above.  
Results  114 deaths (4.3%) occurred during 4.5 
years. Only the highest score group had increased 
mortality risk after adjustment for all relevant 
confounding factors (p=.043). However, trend tests 
supported a dose-response relationship between 
increasing HADS-T score and increasing total 
mortality across the three groups (p for trend = .02).  
All seven suicides occurred in cases detected by 
HADS-T (>19 points) at baseline.  
Conclusion  Our sample is limited and the findings 
therefore tentative, yet there seems to a positive 
correlation between HADS-T symptom level and 
total mortality risk in a 4.5 year perspective. 
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A clinical expression of mixed anxiety and 
depression is common, both at symptomatic and at 
diagnostic levels (1-3). Genetic and neurobiological 
studies have also repeatedly confirmed the strong 
overlap between depression and particularly the 
features of generalized anxiety disorder (GAD) (4-
6). 
Studies of excess mortality in neurotic 
disorders have, however, for the most part been 
studied separately in anxiety (7;8) and depression 
(9), using diagnostic interviews for classification 
purposes. Although self-rating scales for anxiety 
and depression are frequently used in clinical 
practise and in population studies, little is known 
about the association between these common 
subjective symptoms and mortality (10;11). One of 
the most frequently used instruments, the Hospital 
Anxiety and Depression rating Scale (HADS), was 
included in the Nord-Trøndelag Health Study 
(HUNT 2, 1995-97). Its two subscales cover core 
symptoms of depression (HADS-D) and 
generalized anxiety (HADS-A). 
Our aim was to examine the association 
between mixed anxiety and depression symptom 
severity (HADS-T) and the 4.5 year total mortality 
in a subsample from HUNT 2.  
METHOD
Study setting and design 
The HUNT 2 was carried out in 1995-97, and is one 
of the world’s largest population screening and 
intervention surveys (12). The general purposes and 
methods are described thoroughly at the HUNT 
website 
(www.medisin.ntnu.no/hunt/index.php?side=englis
h). All residents of Nord-Trøndelag County in 
Norway aged 20 and above received a written 
invitation by mail. Attached was Questionnaire 1 
(Q 1), which addressed a wide range of 
demographic data, life-style factors, physical 
symptoms and illnesses, and mental health issues 
including the Hospital Anxiety and Depression 
Scale (HADS). Q1 was filled in at home and 
brought to the physical examination a few days 
later. At the examination the attendees received 
Questionnaire 2 (Q 2), which was filled in at home 
and then returned by mail. Q2 further explored the 
topics addressed in Q1.  
2Sample
Of the 92936 individuals eligible above 20 years of 
age, a total of 66140 (71.2%) attended HUNT 2. 
The total number of individuals with valid HADS-T 
score was 61494 (93.0 % of the participants). From 
these, three subgroups (total n=2624) were selected 
based on their HADS-T scores and included in a 
follow up study 4 years after HUNT 2, and 
mortality was one of the endpoints. Participants 
scoring above conventional cut-off on HADS-T (>
19 points) were over-sampled compared to controls. 
All individuals with a HADS-T score of 25 or 
above (99th percentile, n = 662) were defined as the 
“psychiatric high risk group” (PHRG). A random 
sample of 654 individuals of those who had HADS-
T scores between 19 and 24 points (95th to 98th
percentile) constituted the “psychiatric risk group” 
(PRG). Finally, a random sample of 1308 
individuals scoring 18 or less (under the 95th
percentile) was defined as the “reference group”. 
HADS-T score above 19 points represents a 
conventional cut off for co-morbid anxiety and 
depression, whereas 25 points was chosen after a 
pilot testing of the first 2500 individuals in HUNT 
2, and represented the 99th percentile. 
An important part of HUNT 2 was to give 
feedback on identified health risk factors to the 
participants (high blood pressure, elevated 
cholesterol levels, high BMI, etc.). The HUNT 
Board of Directors recommended the same 
procedure for participants with extremely high 
anxiety and depression scores. Thus, all participants 
in the PHRG received a written notification of the 
findings four to six weeks after the examination 
with a request to contact their GP. Next, they were 
invited to the Intervention study against Depression 
and Anxiety in Nord-Trøndelag (IDANT). 
Unfortunately, attendance was poor among 
participants as well as GPs in this sub-study of 
HUNT 2 (13). The participants in the PRG and 
reference groups did not receive information about 
their HADS-T score.  
Measures
HADS
The HADS (14) is a widely used self-rating scale 
that has shown good psychometric properties across 
various patient samples and settings (15). HADS 
consists of seven items for depression (HADS-D) 
and seven for anxiety (HADS-A), each with a four-
point ordinal scale to describe symptom severity: 
from zero (not present) to three points (strongly 
present). The total HADS score (HADS-T) consists 
of the sum of the HADS-A and the HADS-D 
scores, and the range is from zero to 42 points. A 
total HADS-T score of 19 or above has been 
recommended as the cut-off for probable caseness 
of clinically significant mixed anxiety and 
depression (15). Those who filled in only five or six 
items on HADS-A and HADS-D were included in 
the study. Their missing scores were substituted 
based on the sum of completed items multiplied by 
7/5 or 7/6, respectively. HADS-D covers mainly 
anhedonia and loss of interest which are core 
depressive symptoms, while HADS-A mainly 
covers the core anxiety features of worry and 
tension.  
Other variables and confounding factors 
Information on age, place of residence, and marital 
status were obtained from the National Population 
Registry. The other variables were self-reported in 
Q 1 and Q 2. University level of education was 
defined as four or more years at a university or 
college. Persons who did not receive any kind of 
financial social services or pension were classified 
as employed. The smoker group consisted of daily 
cigarette smokers, and excessive alcohol intake was 
defined as alcohol consumption above the 97th
percentile in the total HUNT population (6.6 litre 
pure alcohol/year). The presence of one or more of 
the following conditions was defined as “chronic 
physical illness”: self-report of diagnosis of asthma, 
myocardial infarction, angina pectoris, stroke, 
diabetes, or cancer. Participants with “chronic pain” 
were those who had reported 
rheumatism/degenerative joint disease, 
musculoskeletal pain, and/or headache lasting for 
one year or more.
Total mortality and cause of death 
The Death Registry, Statistics Norway, records the 
date and cause of all deaths in Norway according to 
the WHO standards for classification (16). Statistics 
Norway merged this information with a data file of 
all participants in our sample. Observational time 
varied between 3.5 and 5.5 years in our sample; 
mean observational time was 4.5 years. In the 
current study we distinguished between death from 
defined physical illness(es), non-illness death 
(accidents or uncertain cause(s)), and suicide.  
Statistics/analysis  
SPSS version 11.01 was used for data analysis. 
Univariate ANOVA was used for estimation of 
confidence intervals and differences between group 
means in table 1. Differences between group 
frequencies were examined with chi-square tests in 
table 1 and 3, while Fisher’s exact test was used to 
test for significance in Table 2. Cox`s proportional 
hazards regression model (17) was used to obtain 
the hazard ratios (HR) for mortality in the two 
psychiatric risk groups compared to the reference 
group. Covariates were organised thematically in 
blocks and each block was entered separately into 
the model using forced entry; the last step of the 
analysis was adjusted for all variables. To assess a 
possible trend in the mortality risk with increasing 
symptom severity, the HADS-T score was entered 
3into a separate Cox regression model as a 
continuous variable. A Cox regression analyses was 
also carried out to test for possible biological 
interactions of age, gender, smoking habits, and 
physical illness with mixed anxiety and depression 
in the prediction of mortality. In these analyses, 
HADS-T score was entered as a continuous 
variable and tested with each of the other factors 
separately. Statistical significance was set at p <.05 
and two-sided tests were used where applicable. 
Ethics
The Norwegian Data Inspectorate and the Regional 
Committee for Ethics in Medical Research 
approved the protocols for HUNT 2 and for this 
study. All follow up projects after HUNT 2 
required informed consent from the participants. 
RESULTS
All baseline characteristics differed between PHRG 
and the reference group, except for alcohol 
consumption (Table 1). Subjects in PHRG were 
older, more likely to be female, more often 
unemployed, more frequently living alone, and had 
a lower education level. They also reported daily 
smoking, physical inactivity, chronic physical 
illness(es), and chronic pain more frequently. The 
PRG shared these characteristics, but did not differ 
significantly from the reference group in terms of 
age and cohabitation status. Comparison of the two 
psychiatric risk groups showed that PHRG had a 
lower employment rate (p <.001), lower educational 
level (p < .01), and exercised less (p = .027) 
compared to PRG. HADS-A and HADS-D were 
highly correlated (Pearson`s r = .773, p < .001) in 
the total sample (n=2624).  
According to the Death Registry 114 
(4.3%) of the 2624 individuals had died during the 
observation period. Among the deceased, all seven 
people who committed suicide (6.1%) were HADS-
T cases and members of the PRG or PHRG (table 
2). In the two psychiatric risk groups, seven (10 %) 
out of the 71 deaths were suicides. The annual 
number of suicides between 1995 and 2000 varied 
between 7 and 15 in the total target population for 
HUNT 2 (n=94194). However, individuals within 
the total target population for HUNT 2 who 
committed suicide in this period were less likely to 
be participants than individuals who did not commit 
suicide (attendance rate 51.8% and 71.2% 
respectively, p < .001).  
Table 3 shows that the point-estimated 
Hazard Ratio (HR) for 4.5-year total mortality 
increased across the three groups defined by 
increasing HADS-T score in all steps of the 
analyses. However, only subjects in the PHRG had 
significantly increased mortality risk compared to 
the reference group after final adjustment for 
sociodemographic factors, life-style, and clinical 
characteristics. Still, the trend test supported a dose-
response relationship between increasing HADS-T 
score as a continuous variable and increasing 4.5 
year total mortality across the total sample (p for 
trend = .02).  
Among the covariates, three significantly 
predicted excess mortality in the final model: 
chronic somatic disease(s) (HR 2.70, p < .001), 
male gender (HR 1.91, p = .001), and daily 
smoking (HR 1.60, p = .041). The results from 
interaction tests between HADS-T score and gender 
(p = .39), smoking (p = .41), chronic somatic 
disease (p = .61), and age (p =.52) were all non-
significant in predicting total mortality.  
DISCUSSION  
Main findings
The unfavourable gradient of socio-demographic 
(18), life style (19;20), and somatic health factors 
(21;22) with increasing levels of anxiety and 
depression is in agreement with previous reports, 
and confirms the importance of characterising the
severity level of anxiety and depression rather than 
only adhering to strict dichotomisation (23).  
Our results indicate a dose–response 
relationship between self-rated mixed anxiety and 
depression symptom severity and total mortality in 
the general population. This is in agreement with 
previous studies of self-rated depression in medical 
samples (10) and population studies using 
standardised psychiatric interviews for mortality 
prediction (24;25). However, our sample was 
limited and excess total mortality after final 
adjustment was only evident in the PHRG (HADS-
T >99th percentile). Overall, mortality rates found in 
HADS-T cases in this self-report study are quite 
similar to mortality rates found in population 
studies of persons diagnosed with major depression 
(9) or comorbid depression and GAD (26). In the 
latter study, increased mortality risk was found to 
be significantly associated with the affective 
disorder but not with the co-existent GAD.  
Confounding factors  
The relevance of the confounding factors 
established in the literature (9) were, except for a 
high alcohol consumption, confirmed by our study.  
Though endpoints are few, suicides seem 
to explain an important share of the excess 
mortality even when anxiety and depression 
symptoms are self-reported. Suicide accounted for 
10% of the deaths in the PRG and PHRG 
combined, which is in accordance with Wulsin et 
al’s review of mortality in populations diagnosed 
with major depression (9).  
The majority of studies linking depression 
to early death are poorly controlled, but they agree 
that excess mortality is primarily explained by 
suicides, non-natural deaths, and cardiovascular 
disease (9). Although results are somewhat 
4conflicting, the majority of previous studies find 
that excess mortality related to both anxiety and 
depression is associated with male gender. Our 
results suggest that this is also the case when mixed 
symptoms are assessed by self-report. Although the 
influence of anxiety and depression on mortality 
seems to be independent of age in this study, our 
sample size is too small to clarify previous 
conflicting findings.  
Despite the considerable range of variables 
included in our first analysis of the HUNT 2 data, 
we were not able to identify any additional 
confounding factors that further improved our 
model.   
Strengths and weaknesses of the study 
HUNT 2 is a large health study, with high 
attendance among both medically ill and healthy 
individuals of the population (27). However, the 
generally poor attendance in population surveys 
among residents with psychiatric disorders (28;29) 
has probably contributed to an attenuated 
association between HADS-T score and mortality 
in this study. Also, the low participation in HUNT 2 
among those who committed suicide in the years 
after the study indicates that population studies 
have limited potential both for suicide prevention 
and for improving the understanding of the suicidal 
process per se. The findings should therefore be 
considered tentative.  
Due to the oversampling of subjects with HADS-T 
above 19 points in the current substudy of the 
HUNT 2 there were not enough cases with “pure” 
anxiety or depression in our sample (Table 1) to 
compare mortality in mixed and pure conditions. 
Correspondingly, the reference group only 
represented about 2% of those scoring less than 19 
in HUNT 2, and the prevalence of a rare event like 
suicide could vary widely between different random 
samples.  
It was not possible to perform a validation 
study of the HADS by doing diagnostic interviews 
in our study. Since the HADS is not a diagnostic 
test that exclusively identifies those who meet the 
DSM-IV or ICD-10 diagnostic criteria of anxiety 
disorders and depression, a validation would have 
yielded additional information about the external 
validity of the findings.  
If the notification of the participants in the 
PHRG and their GPs influenced the mortality or 
suicide risk at all, we find it most likely that a 
consultation with the GP, and hopefully better 
treatment, would decrease the mortality and suicide 
rates. This, however, cannot be clarified with our 
design.  
CONCLUSIONS 
Self-report of anxiety and depression is a useful and 
cost-efficient method for therapy evaluation and 
prediction of adverse outcomes. Our findings 
indicate that increasing HADS-T score (anxiety and 
depression) is associated with increasing mortality 
risk. Nevertheless, the sample from this follow-up 
study after HUNT 2 is limited and conclusions 
regarding the association between HADS-T level 
and suicide risk cannot be made. It remains unclear 
whether self-report or clinical interview is the more 
precise predictor for early death (10).
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7TABLES
Table 1.  Sample characteristics at baseline (HUNT 2, 1995-97) for the reference group (HADS-T < 19), the 
psychiatric risk group (HADS-T 19-24), and the psychiatric high-risk group (HADS-T > 25).  
Characteristics Reference group Psychiatric risk  
group (PRG) 
Psychiatric high risk 
group (PHRG) 
Total N= 2624 N=1308 N=654 N=662
Psychometric characteristics   
   HADS-T score, range  0-18 19-24 25-42
   Mean HADS-T score (95% CI)  6.9 (6.7-7.1) 20.9 (20.6-21.1)*    28.2 (28.0-28.5)* 
   Mean HADS-A score (95% CI) 3.8 (3.7-4.0) 11.4 (11.2-11.6)* 15.2 (15.0-15.4)* 
   Mean HADS-D score (95% CI) 3.1 (3.0-3.3) 9.8 (9.6-10.0)* 13.3 (13.1-13.5)* 
   Pure A (HADS-A > 8 & HADS-D < 8)  9.2% 14.9%* 0.8* 
   Pure D (HADS-D > 8 & HADS-A < 8) 4.4% 5.1%  0.2%* 
   Mixed A and D (HADS-D & A > 8) 2.1% 80.1% * 99.1% * 
Demographic characteristics 
   Mean age by screening, years  48.7 (47.8-49.6) 50.0 (48.8-51.2) 51.5 (50.7-52.7)* 
   Gender, female  52.5 (49.8-55.2) 61.8 (58.0-65.6)* 59.7 (55.9-63.4)* 
   University level education, % 20.9 (19.0-22.9) 14.5 (11.7-17.4)* 9.7 (6.9-12.5)* 
   Living alone, %  20.3 (18.0-22.5) 21.7 (18.5-24.9) 26.3 (23.1-29.4)* 
   Employed/under education  70.3 (67.7-72.8) 56.6 (52.9-60.2)* 42.0 (38.4-45.6)* 
Life-style characteristics 
   Smoker  27.6 (25.0-30.2) 41.7 (38.1-45.4)* 46.7 (43.1-50.3)* 
   High alcohol consumption 2.9 (2.0-3.8) 2.6 (1.3-3.9) 3.6 (2.3-4.9) 
   Exercise > once a week  43.0 (40.4-54.7) 35.6 (31.9-39.3)* 29.9 (26.2-33.6)* 
Clinical characteristics 
   Chronic disease1 20.3 (18.0-22.6) 25.4 (22.1-28.6)* 29.6 (26.4-32.8)* 
   Chronic  pain2  19.6 (17.3-22.0) 30.0 (26.7-33.3)* 32.6 (29.3-35.9)* 
* unadjusted p< .05 compared to reference group 
1 Asthma, myocardial infarction, angina pectoris, stroke, diabetes, and cancer.  
2 Rheumatism/degenerative joint disease, musculoskeletal pain or headache 1 year or more.  
8Table 2. Total mortality and cause of death in the reference group (HADS-T < 19), the psychiatric risk group 
(HADS-T 19-24), and the psychiatric high-risk group (HADS-T > 25) 4.5 years after HUNT 2.  
Reference group Psychiatric risk 
group (PRG) 
Psychiatric high risk 
group (PHRG) 
Dead at follow-up, N (% total mortality) 43 (3.3) 30 (4.6) 41 (6.2)* 
CAUSE OF DEATH 
Illness death1, N (%) 39 (91) 24 (80) 30 (73)* 
Non-illness death2, N (%) 4 (9) 4 (13) 6 (15) 
Suicidal death, N (%)  0 2 (7) 5 (12)* 
* unadjusted p<.05 compared to reference group. 
1 Defined medical illness as main cause of death
2 Unclear cause of death/accident
9Table 3. Multivariate analyses of total mortality risk in the reference group (HADS-T < 19), the psychiatric risk 
group (HADS-T 19-24), and the psychiatric high-risk group (HADS-T > 25) 4.5 years after HUNT 2; Hazard 
Ratios (Cox regression model). 
 Reference  
group
 Psychiatric risk 
group (PRG) p1
Psychiatric high 
risk group (PHRG) p2
Total  N=2624 N=1308 N=654 N=662 
TOTAL MORTALITY 
Dead, count (percent) 43 (3.3) 30 (4.6) 41 (6.2) 
HR unadjusted 1.00 1.41 (0.89-2.25) .150 1.92 (1.25-2.94) .003 
HR adj. Age and gender  1.00 1.65 (1.03-2.65) .037 2.10 (1.36 – 3.24) .001 
Further adjustment, blocks entered separately: 
   HR adj. demographic var.3 1.00 1.59 (0.99-2.55) .056 1.93 (1.24 – 3.00) .003 
   HR adj. life style var.4 1.00 1.58 (0.98-2.54) .059 1.96 (1.27-3.04) .003 
   HR adj. somatic health5 1.00 1.43 (0.89-2.29) .137 1.82 (1.17-2.81) .007 
Final model 
   HR adj. for all variables above 1.00 1.33 (0.83 – 2.14) .235 1.59 (1.01-2.48) .043 
1 Testing hypotheses of differences between reference group and PRG.  
2 Testing hypotheses of differences between reference group and PHRG. 
3 Adjusted for age, gender, educational level, living alone, and being in work or under education.  
4 Adjusted for age, gender, smoking, alcohol-consumption, and exercise.  
5 Adjusted for age, gender, somatic diseases (asthma, myocardial infarction, angina pectoris, stroke, diabetes, and cancer) and 
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ABSTRACT   
Background: Both syndromal and sub-syndromal 
symptoms of anxiety and depression are associated 
with residual symptoms and a recurrence or 
chronic course. Although the percentage of persons 
at each symptom level seems to be rather constant 
over time, individual symptom fluctuation between 
levels has been considerable. Our aim was to study 
stability and change in self-rated anxiety and 
depression symptom levels in a large general 
population sample. 
Methods: Three groups (N=2,616) with total score 
on the Hospital Anxiety and Depression rating 
scale (HADS-T) less than 19 points (N=1,308), 19 
to 24 points (N=654), and 25 or above (N=654) in 
HUNT 2 were selected in HUNT 2 and followed 
up after four years. In addition, a random sample 
(N=152) of those at the highest symptom level at 
baseline was evaluated with a diagnostic interview 
at follow-up.   
Results: Unfavourable sociodemographic 
characteristics and lifestyle factors, and the 
prevalence of life-time mental health problems, 
were highly associated with increasing HADS-T 
levels in HUNT 2. Self-rated mixed anxiety and 
depression symptoms followed similar longitudinal 
patterns as described for diagnostic levels found 
previously. From the lowest symptom level at 
baseline, 22% had reached HADS-T caseness level 
(19 points) or above at follow-up. HADS-T 
caseness at baseline predicted a chronic or 
recurrent symptom course in 74%, and HADS-T >
25 at baseline predicted current mental disorder(s) 
in 72% at follow-up.  
Conclusions:  HADS-T caseness (> 19 
points) is a reliable predictor for high long-
term symptom stability in the general 
population, and indicates need for further 
psychiatric assessment and follow-up.  
Key words: Anxiety, depression, HADS, 
self report, stability, and symptom level  
INTRODUCTION
The long-term effects of depressive symptoms are 
associated with excess individual and societal 
burden through social impairment (1-3), increased 
rates of sick leave and disability pension at a young 
age (4), and early death (5;6). Despite great efforts 
to improve detection and treatment of depression (7) 
and a steadily growing prescription of 
antidepressants (8), outcome of major depression 
does not seem to have improved significantly over 
the last decades (9;10).  
Longitudinal studies of psychiatric patient 
samples have reported a remarkably stable 
percentage of patients at each symptom severity 
level over time, yet that individual fluctuation across 
different symptom levels was considerable (11-13). 
Findings from the community-based Zurich Cohort 
Study (14) demonstrated similar patterns, and 
argued that sub-threshold level and threshold level 
symptoms should be considered part of the same 
spectrum for both anxiety and depression. 
Self-rating of anxiety and depression is 
widely used for clinical purposes as well as 
scientific purposes, yet little is known about the 
prognostic validity and long-term symptom course 
associated with this method of assessment. It is of 
particular importance to study to what extent 
individuals at lower symptom levels develop 
syndromal and sub-syndromal symptoms over time.   
Our aim in this study was, therefore, to 
study the change in self-rated anxiety and 
depression symptoms, covering the full range of 
symptom severity in a large general population 
sample. Three groups were selected among the 
participants in the North-Trøndelag Health Study 
(HUNT 2, 1995-97): those scoring less than 19 
points (n=1,308), 19 to 24 points (n=654), and 25 
2or above (n=654) on the Hospital Anxiety and 
Depression rating scale (HADS-T). This cohort 
was invited to a follow-up study four years later. 
We studied the association between anxiety and 
depression symptom level and a wide range of 
sociodemographic, lifestyle, health behaviour, and 
clinical characteristics. The main aim, however, 
was to study the change in mean symptom scores 
of anxiety and depression (HADS-T), anxiety 
(HADS-A) and depression (HADS-D), and the 
change across the three anxiety and depression 
symptom levels from HUNT 2 to four year follow-
up.  
METHOD
HUNT 2 - study setting and design 
The Nord-Trøndelag Health Study was carried out 
in 1995-97 (HUNT 2), and is one of the world’s 
largest population screening and intervention 
surveys (15). The general purposes, methods, and 
questionnaires are described at the HUNT website 
(http://www.hunt.ntnu.no/index_nyforside.php?sid
e=english). All residents of Nord-Trøndelag 
County of Norway aged 20 and above received a 
written invitation to the health study by mail. 
Questionnaire 1 (Q1) was attached to the 
invitation, and addressed a wide range of 
demographic data, lifestyle, and physical and 
mental health variables including the HADS. Q1 
was to be filled in at home and brought to the 
physical examination that took place a few days 
later. At the examination the attendees also 
received Questionnaire 2 (Q2) with an addressed, 
stamped envelope, which was to be filled in at 
home and then returned by mail. Q2 was more 
detailed and further explored topics addressed in 
Q1. 
Subjects 
Of the 92,936 eligible individuals aged 20 years 
and older, a total of 66,140 (71.2%) attended 
HUNT 2. The total number of individuals with 
valid HADS-T scores was 61,494 (93% of the 
participants). From these, three subgroups 
(N=2,616) were selected based on their HADS-T 
scores. All individuals with a HADS-T score of 25 
or above (99th percentile, n = 662) were defined as 
the “psychiatric high risk group” (PHRG). A 
random sample of 654 individuals of those who 
had HADS-T scores between 19 and 24 points (95th
to 98th percentile) constituted the “psychiatric risk 
group” (PRG). Finally, a random sample of 1,308 
individuals scoring 18 or less (under the 95th
percentile) was defined as the reference group 
(REF). 
An important part of HUNT 2 was to give 
feedback on identified health risk factors to the 
participants. Thus, the HUNT Board of Directors 
decided that all participants in the PHRG should 
receive a written notification of the examination 
findings with a request to contact their GP (16). The 
participants in the PRG and reference groups did not 
receive information about their HADS-T score.  
At follow-up four years after 
HUNT 2 all living members of the three 
groups (N=2,502) were contacted by mail. 
They were offered a questionnaire which 
included the most relevant variables from 
Q 1 and Q2 in HUNT 2, including the 
HADS. In addition, a random sample of 
300 subjects from the PHRG was invited to 
a clinical follow-up interview a few days 
after they had filled in the questionnaire. 
They were given the choice between 
meeting the interviewer at a psychiatric 
outpatient clinic, at their GP’s office, or in 
their home. The interviews were performed 
by three experienced clinicians.  
Measures
Anxiety and depression (HADS) 
The 14-item HADS (17) has been validated 
across health care settings in different 
cultures and age-groups, showing a high 
acceptance, stable psychometric properties, 
and good screening abilities (18-22).  
The HADS consists of seven items for 
depression (HADS-D) and seven for 
anxiety (HADS-A), each with a four-point 
ordinal scale to describe symptom severity 
[from 0 (not present) to 3 points 
(maximally present)]. The HADS-D covers 
mainly anhedonia and loss of interest 
which are core depressive symptoms, while 
the HADS-A covers the core anxiety 
features of worry and tension. A total 
HADS score (HADS-T) consists of the 
sum of the HADS-A and the HADS-D 
scores, and the range is from 0 to 42 points. 
Those who filled in only five or six items 
on the HADS-A and the HADS-D were 
also included in the study. Their missing 
scores were substituted based on the sum 
of completed items multiplied by 7/5 or 
7/6, respectively. 
The Mini International Neuropsychiatric 
Interview (MINI) 
The Norwegian version of the MINI (23;24) 
version 5.0 was applied for the diagnoses of DSM-
IV Axis I disorders. The MINI covers 23 current 
and lifetime axis I disorders, it has been translated 
into many languages, and has been used in many 
multi-center studies. MINI has shown good 
concordance with current psychiatric disorders in 
the SCID-I interview for most mild and moderate 
psychopathology (e.g. 0.84 for major depressive 
episode and between 0.64 and 0.76 for most 
anxiety disorders and alcohol abuse), but poor 
3concordance for current psychotic disorder (0.53), 
drug abuse (0.43) and social phobia (0.51). Kappa 
values for inter-rater reliability were all above 0.75, 
and 16 out of 23 values were above 0.90.  
The IOWA personality disorder screen (IPDS) 
The IPDS (25) was developed in order to offer a 
brief and sensitive personality disorder screen for 
both research and clinical settings. Validation in a 
non-psychotic psychiatric patient sample yielded a 
sensitivity of 92 % and specificity of 79 %.     
Other variables
Information concerning age, place of residence, 
and marital status were obtained from the National 
Population Registry; all other variables were self-
reported in Q1 and Q2 in HUNT 2 and in the 
follow-up study. University level of education was 
defined as four or more years at a university or 
college. Persons who did not receive any kind of 
financial social services or pension were classified 
as employed. Increased alcohol intake was defined 
as yearly alcohol consumption above the 75th 
percentile (210 cl pure alcohol) in the total HUNT 
2 population (N=66,140).  
Those who reported >3 hours of moderate leisure-
time physical activity and/or > 1 hour of hard 
physical activity (sweating/out of breath) weekly 
the last year, were defined as physically active. 
Lifetime major depressive episode was defined as 
probable in cases reporting >3 out of 5 listed DSM-
IV criteria for this condition. 
Statistical methods  
SPSS version 12.01 was used for the data analysis. 
Univariate analyses of variance (UNIANOVA) and 
Chi-Square tests were used to analyse differences 
in baseline characteristics between the three 
groups, and Chi-Square tests were also used to 
describe change between the three symptom levels 
from HUNT 2 to follow-up. In a within-subject 
comparison design, paired-sample T-tests were 
used to examine mean HADS-T, HADS-A, and 
HADS-D scores at baseline and at follow-up. The 
effect size of symptom score change for each group 
was estimated with Cohen’s at follow-up: < 0.20 
no change, 0.20-0.50 weak, 0.50-0.80 moderate, 
0.80-1.00 strong, and > 1.00 very strong. We used 
logistic regression analysis to predict non-
attendance at follow-up, using forced entry for the 
independent variables included in the model. The 
positive predictive values (PPVs) of the HADS-T 
in detecting mental disorder(s) with the MINI 
diagnoses as gold standard were calculated using 
standard two by two tables. Statistical significance 
was set at p <. 05 and two-sided tests were used. 
RESULTS
Relationship between HADS-T symptom level 
and baseline characteristics 
As shown in Table 1, increasing severity of HADS-
T symptom levels were closely associated with 
unfavourable demographic characteristics, lifestyle, 
and clinical parameters in our sample. All baseline 
characteristics differed significantly between the 
PHRG and the reference group except for alcohol 
consumption. Subjects in PHRG were older, more 
likely to be female, more frequently living alone, 
had a lower educational level, and were more often 
granted disability pension at a young age or listed 
as unemployed. In addition, they more frequently 
reported daily smoking, physical inactivity, chronic 
physical illness(es), and chronic pain. Self-reported 
life-time major depression (MD), previous 
psychiatric help-seeking, and 
psychopharmacological treatment were 
significantly more common in the PHRG. The 
PRG shared most of these characteristics in 
comparison to the reference group, but did not 
differ significantly in terms of mean age and 
cohabitation status.  
Comparison between the two highest 
symptom levels showed several differences: the 
PHRG had a lower employment rate (p <.001), 
lower educational level (p < .010), and exercised 
less (p = .027) compared to PRG. Also, self-rated 
life-time prevalence of MD (p <.001), psychiatric 
help-seeking (p <.001), functional impairment due 
to mental problems (p <.001), daily intake of 
tranquillizers/hypnotics (p <.001), and use of 
antidepressants (p <.001) were significantly higher 
in the PHRG.  
Four year follow-up 
Differences between participants and non- 
participants in the follow-up study 
At time of follow-up 2,502 individuals (95%) were 
still alive and eligible for participation in the study. 
Of the 1,341 (54%) participants, 1,326 (53%) had 
valid HADS scores and could be included in the 
follow-up study (Figure 1). There was an 
association between increasing HADS-T symptom 
levels and excess mortality; results from this study 
have been described in a previous paper (Bjerkeset 
et al 2006, in Press). Table 2 shows that increasing 
HADS-T symptom level at baseline was associated 
with non-attendance at follow-up (unadjusted 
p<.001). However, logistic regression analysis 
showed that among baseline characteristics, only 
older age (p=.025) and education below university 
level (p<.001) remained significant predictors for 
non-attendance in the follow-up study. Non-
participants of the follow-up did not differ 
significantly from participants concerning their 
mean HADS-T score at baseline within the 
reference group (p=.10), in the PRG (p=.99), or in 
the PHRG (p=.95). 
4Change in mean anxiety and depression
scores at follow-up
Among all responders, there was a
significant increase in mean HADS-T,
HADS-A, and HADS-D scores between
HUNT 2 and follow-up (Table 2). The
PHRG showed a very strong HADS-T
reduction (p<.001), whereas the reference
group reported a strong symptom increase 
(p<.001) from HUNT 2 to follow-up. Mean
symptom score in the PRG did not change
significantly (p=.697) in the same time
interval. Within each study group mean
HADS-A and HADS-D scores changed in 
the same direction and effect sizes were
identical or similar for both subscales.
Women and men did not differ in their
mean HADS-T scores; not at baseline or at 
follow-up in any of the groups (Table 2).
Change in anxiety and depression
symptom levels at follow-up
Overall, the percentage of participants at each of the
three HADS-T symptom levels remained quite 
stable from HUNT 2 to the follow-up four years
later. In the total sample, the percentage at the
lowest level was 54% at both times. At the next
level there was a decrease from 25% to 22%, and 
consequently the percentage scoring in the highest
level increased from 21% to 24% from HUNT 2 to
follow-up (Table 3).
Table 3 shows the considerable individual
changes between symptom levels after four years,
particularly in participants from the PRG where 1/3
were still at the same level, 1/3 had moved down
one level, and 1/3 had emerged to the highest
symptom level. Among those at the lowest symptom
level at baseline (REF), 161 new cases (22%) had
emerged to HADS-T caseness level at follow-up. Of
these new cases, a third had reached the highest
symptom level.
At the four year follow-up, 227 (69%)
subjects in the PRG and 222 (80%) subjects in the 
PHRG were still cases according to the conventional
cut-off on HADS-T (19 points, including the two top
levels). In the PHRG, a HADS-T score of 25 or
above at baseline had a positive predictive value
(PPV) of 0.72 in predicting one or more current
mental disorder(s) at the time of follow-up four
years later. When including the lifetime mental
disorder(s) reported at follow-up, PPV was 0.83.
Diagnostic interviews at follow-up
Of the 300 randomly selected 
subjects from the PHRG, 152 (51%)
accepted the invitation to a clinical
interview four years later. Except for the
participants being slightly younger
(p=.049), baseline characteristics did not 
differ significantly between participants
and non- participants.
The diagnostic performance of the
HADS-T in this sample was only
acceptable for detecting Axis I disorder(s),
and the positive predictive value (PPV) 
was 0.81 at both cut-offs (19 and 25
points). For depression, anxiety disorder(s),
and co-morbid anxiety and depression the
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Figure 1.  Mortality patterns and attendance at follow-up in the three study groups 
5In total, 110 persons (72%) 
fulfilled the criteria for one or more Axis I 
mental disorder(s) at follow-up: of these 20 
(18%) had current affective disorder(s) 
(major depression and/or dysthymia), 39 
(35%) had current anxiety disorder(s), and 
36 (33%) had both conditions. At average, 
women met criteria for 2.1 psychiatric 
disorders compared to the 1.2 disorders 
that men met the criteria for (p=.006). The 
38 (25%) who had positive screening 
results for personality disorder (IPDS) met 
the criteria for significantly more axis I 
disorders at follow-up (2.5 vs. 1.2 disorders 
at average, p<.001) and had significantly 
higher mean HADS-T score in HUNT 2 
(p=.005) and at follow-up (p=.004) 
compared to those who screened negative 
for IPDS. 
DISCUSSION 
Due to differences in sampling and 
assessment, a direct comparison of our 
results with previous studies (11;13;14) 
might be difficult. However, our results 
suggest that self-rated anxiety and 
depression symptoms in the general 
population show similar outcomes as found 
for different diagnostic levels of depression 
in clinical studies, both in terms of overall 
stability and individual symptom level 
fluctuations over time. There was a close 
relationship between increasing HADS-T 
levels and unfavourable baseline 
characteristics.  In contrast to many 
previous studies, we found no significant 
gender differences in outcome. From the 
reference group 22% had emerged to the 
two higher symptom levels at follow-up 
and fulfilled the criteria for HADS-T 
caseness (19 points or above). Though 
those at the highest symptom level at 
baseline (PHRG) showed significant 
symptom reduction, only 20% were below 
HADS-T caseness at follow-up. HADS-T 
caseness seems to predict a chronic or 
recurrent course in the majority of the 
cases.
HADS-T symptom level and baseline 
characteristics  
The observed gradient of unfavourable 
sociodemographic variables, lifestyle 
factors, and clinical characteristics 
associated with increasing HADS-T levels 
is in accordance with other reports (1;26). 
The gradient of the most severe clinical 
and psychosocial markers progressed 
above the cut-off for HADS-T caseness as 
they were more common in the PHRG than 
the PRG. This observation underlines the 
importance of characterising the severity 
level of anxiety and depression rather than 
only adhering to strict dichotomisation 
(13;14;27;28). There are several factors 
that could account for the discrepancy 
between this study and clinical studies 
regarding the intake of antidepressants. 
First, even at the highest symptom levels of 
anxiety and depression in the general 
population, detection  rate could never 
reach the level it does in psychiatric patient 
samples (by definition one hundred 
percent). Second, due to the delay of onset 
of effect for antidepressants, we included 
only those who had used these medications 
daily for at least the last two months before 
baseline (HUNT 2). Finally, self-report of 
psychopharmacological treatment is, in 
general, likely to be underestimated (29).  
Our findings also suggest that the treatment 
of anxiety and depression should be 
approached not only by means of diagnosis 
and symptom score, but also according to 
the associated demographic and 
psychosocial characteristics as these are 
often contributing factors to symptom 
persistence and relapse (30).  
Change in mean anxiety and depression 
scores at follow-up 
Due to the extremely high HADS-T scores 
in the PHRG in HUNT 2, a general 
symptom reduction at follow-up should be 
expected in terms of a regression towards 
the mean (RTM) (31).  
In the reference group, at least 
three mechanisms might explain the 
significant symptom increase. First, it is 
likely that a slight RTM effect is occurring. 
Second, the effects of age and 
observational time need consideration. 
Mean HADS-D score, and consequently 
mean HADS-T score, increased linearly 
with age in both genders in the total HUNT 
2 sample (32). Whether this cross-sectional 
observation primarily reflects age effects or 
cohort effects, or both, cannot be answered 
in this study (33). Though, if it was mainly 
an age effect, four years of observation 
should only account for 0.5-1.0 points 
increase in mean HADS-T score. At the 
same time, a general upward trend of the 
prevalence of depression regardless of age, 
sex, and sociodemographic status was 
demonstrated in a recent eight-wave 
Belgian study (34). Yet, other studies show 
conflicting findings (35-37). Third, 
although mean HADS-T score at baseline 
did not differ between participants and 
6non-participants at follow-up, we cannot 
exclude the idea that attendance bias may 
have influenced the results in our study. 
According to the literature, however, a loss 
of subjects with high HADS scores rather 
than those scoring low at the time of 
follow-up should be expected (38;39).  
The majority of studies have 
found that female gender predicts poor 
outcome in major depression (10;13;40-
42), yet some report similar course and 
outcome in women and men (14;43-45). 
This was also the case in our study. This 
might partly be explained by the instrument 
used (HADS), which has anhedonia as one 
of its seven items and anhedonia has been 
proven to be the least gender specific 
among depressive symptoms (46).  
The simultaneous change of the HADS-A 
and HADS-D sub scores observed in our 
study fits with the established theoretical 
constructs of the relationship between 
anxiety and depression as established by 
Clark and Watson (47). This has also been 
demonstrated in most recent psychometric 
studies of the HADS, which showed that 
despite a two-factor solution and a high 
internal consistency of the anxiety and 
depression subscales, the two subscales 
remain highly interrelated (18;20;48;49).  
Change in anxiety and depression 
symptom levels at follow-up 
Consistent with the literature, initial 
symptom severity was a strong predictor 
for the outcome in our study (13;27;46;50-
52).  
The reduction in mean HADS-T score in 
the PHRG between HUNT 2 and follow-up 
probably had little clinical relevance as 
80% were still HADS-T cases. There was 
also a large proportion that was still above 
caseness level in the PRG at follow-up 
(69%). Considering the levels of 
psychopharmacological treatment and 
help-seeking, this is less than encouraging. 
Again, whether high HADS scores merely 
reflect features of anxiety and depression 
associated with a chronic course, or if the 
available treatment was not adequate, or 
both, is open for speculation. Though it is 
often considered a mild or moderate 
symptom (46), anhedonia has been shown 
to have some predictive value for recurrent 
and chronic depression (53). Compared to 
other subtypes of depression, the anhedonia 
subtype has a later onset (46;54) and is 
more strongly associated with a family 
history of depression (46). Both these 
factors are predictors for a chronic course 
(55). Further, Paykel (51) found that 
psychological symptoms at a mild or 
moderate level, but not major biological 
symptoms, were characteristic for residual 
symptoms in those with a poor outcome.  
Though tentative, in agreement with this 
study we suggest that a brief personality 
screening might have additional prognostic 
value concerning the outcome. 
External validity
We argue that those scoring in the highest percentile 
at baseline (PHRG) represent syndromal level of 
depression and anxiety disorder. The fact that 72% 
in this group met the criteria for one or more current 
mental disorders and 83% met the criteria for current 
and/or lifetime mental disorder(s) at follow-up 
supports this assumption. Also, the mean HADS-T 
scores were equal (PRG) or higher (PHRG) at both 
times in our study compared to a cross-sectional 
validation study among psychiatric outpatients by 
Spinhoven et al (20). In sum, the majority of 
individuals scoring 19 points or above on HADS-T 
in HUNT 2 had chronic or recurrent symptoms at a 
severity level comparable to clinical samples. The 
PRG is likely to be a mix of syndromal and sub-
syndromal cases, while the REF largely represents 
mentally healthy individuals from the general 
population.   
Strengths and weaknesses 
Compared to previous studies, we were 
able to recruit a relatively large general 
population sample. Another advantage was 
that the three study groups covered the full 
range of symptom severity on HADS, 
which made possible the estimation of new 
cases emerging from lower symptom levels 
than previously studied. Anxiety, 
depression, and all other baseline 
characteristics were assessed with the same 
methods and at the same time in all three 
study groups in a general health study 
setting. This has the potential to reduce 
recall bias, which is often a problem when 
data are collected retrospectively in a 
clinical setting.  
 Nevertheless, certain 
limitations concerning this study need to be 
addressed. First, symptoms were assessed 
only at baseline and follow-up. Therefore, 
it was not possible to describe the 
prospective symptom fluctuations during 
the period in between. However, based on 
the 10 year study by Kennedy et al (13), a 
stable number of individuals at each 
symptom level can be expected after the 
two first years of observation. Second, 
even though there were no differences in 
baseline HADS scores between participants 
7and non- participants at follow-up, the low 
follow-up rate could have influenced our 
results.  
Third, the HADS is primarily a screening 
tool for medical or other non-psychiatric 
settings (18;56). In samples with a high 
prevalence of mental disorders, we agree 
that HADS-T at conventional cut-off (19) 
or higher is equally (or better) suited to 
detect mental disorders than are the 
separate subscales (20). It has also been 
previously shown that HADS-T predicts 
mental disorder(s) more precisely than it 
points out affective or anxiety disorders 
specifically, or in combination (20;57). 
Unfortunately, we were not allowed to 
contact and interview persons in the PHRG 
and REF. This could have allowed for a 
proper diagnostic validation of the HADS 
in this study. Finally, if the notification of 
the high scores to participants in the PHRG 
and their GPs (16) influenced the symptom 
course, it is assumed that it would have 
been in a positive direction as a 
consultation with their GP, and hopefully 
better treatment, should decrease 
psychiatric morbidity. This, however, 
could not be investigated with our design. 
Conclusion
In conclusion, increasing HADS-T 
symptom level is associated with a wide 
range of sociodemographic variables, 
lifestyle factors, and clinical risk markers, 
which are relevant when a clinician 
assesses and treats anxiety and depression. 
We suggest that the established HADS-T 
caseness level (> 19 points) is a reliable 
predictor for high long-term symptom 
stability and need for further psychiatric 
assessment and follow-up in the general 
population. Overall, psychiatric morbidity 
in the general population is relatively 
constant, yet shared between many persons 
and several symptom severity levels. 
Particularly in depression, the individual 
high-risk strategy has shown discouraging 
results despite great efforts to improve 
detection and treatment over the last 
decades (7;9). Fortunately, several 
population based, informal self-help 
strategies have proven to be effective, 
inexpensive, and highly acceptable to the 
population (58).  
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Table 1.  Relationship between anxiety and depression symptom severity (HADS) and demographic, lifestyle, and 
clinical characteristics at baseline (HUNT 2, 1995-97).   










Psychometric characteristics   
   HADS-T score, range  0-18 19-24 25-42 
   Mean HADS-T score (95% CI)  6.9 (6.6-7.1) 20.9*(20.8-21.0)    28.2* (28.0-28.4) 
   Mean HADS-A score (95% CI) 3.8 (3.6-4.0) 11.3*(11.3-11.5) 15.1* (14.9-15.3) 
   Mean HADS-D score (95% CI) 3.1 (2.9-3.2) 9.8*(9.6-10.0) 13.3* (13.1-13.5) 
Demographic characteristics 
   Mean age by screening, years (SD) 48.7 (17.7) 49.9.0 (15.3) 51.4* (14.7) 
   Female gender, % 52.5  61.8* 59.8 * 
   University level education, % 21.6  15.9* 9.7 * 
   Living alone, %  20.3 21.8 26.1 * 
   Employed/under education (< 67 yrs), % 84.1  67.5* 51.0* 
   Disability pension (< 67 yrs), % 10.4 22.3* 34.7* 
Lifestyle characteristics, % 
   Daily smoking  29.5 43.8* 49.3* 
   Alcohol consumption > 75th percentile 25.2 24.4 25.5 
   Physical active 43.0 35.6* 29.7* 
Clinical characteristics, % 
    Ever sought psychiatric help 10.0 48.5* 67.9* 
    Self-reported life-time MDE 24.0 76.2* 93.8* 
    Impaired because of mental problems1 1.6 21.6* 46.7* 
    Daily intake of tranquillizers and/or 
hypnotics 
2.6 10.7* 26.0* 
    Intake of antidepressants > 2 months 2.1 15.1* 29.2* 
   Chronic somatic disease2 20.3  25.4* 29.2 * 
   Chronic  pain3 12.5 18.8 * 18.8* 
* unadjusted p< .05 compared to reference group   
1Daily impairment related to mental problems at a moderate or severe level (compared to no or slight impairment).  
2 One or more of the following conditions: asthma, myocardial infarction, angina pectoris, stroke, diabetes, and 
cancer.
3 Rheumatism/degenerative joint disease, musculoskeletal pain or headache 1 year or more.  
9Table 2. Comparison between mean HADS scores (HADS-T, HADS-A and HADS-D) in HUNT 2 (1995-97) and 
at follow-up (2000); paired sample T-tests1, and effect size of change (Cohen’s d).  
HUNT 2 Follow-up p Cohen’s d 
Sample (response at follow-up) 
Total sample (n=1,326, 53.0%) 
  Mean HADS-T score (SD) 14.7 (9.8) 16.5 (8.7) <.001 0.19 
  Mean HADS-A score (SD) 8.1 (5.5) 8.9 (4.8) <.001 0.15 
  Mean HADS-D score (SD) 6.7 (5.0) 7.6 (4.8) <.001 0.16 
Reference group (n=718, 56.8%)
  Mean HADS-T score (SD) 6.7 (4.5) 12.0 (7.6) <.001 0.87 
  Mean HADS-A score (SD) 3.9 (2.9) 6.7 (4.6) <.001 0.75 
  Mean HADS-D score (SD) 2.9 (2.4) 5.4 (4.1) <.001 0.77 
PRG (n=293, 52.8%)
  Mean HADS-T score (SD) 20.9 (1.6) 21.0 (6.9) .697 0.02 
  Mean HADS-A score (SD) 11.4 (2.4) 11.4 (3.6) .966 0.00 
  Mean HADS-D score (SD) 9.7 (2.3) 9.7 (4.1) .854 0.00 
PHRG (n=279, 45.5%)
  Mean HADS-T score (SD) 28.2 (3.2) 22.8 (6.6) <.001 1.10 
  Mean HADS-A score (SD) 15.3 (2.4) 11.9 (3.5) <.001 1.15 
  Mean HADS-D score (SD) 13.2 (2.5) 10.9 (4.1) <.001 0.70 
1 Women and men within the reference group, the PRG, and the PHRG had the same mean HADS-T at baseline 
(p-values .24, .85, and .16, respectively) and at follow-up (p-values .60, .80, and .15, respectively).
Abbreviations: PHRG=Psychiatric high risk group. PRG=Psychiatric risk group.  
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Reference group, REF (n=718)
  HADS-T 0-18 718 (100%) 557 (78%) 
  HADS-T 19-24 109 (15%) 
  HADS-T > 25 52 (7%) 
Psychiatric Risk Group, PRG (n=293)
  HADS-T 0-18 102 (31%) 
  HADS-T 19-24 329 (100%) 102 (31%) 
  HADS-T > 25 125 (38%) 
Psychiatric High Risk Group, PHRG (n=279)
  HADS-T 0-18 57 (20%) 
  HADS-T 19-24 85 (31%) 
  HADS-T > 25 279 (100%) 137 (49%) 
1) All changes in HADS-T level at follow-up were significant (p<.001) compared to baseline 
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Questionnaires used in IDANT (1995-97) and the follow-up study (2000) 
A 3.1 Baseline Form IDANT 
A 3.2 Questionnaire and interview follow-up study 

Intervensjonsundersøkelsen mot depresjon 
og angst i Nord-Trøndelag (IDANT) 
Basisskjema (fylles ut ved første og andre konsultasjon) 
To første bokstaver i pasientens etternavn: _______ 
Kjønn: ______   Fødselsår: ______  Lege: _____________ 
Pasientens reaksjoner på melding/innkalling: (Sett ring rundt riktig tall nedenfor) 
1)  Pasientens reaksjon på meldingen om angst/depresjon: 
   1 Positiv 2 Negativ 3 Nøytral 
2)  Hvordan reagerte pasientens nærmeste pårørende? 
   1 Positiv 2 Negativ 3 Nøytral 4 Ikke informert dem/ingen nære pårørende 
3)  Hvor lang tid fra pasienten fikk melding til han/hun bestilte time? 
   1 <1 uke 2 1-2 uker 3 2-3 uker 4 3-4 uker 5 Innkalt 6 Hjembesøk 
4)  Hvordan reagerte pasienten på forespørsel om å være med i intervensjonsstudien? 
   1 Positiv 2 Negativ 3 Nøytral 
5)  Pasientens status: 
 1 Ikke kjent fra før 2 Kjent fra før uten kjente psykiske problemer 
 3 Kjent fra før med kjente psykiske problemer behandlet i kommunehelsetjenesten 
 4 Kjent fra før med kjente psykiske problemer behandlet i det psykiske helsevern 
Tidligere psykiske problemer: 
6)  Alder første gang behandlet for psykisk problem: _____ år 
7)  Funksjonssvikt – tidligere psykisk problem: 
 1 Sykmeldt  2 Attføring/rehabilitering 3 Uføretrygd 
8)  Pasienten har vært behandlet av? 
 1 Allmennpraktiker 2 Psykiatrisk poliklinikk 3 Psykiatrisk avdeling 
 4 Rusmiddelomsorgen 
9)  Diagnosen var: ________________________________________ 
10)  Diagnosen er:  1 Sikker 2 Noe usikker 3 Helt usikker 
11)  Behandling: 
 1 Støttesamtaler 2 Nevroleptika 3 Antidepressiva 4 Anxiolytika 
12)  Forløp over tid: 
 1 Blitt bedre 2 Uforandret 3 Blitt verre 
Pasientens bakgrunn: 
13)  Psykiske lidelser/suicid blant nære slektninger: 
 1 Ingen 2 Foreldre 3 Søsken 4 Barn 
14) Påkjenninger i barndom: 
 1 Atskillelse fra foreldre  2 Brutt familie før 12 år  3 Alvorlig mobbing 
 4 Overgrep (seksuelle/fysiske) 5 Utrygg atmosfære i hjemmet 6 Lite bekreftelse 
 7 Alvorlig legemlig sykdom 8 Annet: ________________________________ 
15)  Alder for start av psykiske problemer: ______ år 
Pasientenes nåværende situasjon: 
16)  Sivilstatus: 
 1 Ugift 2 Gift 3 Samboende 4 Separert 5 Skilt 6 Enke/enkemann 
17) Bosituasjon: 
 1 Bor alene  2 Bor med familie  3 Bor på institusjon 
18)  Arbeidssituasjon: 
 1 I arbeid/husmor 2 Arbeidsledig 3 Sykmeldt/attføring 4 Trygdet 
19)  Legemlige sykdommer: 1 Betydelig  2 Moderate 3 Alvorlige 
20) Sosioøkonomiske problemer: 1 Betydelig  2 Moderate 3 Alvorlige 
21) Familiære problemer:  1 Betydelig  2 Moderate 3 Alvorlige 
22) Tidligere selvmordsforsøk: 1 Ja 2 Nei 
23) Overforbruk av alkohol: 1 Ja 2 Nei 
24)SPIFA diagnosescreening positiv: 
 1 Tilpasningslidelse 2 Posttraumatisk stresslidelse 3 Depresjon 4 Panikklidelse 
 5 Agorafobi 6 Sosial fobi  7 Generalisert angstlidelse 8 Tvangslidelse 
 13 Suicidalitet 14 Psykose 15 Organisk psykisk lidelse 16 Kognitiv svikt 
 17 Personlighetsproblemer 
25) SPIFA manualdiagnoser positive: 
 1 Tilpasningslidelse 2 Posttraumatisk stresslidelse 3 Depresjon 4 Bipolar lidelse 
 5 Panikklidelse 6 Agorafobi  7 Sosial fobi 8 Generalisert angstlidelse 
 9 Tvangslidelse 10 Anorexia nevrosa 11 Bulimia nevrosa 12 Somatiseringslidelse 
 13 Udifferensiert somatoform lidelse  14 Alkoholmisbruk 15 Alkoholavhengighet 
 16 Stoffmisbruk 17 Stoffavhengighet 18 Suicidalitet: Stor middels liten 19 Psykose 
 20 Organisk psykisk lidelse 21 Kognitiv svikt 
26) Relevante SPIFA skåringsskalaer: 
 MADRS: _____   Klinisk angstskala: _____  Mini mental status: _____ 
 Global funksjonsvurdering (GAF): _____ 
27) Behandlingsplan for pasienten: 
 1 Ingen behandling nå 2 Behandler selv 3 Henviser til psykiatrisk poliklinikk 
1INTERVJU, versjon 170300 
Kodebok/intervjuguide – etterundersøkelsen 2000 
1.Intervjudato:____________ 2. Intervjuer:_______________ 
Intervju start kl:__________ slutt  kl:_____________ 3. Intervjuvarighet:_______ min       
A. Setting: 
2.Intervjusted:            0 = Hjemme, 1 = Poliklinikk, 2 = Lokalt legekontor 
3.Pårørende tilstede:                                                                                         0 = Nei; 1 = Ja 
4.Intervjutidspunkt  0 = Dagtid, 1 = Kveldstid (e. kl 15.30)____________________ 
Man starter intervjuet med en kort presentasjon av seg  selv og studien. 
Har deltakeren (D) spørsmål til selvutfyllingsskjemaet (s.skjema), starter man med å gå 
gjennom disse og hjelper evtentuelt til med utfylling. 
NB ! Ved åpne spørsmål skal D. sitt svar gjentas mest mulig ordrett, unngå ”tolkning” 
B. Melding fra SHUS/intervensjonen (1995-1997) – gå til de enkelte spørsmålene i 
s.skjema for utdyping av de avkryssede svarene
x S.skjema nr 3:”Hvordan reagerte du på den skriftlige meldingen ? __________ 
4. Kommentar/begrunnelse_____________________________________________________ 
___________________________________________________________________________
x S.Skjema nr. 4: ”Man ble i meldingen/brevet anbefalt å ta kontakt med sin lege, gjorde du 
dette?”)  ja/nei 
5. Hva var årsaken til valget ditt ? ( Tips: hva er avgjørende for om den enkelte deltar eller 
ikke ?): 
__________________________________________________________________________
6. Dersom nei, hva kunne evt vært gjort annerledes for at du skulle møtt ?  
__________________________________________________________________________
x S.skjema nr 5 : ”Dersom nei, tok legen din kontakt eller initiativ til en timeavtale ?:”  
ja/nei 
7. Hva synes om det ? 
___________________________________________________________________________
8. Status i Helsevesenet før HUNT : 
etikett
2 0 = Pas ikke kjent hos noen primærlege, 1 = Kjent hos primærlege uten psykiske problemer, 
 2 = Psykiske problemer kjent for og behandlet primærlege, 3 = Psyk. problemer kjent og 
behandlet i 2. linjetjenesten
x S.skjema nr 20: ”Fikk du melding om andre/fysiske helseproblemer etter HUNT?”   ja/nei 
Dersom nei, gå til status presens 
9. Dersom ja, hvordan reagerte du på dette?:  
0 = Svært positiv, 1= Positiv, 2 = Nøytral, 3 = Negativ, 4 = Svært negativ
10. Kan du utdype dette litt nærmere ? ( gjerne i forhold til meldingen om angst/depresjon) 
___________________________________________________________________________
___________________________________________________________________________
x S.skjema nr 20: ”kontaktet du legen din når meldingen kom ?”    nei/ja 
10. Hadde du forventninger om å få hjelp for/forebygge: 
Fysisk sykdom/helseplager                                            0 = Nei, 1 = Ja, 2 = Vet ikke/usikker ( ) 
Psykisk sykdom/plager:                                                 0 = Nei, 1 = Ja, 2 = Vet ikke/usikker ( ) 
3.Status presens 
11. Hvordan er helsa di nå ? 
_______________________________________________________
___________________________________________________________________________
12. Har du betydelige psykiske plager nå ?:                                        0 = Nei  1 = Ja
x S.skjema nr 20: Går du til behandling for psykiske plager nå ?   ja/nei 
13. Hvis ja, hvem er hovedkontakt ?________________________________________




14. Dersom nei, føler du behov for psykiatrisk behandling nå ?: 
                                                                                    0 = Nei, 1 = Ja, 2 = Usikker/vet ikke
15. Hvis ja, helst:   0 = Hos primærlege, 1 = 2.linjetjenesten/psykiatrisk avdeling, 2 = Usikker 
x S.skjema nr. 20: Har du skiftet primærlege de siste 5 årene ? 
316. Dersom ja, hva var årsaken til dette ?:__________________________________________ 
___________________________________________________________________________
4.Før HUNT/bakgrunn 
17. Har du hatt psykiske problemer i årene før HUNT ?: 
 0 = Nei 
 1 = Ja, vedvarende (mer enn 12 mnd sammenhengende) 
 2 = Ja, episodisk/tilbakevendende 
18. Hvis ja, alder for start av psykiske problemer: ______år 
19. Hvis ja, har du fått behandling for psykiske problemer før HUNT ?  
1 = Ja, alder første gang:____________ 
  2 = Nei, aldri fått behandling før HUNT – gå til 23. 
20. Antall ganger innl psyk avd: 
0 = 1 gang, 2 = 2 ganger, 3 = 3-4 ganger, 4 = >5 ganger,5 = >10 ganger, 6 = aldri innlagt ( ) 
21. Poliklinisk behandling
1 = Ja, antall perioder og varighet
2 = Nei, aldri 




Annen  :____________________________________________________________________ 
TILBUD OM KORT PAUSE 
5. Diagnostisk screeningintervju M.I.N.I (vedlagt). 
23. (Fra MINI, ikke spør om dette på nytt) 
Dersom tidligere suicidalforsøk: antall/metode/alvorlighetsgrad: 
Intervjuet avsluttes med en kort oppsummering for deltakeren, særlig i forhold til 
screeningintervjuet.  
Skal det sendes melding til primærlege ? ja/nei 
Samtykkeerklæring, husk en underskrift for hvert punkt i samtykket.
SLUTT
hunt
Helseundersøkelsen i Nord-Trøndelag 
Kjære deltaker ! 
For om lag 4 år siden deltok du i HUNT-undersøkelsen, og vi er svært takknemmelig for at du også stiller 
opp i denne etterundersøkelsen. 
Vi starter med å spørre deg om hvordan du hadde det, og hva som skjedde i tiden rundt den siste HUNT-
undersøkelsen for ca 4 år siden. 
TILBAKEBLIKK PÅ HUNT (1995-97) 
1. Hadde du noen vesentlige psykiske plager (f.eks 
angst- og /eller depresjon) da du møtte til den siste 
HUNT-undersøkelsen? 
 Nei  Ja   Usikker/husker ikke
Hvis ja, beskriv plagene:
 Vedvarende (mer enn 12 mnd sammenhengende) 
 Episodisk/tilbakevendende 
 Aktuell stress/krisesituasjon 
2. Gikk du allerede i behandling for psykiske plager 
(f.eks angst- og/eller depresjonsplager) når du møtte til 
HUNT-undersøkelsen?
 Nei 
 Ja, til primærlege 
 Ja, til psykiatrisk poliklinikk/sykehus eller privat   
      spesialist 
 Ja, både til primærlege og sykehus/spesialist 
3. Hvordan reagerte du på den skriftlige meldingen du 
fikk like etter HUNT (for om lag 4 år siden) om at du 
kunne ha angst- og/eller depresjonssymptomer og 
burde søke hjelp?
 Svært positiv   Negativ 
 Positiv   Svært negativ 
 Nøytral 
4. Man ble i meldingen anbefalt å ta kontakt med sin 
lege, gjorde du dette?
 Nei  Ja 
Dersom du svarte ja, gå til spørsmål nr. 6
5. Hvis nei, tok legen din kontakt med deg?
 Nei  Ja, telefonisk eller skriftlig kontakt   
 Husker ikke 
6. Førte denne meldingen til at det ble startet
behandling for dine psykiske plager?
 Ja, det ble startet ny behandling hos primærlege 
 Ja, jeg ble henvist til psykiatrisk poliklinikk/avdeling  
      pga. meldingen 
 Nei, jeg fortsatte i samme behandling for mine  
      psykiske plager 
 Nei, ingen videre oppfølging/behandling for psykiske  
     plager 
 Usikker/husker ikke 
7. Førte meldingen til at din lege ble mer oppmerksom 
på eller endret sin holdning til dine psykiske plager ?
 Ja, det skjedde en positiv forandring 
 Nei, ingen forandring  
 Husker ikke/vet ikke 
AKTUELL/TIDLIGERE LIVSSITUASJON 
8. Hva er din sivilstand nå ? 
 Gift    Skilt 
 Samboer   Enke/enkemann 
 Separert   Enslig/har aldri vært gift 
9. Hvordan er helsa di nå?  
 Dårlig   
 Ikke helt god 
 God    
 Svært god 
10. Har du, eller har du hatt:         
Ja Nei Alder  
første  gang                     
Lavt stoffskifte   _________ 
Astma    _________ 
Hjerteinfarkt   _________ 
Angina pectoris  
(hjertekrampe)   _________  
Hjerneslag/hjerneblødning  _________ 
Diabetes                              _________ 
Kreftsykdom                        _________ 
Annen langvarig sykdom:   _________ 
11. MUSKEL-/SKJELETTPLAGER 
Har du i løpet av det siste året vært plaget med smerter 
og/eller stivhet i muskler og ledd som har vart i minst 3 
måneder sammenhengende?  
 Ja   Nei 
Dersom ja, hvor lenge har plagene vart 
sammenhengende? 
Svar for det området hvor plagene har vart lengst 
Hvis under 1 år, oppgi antall mnd.  ___________  
Hvis 1 år eller mer, oppgi antall år.  ___________ 
12. DAGLIGE FUNKSJONER 
Har du noen langvarig sykdom, skade eller lidelse av 
fysisk eller psykisk art som nedsetter dine funksjoner i 
ditt daglige liv? (Langvarig = minst ett år) 
 Ja   Nei 
Hvis JA: 
Hvor mye vil du si at dine funksjoner er nedsatt?  
 Litt nedsatt  Middels nedsatt  Mye nedsatt 
     Ja Nei 
Hemmet pga. kroppslig sykdom?
Hemmet pga. psykiske plager?  
13. KAFFE/ALKOHOL/RØYKING 
Hvor mange kopper kaffe drikker du daglig? 




Er du total avholdsmann-/kvinne?
 Ja   Nei 
Hvor mange ganger i måneden drikker du vanligvis 
alkohol?   
Antall ganger
Regn ikke med lettøl. Sett 0 hvis mindre enn 1 gang i mnd. 
Røyker du sigaretter daglig ? Ja Nei
Hvis ja, hvor mange pr. dag?    
14. FYSISK AKTIVITET                                
I fritida: 
Hvordan har din fysiske aktivitet i fritida vært det siste 
året? (Timer pr uke)
Tenk deg et ukentlig gjennomsnitt for året. Arbeidsveg 
regnes som fritid
  ingen under   3 timer 
1-2 timer og mer 
Lett aktivitet  
(ikke svett 
andpusten)
Hard fysisk  
aktivitet  
(svett/andpusten)
15. HVORLEDES FØLER DU DEG 
Har du de siste to ukene følt deg: 
Nei Litt En Svært  
god del mye 
Trygg og rolig                 
Glad og  
optimistisk         
Nervøs og urolig             
Plaget av angst                
Irritabel                            
Nedfor/deprimert           
Ensom                              
Beskriv dine følelser deg den siste uka
(sett et kryss for hvert  spørsmål) 
Jeg gleder meg fortsatt over ting slik jeg pleide før  
Avgjort like mye Bare lite grann   
Ikke fullt så mye Ikke i det hele tatt  
Jeg har en urofølelse som om noe forferdelig vil skje  
Ja, og noe svært ille Litt, bekymrer meg lite  
Ja, ikke så veldig ille     Ikke i det hele tatt           
Jeg kan le og se det morsomme i situasjoner  
Like mye nå som før     Avgjort ikke som før      
Ikke like mye nå som  Ikke i det hele tatt 
    før    
Jeg har hodet fullt av bekymringer
Veldig ofte         Av og til             
Ganske ofte          En gang i blant   
Jeg er i godt humør 
Aldri                             Ganske ofte            
Noen ganger                  For det meste        
Jeg kan sitte i fred og ro og kjenne meg avslappet  
Ja, helt klart                Ikke så ofte             
Vanligvis           Ikke i det hele tatt   
Jeg føler meg som om alt går langsommere  
Nesten hele tiden    Fra tid til annen  
Svært ofte   Ikke i det hele tatt   
Jeg føler meg urolig som om jeg har sommerfugler i 
magen
Ikke i det hele tatt   Ganske ofte           
Fra tid til annen     Svært ofte            
Jeg bryr meg ikke lenger om hvordan jeg ser ut  
Ja, har sluttet å bry meg Kan hende ikke nok   
Ikke som jeg burde  Bryr meg som før       
Jeg er rastløs som om jeg stadig må være aktiv  
Uten tvil svært mye Ikke så veldig mye     
Ganske mye  Ikke i det hele tatt     
Jeg ser med glede frem til hendelser og ting  
Like mye som før         Avgjort mindre enn før     
Heller mindre enn før   Nesten ikke i det hele tatt
Jeg kan plutselig få en følelse av panikk 
Uten tvil svært ofte      Ikke så veldig ofte            
Ganske ofte                  Ikke i det hele tatt            
Jeg kan glede meg over gode bøker, radio og TV  
Ofte                             Ikke så ofte                      
Fra tid til annen           Svært sjelden                   
16. ØKONOMI  
Mottar du noen av følgende offentlige ytelser?
    Ja Nei 
Sykepenger/sykelønn/ 
rehabiliteringspenger  
Ytelser under yrkesrettet attføring 
Uførepensjon              
Dersom ja:  
Innvilget årstall: _____________    
Hva var årsaken til uførhet (diagnosen)?:
______________________________________ 
Alderspensjon                  
Sosialstøtte                    
Arbeidsløshetstrygd           
Overgangsstønad              
Etterlattepensjon                     
Andre ytelser                           
17. VENNER/SOSIALT 
Hvor ofte tar du vanligvis del i foreningsvirksomhet 
som f.eks. syklubb, idrettslag, politiske lag, religiøse 
eller andre foreninger? 
 Aldri, eller noen få ganger i året  
 1-2 ganger i måneden 
 Omtrent en gang i uka 
 Mer enn en gang i uka   
Antall  kopper 
                sigaretter daglig 
18. MEDISINBRUK 
Har du i deler av de siste 12 måneder brukt noen 
medisiner daglig eller nesten daglig?  
 Ja    Nei 
Hvis ja, angi type medisin og dosering som du bruker 
nå:
Navn Styrke Antall tabl. 
daglig 
Eks: Renitec tabeltter 20 mg 1 
1.   
2.   
3.   
4.   
5.   
6.   
7.   
8.   
9.   
10.   
Hvis JA: 
Hvor mange måneder har du brukt følgende medisiner  
(skriv antall måneder) 
Sett 0 hvis du ikke har brukt medisinene 
Smertestilllende                _______________ 
Beroligende medisin      _______________ 
Sovemedisin                   _______________ 
Medisin mot depresjon  _______________ 
Hvor ofte har du brukt avslappende/beroligende 
medisin eller sovemedisin den siste måneden? 
Daglig              sjeldnere enn   
hver uke, men        hver uke  
     ikke hver dag   aldri
19. ALT I ALT  
Når du tenker på hvordan du har det for tida, er du 
stort sett fornøyd med tilværelsen eller er du stort sett 
misfornøyd? (Bare ett kryss)
Svært fornøyd     Nokså misfornøyd       
Meget fornøyd    Meget misfornøyd       
Ganske fornøyd      Svært misfornøyd       
Både/og                         
20. ARBEID 
Hva slags arbeidssituasjon har du nå?
(Ett eller flere kryss)
Lønnet arbeid                             
Utdanning, militærtjeneste         
Lønnet arbeid, sykemeldt nå      
Arbeidsledig, permittert             
Selvstendig næringsdrivende      
Pensjonist/trygdet                       
Heltids husarbeid                        
Hvis du NÅ ikke har inntektsgivende arbeid eller du ikke 
har heltids husarbeid: Gå til BRUK AV 
HELSETJENESTER. 
Har du i løpet av de siste 12 månedene hatt 
sykefravær?   
Ja Nei 
Med egenmelding 
Med sykmelding fra lege 
Hvis JA:  
Hvor lenge til sammen? (Bare ett kryss)
2 uker eller mindre mer enn 8 uker          
2-8 uker                      
Har du i løpet av de siste 4-5 årene skiftet yrke eller 
arbeidsplass?   Ja    Nei 
21. BRUK AV HELSETJENESTER 
Har du gått til lege/behandling for kroppslige plager 
det siste året ? 
Ukentlig eller oftere  
1-3 ganger pr mnd 
2-3 ganger pr halvår  
1-2 ganger pr år     
 nei/aldri 
Har du gått til lege/behandling for psykiske plager det 
siste året ? 
Ukentlig eller oftere  
1-3 ganger pr mnd 
2-3 ganger pr halvår 
1-2 ganger pr år    
nei/aldri    
Ja Nei 
Har du vært innlagt i sykehus i løpet av  
de siste 5 årene?    
Har du hatt frikort hos legen i løpet av  
de siste 5 årene ?    
Hvis Ja: 
 et år  2-3 år  mer enn 3 år 
Har du skiftet primærlege i løpet av de  
siste 5 årene ?    
Hvis Ja: 
 1 gang  2 ganger  3 ganger eller mer 
Fikk du etter siste HUNT undersøkelse (95-97) melding 
om noen fysiske helsetilstander som burde følges opp?   
(f.eks blodtrykk, astma, hørsel/syn, vekt etc.)
 Ja   Nei 
Kontaktet du legen din når  meldingen kom ?
 Ja   Nei 
22. HUMØR OG TRIVSEL 
Angi hvordan du har følt deg den siste måneden:  
  Aldri Noen Ganske For det  
ganger  ofte meste   
I godt humør                
I dårlig humør?  
23. SINNE 
Sett kryss på det svaret som best beskriver deg i forhold til 
de to påstandene nedenfor: 
Jeg gir uttrykk for mitt sinne, og andre mennesker vet 
at jeg er sint 
 nesten aldri  ganske ofte 
 noen ganger  nesten alltid 
Jeg koker av sinne, men jeg viser det ikke til andre 
 nesten aldri  ganske ofte 
 noen ganger  nesten alltid 
24. HVORDAN DU SER PÅ DEG SELV 
Folk ser på seg selv på ulike måter. Kryss av for hvert 
utsagn hvor enig eller uenig du er.
Jeg har en positiv holdning til meg selv
 svært enig   uenig 
 enig    svært uenig 
25. HVORDAN DU FØLER DEG NÅ 
Føler du deg stort sett sterk og opplagt, eller trøtt og 
sliten? (Bare ett kryss)
 meget sterk og opplagt  
 sterk og opplagt  
 ganske sterk og  opplagt 
 både – og 
 ganske trøtt og sliten 
 trøtt og sliten 
 svært trøtt og sliten 
26. HVILE OG AVSLAPPING  
Har du i løpet av siste måned hatt 
innsovningsproblemer? (Bare ett kryss) 
 nesten hver natt  av og til 
 ofte    aldri 
Har du i løpet av siste måned våknet for tidlig og ikke 
fått sove igjen? (Bare ett kryss) 
 nesten hver natt  av og til 
 ofte    aldri 
27. HVORDAN DU HAR HATT DET 
Har det noen gang i løpet av ditt liv vært 
sammenhengende perioder på 2 uker eller mer da du:  
    Ja Nei 
Følte deg deprimert, trist  
og nedfor                        
Hadde problemer med matlysten  
eller spiste alt for lite                                                                                
Var plaget av kraftløshet eller  
mangel på overskudd  
Virkelig bebreidet deg selv og  
følte deg verdiløs   
Hadde problemer med å  
konsentrere deg eller vanskelig  
for å ta beslutninger                                                       
Hadde minst tre av de problemene  
som er nevnt ovenfor samtidig                                                               

Appendix 4 
A 4.1 HUNT-brochure (HUNT II) 
A 4.2 Consent statement HUNT II 
A 4.3 Confirmed consent 2002 with brochure
A 4.4 Educational program, notification letter and invitation to IDANT 










Den norske Lægeforenings emnekurs i psykiatri for allmennpraktikere 
Tema: Vurdering av selvmordsfare i allmennpraksis ved angst og depresjon.
Tidsrom: Torsdag 31. august og fredag l. september 1995. 
Sted: Jægtvolden Fjordhotell, Inderøy, Nord- Trøndelag 




1010- 1030: Hvilken betydning har arbeid med selvmordsforebyggende tiltak for 
arbeidet i SHUS -Statens helseundersøkelse.  
Adm. overlege Kjell Bjartveit 
1030- 1200: Vurdering av risikofaktorer for selvmord. 
Avd. overlege Marit Bjartveit Kriiger, psykiatrisk avdeling, Innherred sykehus 
1200-1300: Lunch
1300- 1430: Allmenpraktikerens diagnostisering av depresjon. 
Gruppeøvelser med video. Seksjonsoverlege Nils Håvard Dahl 
1430-1500: Kaffe
1500 –1700 Behandling av depressive plager 
Kognitiv tilnærming vI psykolog dr.phil. Tore C. Stiles, Universitetet i Trondheim 
MedikamentelI tilnærming vI avdelingsoverlege Bystein Stordahl, Namdal Sykehus 
17-1730: Beinstrekk 
1730- 1900: Samtidig angst og depresjon. Diagnostiske aweininger når pasienten 
formidler selvmordstanker .  
Professor dr.med. Alv A. Dahl, Inst.gruppe for psykiatri, Universitetet i Oslo 
0900- 1000: Kva seier allmennpraktikaren til ein psykiatrisk poliklinikk når pasienten 
ikkje orkar leve lenger?  
Kommunelegane Erling Dalen og Arve Strandheim, Levanger, avdelingsoverlege 
Eystein Stordal, seksjonsoverlege Nils Håvard Dahl,
1000-1030: Kaffe
1030- 1200: Kvalitetssikring av selvmordsvurdering.Bruk av psykometriske metoder i 
allmenpraksis 
Professor dr.med. Alv A. Dahl 
1200-1300: Lunch
130O -1345: Evaluering av selvmordsrisiko. Gruppeøvelser med video. 
Professor dr.med. Alv A. Dahl, avderlingsoverlege Marit Bjartveit Kn1ger 
1345- 1415: Kaffe
1415- 1545: Hva kan allmenpraktikeren gjøre i egen praksis? Presentasjon aven 
intervensjonsmodell 
Professor dr .med. Alv A. Dahl og seksjonsoverlege Nils Håvard Dahl 
Ottar Bjerkeset 
Folkehelsa, 7650 Verdal
Psykiatrisk klinikk Innherred sykehus, 7600 Levanger 
Kommunelege I 
(adresse) 
………………..kommune       Verdal 090300 
ANGÅENDE PROSJEKTET ”ETTERUNDERSØKELSE AV PSYKIATRISKE 
RISIKOINDIVIDER IDENTIFISERT VED HUNT” 
Et utvalg av de psykiatriske risikoindividene i HUNT II (1995-97), vil nå få tilbud om en 
etterundersøkelse.
Jeg er stipendiat i prosjektet og vil sammen med to medarbeidere gjennomføre intervjuene på 
psykiatrisk poliklinikk i Levanger/Namsos  og ute i kommunene fra mars/april og ut året.  
Alle deltakere har samtykket skriftlig på forspørsel om deltakelse. Risikogruppen scoret over 
99 percentil (25 poeng) på selvutfyllingsskjemaet HADS (Hospital Anxiety and Depression 
rating scale) i HUNT II. Disse fikk skriftlig melding fra Statens helseundersøkelser (SHUS) 
om høyt angst- og depresjonsnivå og ble tilbudt intervensjon i kommunehelsetjenesten 
(IDANT-studien). Det var første gang en psykiatrisk masseundersøkelse med tilbud om 
intervensjon ble gjennomført. 
Målsetning med etterundersøkelsen: 
x Vi vil undersøke hvordan det har gått med disse risikoindividene, vurdere psykiatrisk 
status/behandlingsbehov i dag.
x Vurdere effektiviteten og gjennomførbarheten (”feasibility”) av slik intervensjon i en 
befolkningsundersøkelse, særlig med tanke på samarbeid mellom 1. og 2. linjetjenesten. 
x Skaffe mer viten om hvordan folk reagerer på en slik skriftlig melding og hva som avgjør 
om de deltar eller ikke.  
Etterundersøkelsen omfatter ikke noe behandleransvar, men vi sender en meldingsblankett 
(vedlagt) til fastlege dersom tilstanden er ubehandlet eller ikke kjent og hvis deltakeren ønsker 
det.
I noen av utkantkommunene kan det bli aktuelt å be om å få låne et kontor/rom til 
gjennomføring av intervju. Jeg vil selv ta kontakt med de aktuelle legekontorene på forhånd.
Med vennlig hilsen 
    Ottar Bjerkeset 
    Lege/stipendiat 
IDANT-utvalget (PHRG) 
Kjære HUNT-deltaker !
Takk for at du deltok i denne store helseundersøkelsen for noen år siden. Den har gitt oss mye 
viktig informasjon om hvilke faktorer som øker risiko for sykdom og hvilke som beskytter 
mot sykdom. 
Jeg er lege ved psykiatrisk klinikk Innherred sykehus og skal gjøre en oppfølgings- 
undersøkelse av de nord-trønderne som rapporterte om mye angst- og/eller depresjon ved den 
siste HUNT-undersøkelsen (1995-97). Du var en av dem som fikk brev fra Statens 
helseundersøkelser noen uker etter HUNT, hvor du ble bedt om å ta kontakt med din lege på 
grunn av slike plager. Det er Statens helseundersøkelser som har tilgang til navnene på den 
gruppen som fikk meldingen, og dette brevet er derfor sendt av dem. 
Hovedmålet er å se hvordan det har gått med deg, og om meldingen du fikk etter HUNT førte 
til at sykdom ble oppdaget og/eller behandling ble startet eller endret. Det er første gang en 
slik undersøkelse blir gjort, og vi har ved din hjelp en mulighet til å lære mer om hvordan vi 
kan oppdage og hjelpe de psykisk lidende i befolkningen. For å være i stand til dette, trenger 
vi imidlertid oppslutning fra så mange som mulig. Dette gjelder uansett om du fortsatt er syk 
eller nå føler deg frisk. 
Det tar ca 5-7 minutter å fylle ut det vedlagte skjemaet, og jeg ville vært svært takknemmelig 
om du tok deg tid til dette Det er selvsagt helt frivillig om du vil gjøre dette, dersom du ikke 
ønsker å delta vil ikke dette få noen konsekvenser for ditt videre forhold til Helsevesenet. 
Opplysningene du gir vil kun bli brukt i anonymisert statistikk hvor du kan ikke på noen måte 
kan gjenkjennes. Jeg og de andre som arbeider med studien er pålagt taushetsplikt. Prosjektet 
er godkjent av Datatilsynet og av den forskningsetiske komiteen i vår helseregion. 




REF- og PRG-utvalget 
Kjære HUNT-deltaker !
Takk for at du deltok i denne store helseundersøkelsen for noen år siden. Den har gitt oss mye 
viktig informasjon om hvilke faktorer som øker risiko for sykdom og hvilke som beskytter 
mot sykdom. 
Jeg er lege ved psykiatrisk klinikk Innherred sykehus og skal gjøre en 
oppfølgingsundersøkelse av de nord-trønderne som rapporterte mest angst- og 
depresjonssymptomer ved den siste HUNT-undersøkelsen (1995-97). 
Hovedmålet med oppfølgingen er å se hvordan det har gått med disse personene og om 
helsetilbudet de fikk har hjulpet dem. Det er første gang en slik undersøkelse blir gjort, og vi 
har med din hjelp en mulighet til å lære mer om hvordan vi kan oppdage og hjelpe de psykisk 
lidende i befolkningen. 
I den forbindelse er det viktig å stille noen av de samme spørsmålene til et tilfeldig utvalg av 
de andre deltakerne i HUNT. Om lag 1300 HUNT-deltakere vil bli trukket ut til denne 
gruppen (ofte kalt kontrollgruppe), som du altså er en del av. Det er svært viktig at du fyller ut 
skjemaet ,enten du føler deg frisk eller har psykiske plager. 
Du vil ikke bli innkalt til noe personlig undersøkelse eller kontaktet igjen senere, vi ber bare 
om at du fyller ut det vedlagte skjemaet. 
Det tar ca 5-7 minutter å fylle ut det vedlagte skjemaet, og jeg ville vært svært takknemmelig 
om du tok deg tid til dette Det er selvsagt helt frivillig om du vil gjøre dette, dersom du ikke 
ønsker å delta vil ikke dette få noen konsekvenser for ditt videre forhold til Helsevesenet. 
Opplysningene du gir vil kun bli brukt i anonymisert statistikk hvor du kan ikke på noen måte 
kan gjenkjennes. Jeg og de andre som arbeider med studien er pålagt taushetsplikt. Prosjektet 
er godkjent av Datatilsynet og av den forskningsetiske komiteen i vår helseregion. 





Kjære deltaker ! 
Det er nå få dager til etterundersøkelsen skal finne sted  og vi ber deg derfor 
fylle ut det vedlagte spørreskjemaet og ta det med til intervjuet.
Hvor skal du møte ? 
De som skal møte ved psykiatrisk poliklinikk Innherred sykehus (tlf. 
74098600) og har time til og med  kl. 15.30, melder seg i ekspedisjonen i 
inngangen til psykiatrisk klinikk. Psykiatrisk klinikk ligger ca 150 meter fra 
hovedsykehuset mot jernbanen og er et relativt lavt og nytt mursteinsbygg. 
Lokaltogene stopper rett foran psykiatrisk klinikk. Parkeringsplasser finnes 
både foran hovedsykehuset og ved inngangen til psykiatrisk klinikk. 
Dersom du har time etter kl. 15.30 kan du møte inne til høyre i vestibylen til 
psykiatrisk sengeavdeling/post 1 (ca 40 m til høyre for hovedinngangen for 
psykiatrisk klinikk). Den du har avtale med vil komme og møte deg. 
Ta med deg denne lappen til timen om du ikke skulle finne oss og må spørre 
om veien/ringe. 
Skyssgodtgjørelse for de som reiser til Levanger vil bli utbetalt rett etter 
samtalen.  
Vel møtt til etterundersøkelsen !    
Ottar Bjerkeset  Sara Larsson   Erling Østnes
MELDESKJEMA TIL PRIMÆRLEGE ____________________________________ 
ANGÅENDE PASIENT________________________________ FØDT____________ 
Bakgrunn:  Jeg er ansatt ved psykiatrisk klinikk, Innherred sykehus og intervjuet den _______ 
nevnte pasient  i forbindelse med prosjektet ”Etterundersøkelse av psykiatriske risikoindivider 
identifisert ved Helseundersøkelsen i Nord-Trøndelag (HUNT)”.
Alle deltakere har samtykket skriftlig på forespørsel om deltakelse. Risikogruppen som nå blir 
tilbudt etterundersøkelse scoret over 99 percentil (25 poeng) på selvutfyllingsskjemaet HADS 
(Hospital Anxiety and Depression rating scale) i HUNT II for ca 4 år siden. Disse fikk 
skriftlig melding fra Statens helseundersøkelser (SHUS) om høyt angst- og depresjonsnivå og 
ble tilbudt intervensjon i kommunehelsetjenesten (IDANT-studien). Det var første gang en 
slik psykiatrisk masseundersøkelse med tilbud om intervensjon ble gjennomført. 
Målsetning: Vi vil undersøke hvordan det har gått med disse risikoindividene, vurdere 
psykiatrisk status og behandlingsbehov i dag. Andre viktige spørsmål er hvordan deltakerne 
reagerte på denne meldingen og hvordan intervensjonen fungerte i praksis. 
Denne etterundersøkelsen omfatter ikke noe behandleransvar, men vi sender denne meldingen 
til fastlege dersom tilstanden er ubehandlet eller ikke kjent og hvis deltakeren ønsker det. 
   Pasienten bestiller selv time                Vi ber deg kalle inn pasienten
Samtykke til at melding blir sendt: 




Når det gjelder terapianbefalinger for de aktuelle tilstandene, henvises det til: 
Legemiddelhåndboka1
SLKs terapiverksteder om angst2 og depresjon3
Dahl, Eitinger, Malt & Retterstøl:   Lærebok i psykiatri. 
Referanser:
1 Norsk legemiddelhåndbok for helsepersonell 
2 Farmakoterapi ved angst, Nytt fra Statens legemiddelkontroll 1995, (8 ) 
3  Behandling av depresjon (Terapianbefalinger), Nytt om legemidler fra Statens legemiddelkontroll               
1996;(Suppl 1)
Med vennlig hilsen 
for lege/stipendiat Ottar Bjerkeset 
Inger D. Holbø 
førstesekretær
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VITRO
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3. Karel Bjørn Cyvin: CONGENITAL DISLOCATION OF THE HIP JOINT. 
4. Alf O. Brubakk: METHODS FOR STUDYING FLOW DYNAMICS IN THE LEFT 
VENTRICLE  AND THE AORTA IN MAN. 
1979 
5. Geirmund Unsgaard: CYTOSTATIC AND IMMUNOREGULATORY ABILITIES OF HUMAN    
BLOOD MONOCYTES CULTURED IN VITRO 
1980 
6. Størker Jørstad: URAEMIC TOXINS 
7. Arne Olav Jenssen: SOME RHEOLOGICAL, CHEMICAL AND STRUCTURAL PROPERTIES    
OF MUCOID SPUTUM FROM PATIENTS WITH CHRONIC OBSTRUCTIVE BRONCHITIS 
1981 
8. Jens Hammerstrøm: CYTOSTATIC AND CYTOLYTIC ACTIVITY OF HUMAN 
MONOCYTES AND EFFUSION MACROPHAGES AGAINST TUMOR CELLS IN VITRO 
1983 
9. Tore Syversen: EFFECTS OF METHYLMERCURY ON RAT BRAIN PROTEIN. 
10. Torbjørn Iversen: SQUAMOUS CELL CARCINOMA OF THE VULVA. 
1984 
11. Tor-Erik Widerøe: ASPECTS OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS. 
12. Anton Hole: ALTERATIONS OF MONOCYTE AND LYMPHOCYTE FUNCTIONS IN 
REALTION TO SURGERY UNDER EPIDURAL OR GENERAL ANAESTHESIA. 
13. Terje Terjesen: FRACTURE HEALING AN STRESS-PROTECTION AFTER METAL PLATE 
FIXATION AND EXTERNAL FIXATION. 
14. Carsten Saunte: CLUSTER HEADACHE SYNDROME. 
15. Inggard Lereim: TRAFFIC ACCIDENTS AND THEIR CONSEQUENCES. 
16. Bjørn Magne Eggen: STUDIES IN CYTOTOXICITY IN HUMAN ADHERENT 
MONONUCLEAR BLOOD CELLS. 
17. Trond Haug: FACTORS REGULATING BEHAVIORAL EFFECTS OG DRUGS. 
1985 
18. Sven Erik Gisvold: RESUSCITATION AFTER COMPLETE GLOBAL BRAIN ISCHEMIA. 
19. Terje Espevik: THE CYTOSKELETON OF HUMAN MONOCYTES. 
20. Lars Bevanger: STUDIES OF THE Ibc (c) PROTEIN ANTIGENS OF GROUP B 
STREPTOCOCCI.
21. Ole-Jan Iversen: RETROVIRUS-LIKE PARTICLES IN THE PATHOGENESIS OF PSORIASIS. 
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